Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors

ABSTRACT

The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.

This application is a national stage of Application No.PCT/US2012/067877, filed Dec. 5, 2012, which claims of the benefit of U.S. Provisional Application 61/567,185, filed on Dec. 6, 2011.

FIELD OF THE INVENTION

The present invention is directed to novel piperidinyl-pyridazinylderivatives, pharmaceutical compositions containing them and their useas inhibitors of SCD 1, useful in the treatment of obesity, type-IIdiabetes and other related metabolic disorders.

BACKGROUND OF THE INVENTION

Stearoyl-CoA desaturase 1 (SCD 1) is a critical microsomal enzyme thatcatalyzes the conversion of saturated fatty acid-CoAs tomono-unsaturated fatty acid-CoAs (at C-9 position) (DOBRZYN, A., et al.,Obes. Rev., 2005, pp 169, Vol. 6; NTAMBI, J., et al., Curr. Opin.Lipidol., 2003, pp 255, Vol. 14). These mono-unsaturated fattyacid-CoAs, such as palmitoleic (C16) acid-CoA and oleic (C18) acid-CoA,are major building blocks in biosynthesis of lipids includingphospholipids, triglycerides, cholesterol esters and wax esters(MIYAZAKI, M., et al., J. Lipid Res., 2002, pp 2146, Vol. 43). Four SCDisoforms (SCD 14) in rodents and two human genes (SCD 1 and 2) have beenidentified and characterized. SCD 1 (MIYAZAKI, M., et al., J. Biol.Chem., 2003, pp 33904, Vol 278; WANG, J., et al., Biochem. Biophys. Res.Commun., 2005, pp 735, Vol. 332), with ca. 85% identity across species(ZHANG, L., et a., Biochem. J., 1999, pp 255, Vol. 340), is abundantlyexpressed in liver and adipose tissue and is regulated by severalnutritional and hormonal factors, such as insulin, cholesterol, andpoly-unsaturated fatty acids (WATERS, K. M., et al., J. Biol. Chem.,1994, pp 27773, Vol. 269; NTAMBI, J. M., et al., J. Lipid Res., 1999, pp1549, Vol. 40). Moreover, SCD 1 deficiency in mice, either naturallydeficient Asebia mice (ZHENG, Y., et al., Nat. Genet., 1999, pp 268,Vol. 23) or laboratory-created SCD 1 knockout (SCD 1^(−/−)) mice(NTAMBI, J. M. et al., Proc. Natl. Acad. Sci. U.S.A., 2002, pp 11482,Vol. 99), has been shown to reduce body adiposity, increase insulinsensitivity, and impart resistance to diet-induced obesity (NTAMBI, J.M., et al., Prog. Lipid Res., 2004, pp 91, Vol. 43). The SCD 1^(−/−)mice also have lower levels of hepatic cholesterol esters andtriglycerides (MIYAZAKI, M., et al., J. Biol. Chem., 2000, pp 30132,Vol. 275).

These observations indicated that inhibition of SCD 1 activity may serveas a potential treatment for obesity, type-II diabetes, and otherrelated metabolic disorders.

SUMMARY OF THE INVENTION

The present invention is directed to compounds of formula (I)

wherein

R¹ is selected from the group consisting of

a is an integer from 0 to 3;

each R² is independently selected from the group consisting of halogen,C₁₋₄alkyl, C₁₋₄alkoxy, halogenated C₁₋₂alkyl, and halogenatedC₁₋₂alkoxy;

R³ is selected from the group consisting of

wherein R⁴ is selected from the group consisting of hydrogen, halogen,C₁₋₄alkyl, halogenated C₁₋₂alkyl, —C₁₋₂alkyl-OH, C₁₋₄alkoxy, halogenatedC₁₋₂alkoxy, —C₁₋₂alkyl-O—C₁₋₂alkyl, —CO₂H, —C(O)O—C₁₋₄alkyl,—C₁₋₂alkyl-C(O)O—C₁₋₂alkyl, —C₁₋₂alkyl-OC(O)—C₁₋₂alkyl, —NR^(A)R^(B),—C₁₋₂alkyl-NR^(A)R^(B), —C(O)—NR^(A)R^(B), —C₁₋₂alkyl-C(O)—NR^(A)R^(B)and —NR^(A)—C(O)—(C₁₋₂alkyl);

wherein R⁵ is selected from the group consisting of hydrogen, C₁₋₄alkyl,—C₂₋₄alkyl-OH, —C₂₋₃alkyl-O—C₁₋₂alkyl, —C₁₋₂alkyl-C(O)O—C₁₋₂alkyl,—C₂₋₃alkyl-OC(O)—C₁₋₂alkyl, —C₂₋₄alkyl-NR^(A)R^(B) and—C₁₋₂alkyl-C(O)NR^(A)R^(B);

and

wherein b is an integer from 0 to 2;

wherein each R⁶ is independently selected from the group consisting ofhalogen, C₁₋₄alkyl, halogenated C₁₋₄alkyl, —C₁₋₂alkyl-OH, C₁₋₄alkoxy,halogenated C₁₋₄alkoxy, —C₁₋₂alkyl-O—C₁₋₂alkyl, —CO₂H, —C(O)O—C₁₋₄alkyl,—C₁₋₂alkyl-C(O)O—C₁₋₂alkyl, —C₁₋₂alkyl-OC(O)—C₁₋₂alkyl,—C(O)—NR^(A)R^(B), —C₁₋₂alkyl-C(O)—NR^(A)R^(B), —NR^(A)R^(B),—C₁₋₂alkyl-NR^(A)R^(B) and —NR^(A)—C(O)—C₁₋₂alkyl;

and wherein R^(A) and R^(B) are each independently selected from thegroup consisting of hydrogen and C₁₋₂alkyl; alternatively R^(A) andR^(B) are taken together with the nitrogen atom to which they are boundto form piperidin-1-yl, piperazin-1-yl, morpholin-4-yl andpyrrolidin-1-yl;

provided that when R³ is 3-methyl-1,2,4-thiadiazol-5-yl, then R¹ isother than unsubstituted indoly-3-yl;

and pharmaceutically acceptable salts thereof.

The present invention is further directed to processes for thepreparation of the compounds of formula (I). The present invention isfurther directed to a product prepared according to the processdescribed herein.

Illustrative of the invention is a pharmaceutical composition comprisinga pharmaceutically acceptable carrier and the product prepared accordingto the process described herein. An illustration of the invention is apharmaceutical composition made by mixing the product prepared accordingto the process described herein and a pharmaceutically acceptablecarrier. Illustrating the invention is a process for making apharmaceutical composition comprising mixing the product preparedaccording to the process described herein and a pharmaceuticallyacceptable carrier.

Exemplifying the invention are methods of treating a disorder mediatedby SCD1 (selected from the group consisting of obesity, type-IIdiabetes, Syndrome X (also known as metabolic syndrome),hypertriglyceridemia, dyslipidemia, hypercholesterolemia,hyperlipidemia, mixed dyslipidemia, fatty liver, nonalcoholic fattyliver disease, liver fibrosis and NASH) comprising administering to asubject in need thereof a therapeutically effective amount of any of thecompounds or pharmaceutical compositions described herein.

In an embodiment, the present invention is directed to a compound offormula (I) for use as a medicament. In another embodiment, the presentinvention is directed to a compound of formula (I) for use in thetreatment of a disorder mediated by SCD1 (selected from the groupconsisting of obesity, type-II diabetes, Syndrome X (also known asmetabolic syndrome), hypertriglyceridemia, dyslipidemia,hypercholesterolemia, hyperlipidemia, mixed dyslipidemia, fatty liver,nonalcoholic fatty liver disease, liver fibrosis and NASH). In anotherembodiment, the present invention is directed to a compositioncomprising a compound of formula (I) for the treatment of a disordermediated by SCD1 (selected from the group consisting of obesity, type-IIdiabetes, Syndrome X (also known as metabolic syndrome),hypertriglyceridemia, dyslipidemia, hypercholesterolemia,hyperlipidemia, mixed dyslipidemia, fatty liver, nonalcoholic fattyliver disease, liver fibrosis and NASH).

Another example of the invention is the use of any of the compoundsdescribed herein in the preparation of a medicament for treating: (a)obesity, (b) type-II diabetes, (c) Syndrome X (also known as metabolicsyndrome), (d) hypertriglyceridemia, (e) dyslipidemia, (f)hypercholesterolemia, (g) hyperlipidemia, (h) mixed dyslipidemia, (i)fatty liver, (j) nonalcoholic fatty liver disease, (k) liver fibrosis or(I) NASH, in a subject in need thereof.

In another example, the present invention is directed to a compound asdescribed herein for use in a methods for treating a disorder selectedfrom the group consisting of obesity, type-II diabetes, Syndrome X (alsoknown as metabolic syndrome), hypertriglyceridemia, dyslipidemia,hypercholesterolemia, hyperlipidemia, mixed dyslipidemia, fatty liver,nonalcoholic fatty liver disease, liver fibrosis and NASH, in a subjectin need thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds of formula (I)

wherein R¹, R², R³, R⁴, R⁵, R⁶, a, and b are as herein defined. Thecompounds of the present invention are inhibitors of SCD1 useful in thetreatment of metabolic disorders including, but not limited to, obesity,type-II diabetes, Syndrome X (also known as metabolic syndrome),hypertriglyceridemia, dyslipidemia, NASH, hypercholesterolemia,hyperlipidemia, mixed dyslipidemia, fatty liver, nonalcoholic fattyliver disease, liver fibrosis, and the like.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, R¹ is selected from the group consisting of

a is an integer from 0 to 2; and each R² is independently selected fromthe group consisting of halogen, C₁₋₂alkyl, C₁₋₂alkoxy, fluorinatedC₁₋₂alkyl, and fluorinated C₁₋₂alkoxy.In another embodiment, the present invention is directed to compound offormula (I) wherein R¹ is selected from the group consisting of

a is an integer from 0 to 2; and each R² is independently selected fromthe group consisting of halogen, C₁₋₂alkyl, C₁₋₂alkoxy andtrifluoromethyl.

In another embodiment, the present invention is directed to compound offormula (I) wherein R¹ is selected from the group consisting ofindol-1-yl, 6-fluoro-indol-1-yl, indolin-1-yl, 4-fluoro-indolin-1-yl,5-fluoro-indolin-1-yl, 6-fluoro-indolin-1-yl, 4-chloro-indolin-1-yl,5-chloro-indolin-1-yl, 6-chloro-indolin-1-yl, 4,6-dichloro-indolin-1-yl,6-methyl-indolin-1-yl, 6-methoxy-indolin-1-yl,6-trifluoromethyl-indolin-1-yl, 1H-indazol-1-yl,4-fluoro-1H-indazol-1-yl, 5-fluoro-1H-indazol-1-yl,6-fluoro-1H-indazol-1-yl, 3-chloro-1H-indazol-1-yl,4-chloro-1H-indazol-1-yl, 6-chloro-1H-indazol-1-yl,4-trifluoromethyl-1H-indazol-1-yl, 6-trifluoromethyl-1H-indazol-1-yl,2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl,1H-benzo[d][1,2,3]triazol-1-yl, 5-fluoro-benzo[d]isoxazol-3-yl,6-fluoro-benzo[d]isoxazol-1-yl, and 1,2,3,4-tetrahydroquinolin-1-yl.

In another embodiment, the present invention is directed to compound offormula (I) wherein R¹ is selected from the group consisting ofindol-1-yl, 6-fluoro-indolyl, indolin-1-yl, 6-fluoro-indolin-1-yl,1H-indazol-1-yl, 4-fluoro-1H-indazol-1-yl, 6-fluoro-1H-indazol-1-yl,3-chloro-1H-indazol-1-yl, 4-chloro-1H-indazol-1-yl,6-chloro-1H-indazol-1-yl, 4-trifluoromethyl-1H-indazol-1-yl,6-trifluoromethyl-1H-indazol-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl. Inanother embodiment, the present invention is directed to compound offormula (I) wherein R¹ is selected from the group consisting ofindol-1-yl, 6-fluoro-indolyl, indolin-1-yl, 6-fluoro-indolin-1-yl,6-fluoro-1H-indazol-1-yl, 3-chloro-1H-indazol-1-yl,4-chloro-1H-indazol-1-yl, 6-chloro-1H-indazol-1-yl,6-trifluoromethyl-1H-indazol-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl. Inanother embodiment, the present invention is directed to compound offormula (I) wherein R¹ is selected from the group consisting ofindol-1-yl, indolin-1-yl, 6-fluoro-indolin-1-yl,3-chloro-1H-indazol-1-yl, 4-chloro-1H-indazol-1-yl,6-chloro-1H-indazol-1-yl, 6-trifluoromethyl-1H-indazol-1-yl and5-fluoro-benzo[d]isoxazol-3-yl.

In another embodiment, the present invention is directed to compound offormula (I) wherein R¹ is selected from the group consisting ofindol-1-yl, 6-fluoro-indol-1-yl, indolin-1-yl, 5-fluoro-indolin-1-yl,6-fluoro-indolin-1-yl, 6-chloro-indolin-1-yl,6-trifluoromethyl-indolin-1-yl, 1H-indazol-1-yl,4-fluoro-1H-indazol-1-yl, 6-fluoro-1H-indazol-1-yl,3-chloro-1H-indazol-1-yl, 4-chloro-1H-indazol-1-yl,6-chloro-1H-indazol-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl. In anotherembodiment, the present invention is directed to compound of formula (I)wherein R¹ is selected from the group consisting of 6-fluoro-indol-1-yl,indolin-1-yl, 6-fluoro-indolin-1-yl, 6-chloro-indolin-1-yl,6-trifluoromethyl-indolin-1-yl, 1H-indazol-1-yl,6-fluoro-1H-indazol-1-yl, 3-chloro-1H-indazol-1-yl,4-chloro-1H-indazol-1-yl, 6-chloro-1H-indazol-1-yl and5-fluoro-benzo[d]isoxazol-3-yl. In another embodiment, the presentinvention is directed to compound of formula (I) wherein R¹ is selectedfrom the group consisting of 6-fluoro-indolin-1-yl,6-fluoro-1H-indazol-1-yl, 3-chloro-1H-indazol-1-yl,4-chloro-1H-indazol-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl.

In another embodiment, the present invention is directed to compound offormula (I) wherein R¹ is selected from the group consisting of6-fluoro-indolin-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl.

In additional embodiments, the present invention is directed tocompounds of formula (I) wherein R¹ is selected to be any one of thefollowing optionally substituted, bicyclic ring structures:

In an embodiment, the present invention is directed to compounds offormula (I) wherein, a is an integer from 0 to 2. In another embodiment,the present invention is directed to compound of formula (I) wherein, ais an integer from 0 to 1. In another embodiment, the present inventionis directed to compound of formula (I) wherein, a is an integer from 1to 2. In another In another embodiment, the present invention isdirected to compound of formula (I) wherein a is 1.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, each R² is independently selected from the groupconsisting of fluoro, chloro, methyl, methoxy and trifluoromethyl. Inanother embodiment, the present invention is directed to compounds offormula (I) wherein each R² is independently selected from the groupconsisting of fluoro, chloro and trifluoromethyl. In another embodiment,the present invention is directed to compounds of formula (I) whereineach R² is independently selected from the group consisting of fluoroand chloro. In another embodiment, the present invention is directed tocompounds of formula (I) wherein each R² is fluoro.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, R³ is selected from the group consisting of

wherein R⁴ is selected from the group consisting of hydrogen, halogen,C₁₋₄alkyl, fluorinated C₁₋₂alkyl, —C₁₋₂alkyl-OH, C₁₋₂alkoxy, fluorinatedC₁₋₂alkoxy, —C₁₋₂alkyl-O—C₁₋₂alkyl, —CO₂H, —C(O)O—C₁₋₂alkyl,—C₁₋₂alkyl-OC(O)—C₁₋₂alkyl, —NR^(A)R^(B), —C₁₋₂alkyl-NR^(A)R^(B),—C(O)—NR^(A)R^(B), —C₁₋₂alkyl-C(O)—NR^(A)R^(B) and—NR^(A)—C(O)—(C₁₋₂alkyl);

wherein R⁵ is selected from the group consisting of hydrogen, C₁₋₄alkyl,—C₂₋₄alkyl-OH, —C₂₋₃alkyl-O—C₁₋₂alkyl, —C₁₋₂alkyl-C(O)O—C₁₋₂alkyl,—C₂₋₄alkyl-NR^(A)R^(B) and —C₁₋₂alkyl-C(O)NR^(A)R^(B);

and

wherein b is an integer from 0 to 1; and wherein each R⁶ isindependently selected from the group consisting of halogen, C₁₋₄alkyl,fluorinated C₁₋₂alkyl, —C₁₋₂alkyl-OH, C₁₋₂alkoxy, fluorinatedC₁₋₂alkoxy, —CO₂H, —C(O)O—C₁₋₄alkyl, —C₁₋₂alkyl-C(O)O—C₁₋₂alkyl,—C(O)—NR^(A)R^(B), —C₁₋₂alkyl-C(O)—NR^(A)R^(B), —NR^(A)R^(B) and—C₁₋₂alkyl-NR^(A)R^(B).

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of

wherein R⁴ is selected from the group consisting of hydrogen, halogen,C₁₋₂alkyl, trifluoromethyl, —C₁₋₂alkyl-OH, C₁₋₂alkoxy,—C₁₋₂alkyl-O—C₁₋₂alkyl, —C₁₋₂alkyl-OC(O)—C₁₋₂alkyl, —NR^(A)R^(B),—C₁₋₂alkyl-NR^(A)R^(B), —C(O)—NR^(A)R^(B). and —NR^(A)—C(O)—(C₁₋₂alkyl);

wherein R⁵ is selected from the group consisting of hydrogen, C₁₋₃alkyl,—C₂alkyl-OH, —C₂₋₃alkyl-O—C₁₋₂alkyl, —C₁₋₂alkyl-C(O)O—C₁₋₂alkyl,—C₂₋₄alkyl-NR^(A)R^(B) and —C₁₋₂alkyl-C(O)NR^(A)R^(B);

and

wherein b is 1; and wherein R⁶ is selected from the group consisting of,halogen, C₁₋₂alkyl, trifluoromethyl, —C₁₋₂alkyl-OH, —CO₂H,—C(O)O—C₁₋₄alkyl and —C(O)—NR^(A)R^(B).

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of

-   (a) pyrazol-1-yl, 3-methyl-pyrazol-1-yl, 4-methyl-pyrazol-1-yl,    4-(hydroxymethyl)-pyrazol-1-yl, 4-(hydroxyethyl)-pyrazol-1-yl,    4-(methoxy-methyl)-pyrazol-1-yl, 4-(ethoxy-methyl)-pyrazol-1-yl,    4-(methylamino-methyl)-pyrazol-1-yl;-   (b) imidazol-1-yl, 2-methyl-imidazol-1-yl, 4-methyl-imidazol-1-yl,    4-(hydroxymethyl)-imidazol-1-yl;-   (c) 5-methyl-1,3,4-oxadiazol-2-yl,    5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl,    5-(methylcarbonyl-oxy-methyl)-1,3,4-oxadiazol-2-yl;-   (d) 4-methyl-thien-2-yl, 5-methyl-thien-2-yl;-   (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2-yl;-   (f) 3-methyl-1,2,4-thiadiazol-5-yl;-   (g) pyrid-3-yl, 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,    6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,    6-(methylamino-carbonyl)-pyrid-3-yl, 6-(dimethylamino)-pyrid-3-yl,    6-(methylcarbonyl-amino)-pyrid-3-yl;-   (h) 2-methyl-pyrid-4-yl;-   (i) 2-methyl-pyrimidin-5-yl, 2-methoxy-pyrimidin-5-yl;-   (j) 1H-pyrazol-4-yl, 1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl,    1-(n-propyl)-pyrazol-4-yl, 1-(hydroxyethyl)-pyrazol-4-yl,    1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,    1-(aminocarbonyl-methyl)-pyrazol-4-yl,    1-(methylamino-carbonyl-methyl)-pyrazol-4-yl,    1-(morpholin-4-yl-ethyl)-pyrazol-4-yl,    1-(ethoxy-ethyl)-pyrazol-4-yl; and-   (k) 4-fluoro-phenyl, 4-methyl-phenyl, 4-(hydroxymethyl)-phenyl,    4-(trifluoromethyl)-phenyl, 4-(tert-butoxycarbonyl)-phenyl,    4-(carboxy)-phenyl, 4-(aminocarbonyl)-phenyl.

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of

-   (a) 4-methyl-pyrazol-1-yl, 4-(hydroxymethyl)-pyrazol-1-yl,    4-(hydroxyethyl)-pyrazol-1-yl, 4-(methoxy-methyl)-pyrazol-1-yl,    4-(ethoxy-methyl)-pyrazol-1-yl;-   (b) 4-methyl-imidazol-1-yl, 4-(hydroxymethyl)-imidazol-1-yl;-   (c) 5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl;-   (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2-yl;-   (f) 3-methyl-1,2,4-thiadiazol-5-yl;-   (g) 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,    6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,    6-(methylamino-carbonyl)-pyrid-3-yl, 6-(dimethylamino)-pyrid-3-yl,    6-(methylcarbonyl-amino)-pyrid-3-yl;-   (i) 2-methoxy-pyrimidin-5-yl;-   (j) 1H-pyrazol-4-yl, 1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl,    1-(n-propyl)-pyrazol-4-yl, 1-(hydroxyethyl)-pyrazol-4-yl,    1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,    1-(methylamino-carbonyl-methyl)-pyrazol-4-yl,    1-(ethoxy-ethyl)-pyrazol-4-yl; and-   (k) 4-methyl-phenyl, 4-(hydroxymethyl)-phenyl.

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of

-   (a) 4-methyl-pyrazol-1-yl, 4-(hydroxymethyl)-pyrazol-1-yl,    4-(hydroxyethyl)-pyrazol-1-yl, 4-(methoxy-methyl)-pyrazol-1-yl,    4-(ethoxy-methyl)-pyrazol-1-yl;-   (b) 4-methyl-imidazol-1-yl, 4-(hydroxymethyl)-imidazol-1-yl;-   (c) 5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl;-   (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2-yl;-   (f) 3-methyl-1,2,4-thiadiazol-5-yl;-   (g) 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,    6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,    6-(methylamino-carbonyl)-pyrid-3-yl, 6-(dimethylamino)-pyrid-3-yl,    6-(methylcarbonyl-amino)-pyrid-3-yl;-   (i) 2-methoxy-pyrimidin-5-yl;-   (j) 1H-pyrazol-4-yl, 1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl,    1-(n-propyl)-pyrazol-4-yl, 1-(hydroxyethyl)-pyrazol-4-yl,    1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,    1-(methylamino-carbonyl-methyl)-pyrazol-4-yl, 1-(ethoxy-ethyl)    pyrazol-4-yl; and-   (k) 4-(hydroxymethyl)-phenyl.

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of

-   (a) 4-methyl-pyrazol-1-yl, 4-(hydroxymethyl)-pyrazol-1-yl,    4-(methoxy-methyl)pyrazol-1-yl, 4-(ethoxy-methyl)-pyrazol-1-yl;-   (b) 4-methyl-imidazol-1-yl, 4-(hydroxymethyl)-imidazol-1-yl;-   (c) 5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl;-   (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2-yl;-   (f) 3-methyl-1,2,4-thiadiazol-5-yl;-   (g) 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,    6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,    6-(dimethylamino)-pyrid-3-yl, 6-(methylcarbonyl-amino)pyrid-3-yl;-   (i) 2-methoxy-pyrimidin-5-yl;-   (j) 1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl,    1-(n-propyl)-pyrazol-4-yl,    1-(methylamino-carbonyl-methyl)-pyrazol-4-yl and    1-(ethoxy-ethyl)-pyrazol-4-yl.

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of

-   (a) 3-methyl-pyrazol-1-yl, 4-methyl-pyrazol-1-yl,    4-(hydroxymethyl)-pyrazol-1-yl, 4-(hydroxyethyl)-pyrazol-1-yl,    4-(methoxy-methyl)-pyrazol-1-yl, 4-(ethoxy-methyl)-pyrazol-1-yl;-   (b) 4-methyl-imidazol-1-yl, 4-(hydroxymethyl)-imidazol-1-yl;-   (c) 5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl;-   (d) 4-methyl-thien-2-yl, 5-methyl-thien-2-yl;-   (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2-yl;-   (f) 3-methyl-1,2,4-thiadiazol-5-yl;-   (g) 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,    6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,    6-(methylamino-carbonyl)-pyrid-3-yl, 6-(dimethylamino)-pyrid-3-yl,    6-(methylcarbonyl-amino)-pyrid-3-yl;-   (h) 2-methyl-pyrid-4-yl;-   (i) 2-methoxy-pyrimidin-5-yl;-   (j) 1H-pyrazol-4-yl, 1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl,    1-(n-propyl)-pyrazol-4-yl, 1-(hydroxyethyl)-pyrazol-4-yl,    1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,    1-(methylamino-carbonyl-methyl)-pyrazol-4-yl,    1-(ethoxy-ethyl)-pyrazol-4-yl; and-   (k) 4-methyl-phenyl, 4-(hydroxymethyl)-phenyl,    4-(trifluoromethyl)-phenyl.

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of

-   (a) 4-methyl-pyrazol-1-yl, 4-(hydroxymethyl)-pyrazol-1-yl,    4-(hydroxyethyl)-pyrazol-1-yl, 4-(methoxy-methyl)-pyrazol-1-yl,    4-(ethoxy-methyl)-pyrazol-1-yl;-   (b) 4-(hydroxymethyl)-imidazol-1-yl;-   (c) 5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl;-   (d) 4-methyl-thien-2-yl, 5-methyl-thien-2-yl;-   (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2-yl;-   (f) 3-methyl-1,2,4-thiadiazol-5-yl;-   (g) 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,    6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,    6-(methylamino-carbonyl)-pyrid-3-yl, 6-(dimethylamino)-pyrid-3-yl,    6-(methylcarbonyl-amino)-pyrid-3-yl;-   (h) 2-methyl-pyrid-4-yl;-   (i) 2-methoxy-pyrimidin-5-yl;-   (j) 1H-pyrazol-4-yl, 1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl,    1-(hydroxyethyl)-pyrazol-4-yl,    1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,    1-(methylamino-carbonyl-methyl)-pyrazol-4-yl; and-   (k) 4-methyl-phenyl, 4-(hydroxymethyl)-phenyl.

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of

-   (a) 4-(hydroxymethyl)-pyrazol-1-yl, 4-(hydroxyethyl)-pyrazol-1-yl,    4-(ethoxy-methyl)-pyrazol-1-yl;-   (b) 4-(hydroxymethyl)-imidazol-1-yl;-   (c) 5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl;-   (d) 4-methyl-thien-2-yl, 5-methyl-thien-2-yl;-   (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2-yl;-   (g) 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,    6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,    6-(methylamino-carbonyl)-pyrid-3-yl;-   (h) 2-methyl-pyrid-4-yl;-   (i) 2-methoxy-pyrimidin-5-yl;-   (j) 1-methyl-pyrazol-4-yl, 1-(hydroxyethyl)-pyrazol-4-yl,    1-(methylamino-carbonyl-methyl)-pyrazol-4-yl; and-   (k) 4-methyl-phenyl, 4-(hydroxymethyl)-phenyl.

In another embodiment, the present invention is directed to compound offormula (I) wherein, R³ is selected from the group consisting of (a)4-(ethoxymethyl)-pyrazol-1-yl; (e) 4-methyl-thiazol-2-yl; (i)6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-(hydroxymethyl)-pyrid-3-yl;and (k) 1-methyl-pyrazol-3-yl).

In additional embodiments, the present invention is directed tocompounds of formula (I) wherein R³ is selected to be any one of thefollowing optionally substituted, bicyclic ring structures:

In an embodiment, the present invention is directed to compounds offormula (I) wherein, R⁴ is selected from the group consisting of methyl,trifluoromethyl, hydroxymethyl-, hydroxyethyl-, methoxy,methoxy-methyl-, ethoxy-methyl-, methylcarbonyl-oxy-methyl-,dimethylamino-, methylamino-methyl-, methylamino-carbonyl- andmethylcarbonyl-amino.

In another embodiment, the present invention is directed to compounds offormula (I) wherein R⁴ is selected from the group consisting of methyl,trifluoromethyl, hydroxymethyl-, hydroxyethyl-, methoxy,methoxy-methyl-, ethoxy-methyl-, dimethylamino-, methylamino-carbonyl-and methylcarbonyl-amino. In another embodiment, the present inventionis directed to compounds of formula (I) wherein R⁴ is selected from thegroup consisting of methyl, trifluoromethyl, hydroxymethyl-, methoxy,methoxy-methyl-, ethoxy-methyl-, dimethylamino- andmethylcarbonyl-amino. In another embodiment, the present invention isdirected to compounds of formula (I) wherein R⁴ is selected from thegroup consisting of methyl, trifluoromethyl, hydroxymethyl-,hydroxyethyl-, methoxy, ethoxy-methyl- and methylamino-carbonyl-. Inanother embodiment, the present invention is directed to compounds offormula (I) wherein R⁴ is selected from the group consisting of methyl,hydroxymethyl-, methoxy and ethoxy-methyl-. In another embodiment, thepresent invention is directed to compounds of formula (I) wherein R⁴ isselected from the group consisting of methyl and hydroxymethyl. Inanother embodiment, the present invention is directed to compounds offormula (I) wherein R⁴ is methyl.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, R⁵ is selected from the group consisting of methyl,ethyl, n-propyl, hydroxyethyl-, ethoxycarbonyl-methyl-,aminocarbonyl-methyl-, methylamino-carbonyl-methyl-, morpholinyl-ethyl-and ethoxy-ethyl-.

In another embodiment, the present invention is directed to compounds offormula (I) wherein R⁵ is selected from the group consisting of methyl,ethyl, n-propyl, hydroxyethyl-, ethoxycarbonyl-methyl-,methylamino-carbonyl-methyl- and ethoxy-ethyl-. In another embodiment,the present invention is directed to compounds of formula (I) wherein R⁵is selected from the group consisting of methyl, ethyl, n-propyl,methylamino-carbonyl-methyl- and ethoxy-ethyl-.

In another embodiment, the present invention is directed to compounds offormula (I) wherein R⁵ is selected from the group consisting of methyl,ethyl, hydroxethyl-, ethoxycarbonyl-methyl- andmethylaminocarbonyl-methyl-. In another embodiment, the presentinvention is directed to compounds of formula (I) wherein R⁵ is selectedfrom the group consisting of methyl, hydroxyethyl- andmethylamino-carbonyl-methyl-. In another embodiment, the presentinvention is directed to compounds of formula (I) wherein R⁵ is methyl.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, b is an integer from 0 to 1. In another embodiment,the present invention is directed to compound of formula (I) wherein, bis an integer from 1 to 2. In another embodiment, the present inventionis directed to compound of formula (I) wherein b is 1.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, each R⁶ is independently selected from the groupconsisting of fluoro, methyl, hydroxymethyl, trifluoromethyl,tert-butoxycarbonyl, carboxy and aminocarbonyl. In another embodiment,the present invention is directed to compounds of formula (I) whereineach R⁶ is independently selected from the group consisting of methyl,hydroxymethyl and trifluoromethyl. In another embodiment, the presentinvention is directed to compounds of formula (I) wherein each R⁶ isindependently selected from the group consisting of methyl andhydroxymethyl. In another embodiment, the present invention is directedto compounds of formula (I) wherein R⁶ is hydroxymethyl.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, R^(A) and R^(B) are each independently selectedfrom the group consisting of hydrogen and methyl.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, R^(A) and R^(B) are taken together with thenitrogen atom to which they are bound to form piperidin-1-yl,piperazin-1-yl, morpholin-4-yl and pyrrolidin-1-yl. In anotherembodiment, the present invention is directed to compound of formula (I)wherein, R^(A) and R^(B) are taken together with the nitrogen atom towhich they are bound to form piperidin-1-yl, piperazin-1-yl andmorpholin-4-yl. In another embodiment, the present invention is directedto compound of formula (I) wherein, R^(A) and R^(B) are taken togetherwith the nitrogen atom to which they are bound to form piperidin-1-yl.In another embodiment, the present invention is directed to compound offormula (I) wherein, R^(A) and R^(B) are taken together with thenitrogen atom to which they are bound to form pyrrolidin-1-yl.

In an embodiment, the present invention is directed to compounds offormula (I) wherein, when R¹ is indol-3-yl, then R³ is other than

wherein R⁴ is selected from the group consisting of hydrogen, C₁₋₄alkyl,—C₁₋₂alkyl-OH, C₁₋₄alkoxy and —NR^(A)R^(B). In another embodiment, thepresent invention is directed to compounds of formula (I) wherein, whenR¹ is

then R³ is other than

In another embodiment, the present invention is directed to compounds offormula (I) wherein R¹ is other than

In another embodiment, the present invention is directed to compounds offormula (I) wherein R¹ is other than

In another embodiment, the present invention is directed to compounds offormula (I) wherein R³ is other than

wherein R⁴ is C₁₋₄alkyl. In another embodiment, the present invention isdirected to compounds of formula (I) wherein R³ is other than

wherein R⁴ is selected from the group consisting of hydrogen, C₁₋₄alkyl,—C₁₋₂alkyl-OH, C₁₋₄alkoxy and —NR^(A)R^(B). In another embodiment, thepresent invention is directed to compounds of formula (I) wherein R³ isother than

Additional embodiments of the present invention, include those whereinthe substituents selected for one or more of the variables definedherein (i.e. R¹, R², R³, R⁴, R⁵, R⁶, a, and b) are independentlyselected to be any individual substituent or any subset of substituentsselected from the complete list as defined herein.

In another embodiment of the present invention is any single compound orsubset of compounds selected from the representative compounds listed inTable 1, below. Representative compounds of the present invention are aslisted in Table 1, below. Unless otherwise noted, wherein a stereogeniccenter is present in the listed compound, the compound was prepared as amixture of stereo-configurations. Where a stereogenic center is present,the S*- and R* designations are intended to indicate that the exactstereo-configuration of the center has not been determined.

TABLE 1 Representative Compounds of Formula (I)

ID No. R¹ R³ 1 indolin-1-yl 4-methyl-imidazol-1-yl 35-fluoro-benzo[d]isoxazol-3-yl 1-methyl-pyrazol-4-yl 46-fluoro-indolin-1-yl 4-methyl-imidazol-1-yl 55-fluoro-benzo[d]isoxazol-3-yl 3-methyl-1,2,4-thiadiazol-5-yl 6indol-1-yl 3-methyl-1,2,4-thiadiazol-5-yl 7 indolin-1-yl3-methyl-1,2,4-thiadiazol-5-yl 8 5-fluoro-benzo[d]isoxazol-3-ylpyrid-3-yl 9 indol-1-yl 1-methyl-pyrazol-4-yl 10 indolin-1-yl1-methyl-pyrazol-4-yl 11 6-fluoro-indolin-1-yl 1-methyl-pyrazol-4-yl 126-fluoro-indolin-1-yl 3-methyl-1,2,4-thiadiazol-5-yl 135-fluoro-benzo[d]isoxazol-3-yl 1-ethyl-pyrazol-4-yl 156-fluoro-indolin-1-yl 4-(hydroxymethyl)-imidazol- 1-yl 166-fluoro-indolin-1-yl 4-methyl-pyrazol-1-yl 185-fluoro-benzo[d]isoxazol-3-yl 5-methyl-1,3,4-oxadiazol-2-yl 195-fluoro-benzo[d]isoxazol-3-yl 5-(methylcarbonyl-oxy-methyl)-1,3,4-oxadiazol-2-yl 20 5-fluoro-benzo[d]isoxazol-3-yl5-(hydroxymethyl)-1,3,4- oxadiazol-2-yl 21 6-fluoro-indolin-1-yl1-ethyl-pyrazol-4-yl 22 6-fluoro-indolin-1-yl 4-(hydroxymethyl)-pyrazol-1-yl 23 5-fluoro-benzo[d]isoxazol-3-yl 4-methyl-thiazol-2-yl 245-fluoro-benzo[d]isoxazol-3-yl 6-methyl-pyrid-3-yl 255-fluoro-benzo[d]isoxazol-3-yl 2-methyl-pyrid-4-yl 265-fluoro-benzo[d]isoxazol-3-yl 1H-pyrazol-4-yl 275-fluoro-benzo[d]isoxazol-3-yl 4-methyl-thien-2-yl 285-fluoro-benzo[d]isoxazol-3-yl 5-methyl-thiazol-2-yl 296-fluoro-indolin-1-yl 4-methyl-thiazol-2-yl 30 6-fluoro-indolin-1-yl6-methyl-pyrid-3-yl 31 6-fluoro-indolin-1-yl 5-methyl-thiazol-2-yl 325-fluoro-benzo[d]isoxazol-3-yl 4-methyl-phenyl 335-fluoro-benzo[d]isoxazol-3-yl 6-methoxy-pyrid-3-yl 345-fluoro-benzo[d]isoxazol-3-yl 2-methoxy-pyrimidin-5-yl 355-fluoro-benzo[d]isoxazol-3-yl 6-(hydroxymethyl)-pyrid-3-yl 366-fluoro-indolin-1-yl 4-methyl-phenyl 37 6-fluoro-indolin-1-yl6-methoxy-pyrid-3-yl 38 6-fluoro-indolin-1-yl 2-methoxy-pyrimidin-5-yl39 6-fluoro-indolin-1-yl 6-(hydroxymethyl)-pyrid-3-yl 40 1H-indazol-1-yl1-methyl-pyrazol-4-yl 41 2-(trifluoromethyl)-1H- 1-methyl-pyrazol-4-ylbenzo[d]imidazol-1-yl 42 6-fluoro-indolin-1-yl6-(methylamino)-pyrazol-3-yl 43 6-fluoro-indolin-1-yl4-(hydroxyehtyl)-pyrazol-1-yl 44 6-fluoro-indolin-1-yl6-(dimethylamino)-pyrid-3-yl 45 6-fluoro-indolin-1-yl6-(methylcarbonyl-amino)- pyrid-3-yl 46 6-fluoro-indolin-1-yl1-methyl-pyrazol-4-yl 47 6-fluoro-1H-indolin-1-yl 1-methyl-pyrazol-4-yl48 1H-benzo[d][1,2,3]-triazol-1-yl 1-methyl-pyrazol-4-yl 496-fluoro-indolin-1-yl 1-(hydroxyethyl)-pyrazol 4-yl 506-fluoro-indolin-1-yl 1-(ethoxycarbonyl-methyl)- pyrazol-4-yl 516-fluoro-indolin-1-yl 4-(hydroxymethyl)-phenyl 52 6-fluoro-indolin-1-yl5-methyl-thien-2-yl 53 6-fluoro-indolin-1-yl 4-fluoro-phenyl 546-fluoro-indolin-1-yl 4-(trifluoromethyl)-phenyl 556-fluoro-indolin-1-yl 4-(tert-butoxy-carbonyl)- phenyl 566-fluoro-indolin-1-yl 4-(aminocarbonyl)-phenyl 57 6-methyl-indolin-1-yl1-methyl-pyrazol-4-yl 58 6-fluoro-indolin-1-yl 4-(carboxy)-phenyl 596-chloro-indolin-1-yl 1-methyl-pyrazol-4-yl 606-trifluoromethyl-indolin-1-yl 1-methyl-pyrazol-4-yl 614-chloro-1H-indazol-1-yl 1-methyl-pyrazol-4-yl 62 6-methoxy-indolin-1-yl1-methyl-pyrazol-4-yl 63 6-fluoro-indolin-1-yl 1-methyl-pyrazol-4-yl 646-fluoro-indolin-1-yl 1-(methylamino-carbonyl- methyl)-pyrazol-4-yl 655-chloro-indolin-1-yl 1-methyl-pyrazol-4-yl 66 4-fluoro-indolin-1-yl1-methyl-pyrazol-4-yl 67 4-chloro-indolin-1-yl 1-methyl-pyrazol-4-yl 684,6-dichloro-indolin-1-yl 1-methyl-pyrazol-4-yl 69 6-fluoro-indolin-1-yl1-(aminocarbonyl-methyl)- pyrazol-4-yl 70 4-fluoro-1H-indolin-1-yl1-methyl-pyrazol-4-yl 71 6-fluoro-indolin-1-yl 1-(morpholin-4-yl-ethyl)-pyrazol-4-yl 72 6-fluoro-indolin-1-yl 4-(ethoxy-ethyl)-pyrazol-1-yl 735-fluoro-1H-indazol-1-yl 1-methyl-pyrazol-4-yl 746-chloro-1H-indazol-1-yl 1-methyl-pyrazol-4-yl 755-fluoro-benzo[d]isoxazol-3-yl 1-(ethoxy-ethyl)-pyrazol-4-yl 766-fluoro-indolin-1-yl 6-(trifluoromethyl)-pyrid-3-yl 776-fluoro-indolin-1-yl 1H-pyrazol-4-yl 78 6-fluoro-indolin-1-yl1-(ethoxy-ethyl)-pyrazol-4-yl 79 6-fluoro-indolin-1-yl1-(n-propyl)-pyrazol-4-yl 80 4-trifluoromethyl-1H-indazol-1-methyl-pyrazol-4-yl 1-yl 81 6-trifluoromethyl-1H-indazol-1-methyl-pyrazol-4-yl 1-yl 82 6-fluoro-1H-indazol-1-yl1-(hydroxyethyl)-pyrazol-4-yl 83 3-chloro-1H-indazol-1-yl1-methyl-pyrazol-4-yl 84 5-fluoro-benzo[d]isoxazol-3-yl imidazol-1-yl 855-fluoro-benzo[d]isoxazol-3-yl 4-methyl-imidazol-1-yl 875-fluoro-benzo[d]isoxazol-3-yl pyrazol-1-yl 88 indol-1-yl4-methyl-imidazol-1-yl 89 6-fluoro-benzo[d]isoxazol-3-yl4-methyl-imidazol-1-yl 90 1,2,3,4-tetrahydroquinolin-1-yl4-methyl-imidazol-1-yl 91 5-fluoro-benzo[d]isoxazol-3-yl4-(hydroxymethyl)-imidazol- 1-yl 92 5-fluoro-benzo[d]isoxazol-3-yl3-methyl-pyrazol-1-yl 93 5-fluoro-benzo[d]isoxazol-3-yl2-methyl-imidazol-1-yl 94 5-fluoro-benzo[d]isoxazol-3-yl4-methyl-pyrazol-1-yl 95 5-fluoro-benzo[d]isoxazol-3-yl4-(hydroxymethyl)-pyrazol- 1-yl 96 5-fluoro-benzo[d]isoxazol-3-yl4-(methoxy-methyl)-pyrazol- 1-yl 97 5-fluoro-benzo[d]isoxazol-3-yl4-(methylamino-methyl)- pyrazol-1-yl 98 5-fluoro-benzo[d]isoxazol-3-yl4-(hydroxyethyl)-pyrazol-1-yl

Table 2 below, lists representative intermediates in the synthesis ofthe compounds of formula (I) of the present invention.

TABLE 2 Intermediates in Synthesis of Compounds of Formula (I)

ID No R¹ R⁰ I1 5-fluoro-benzo[d]isoxazol-3-yl —C(O)—NH—NH₂ I25-fluoro-benzo[d]isoxazol-3-yl —C(O)—NH—NH—C(O)—CH₃

As used herein, “halogen” shall mean chlorine, bromine, fluorine andiodine.

As used herein, the term “alkyl” whether used alone or as part of asubstituent group, include straight and branched chains. For example,alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl,isobutyl, sec-butyl, tert-butyl, pentyl and the like. Similarly, theterm “C_(X-Y)alkyl”, wherein X and Y are each integers shall includestraight and branched chains containing between X and Y carbon atoms.For example, “C₁₋₄alkyl” shall mean straight and branched chains between1 and 4 carbon atoms and include methyl, ethyl, propyl, isopropyl,butyl, isobutyl, sec-butyl and t-butyl. One skilled in the art willrecognize that the term “—(C₁₋₄alkyl)-” shall denote any C₁₋₄alkylcarbon chain as herein defined, wherein said C₁₋₄alkyl chain is divalentand is further bound through two points of attachment, preferablythrough two terminal carbon atoms.

As used herein, unless otherwise noted, the term “halogenated C₁₋₄alkyl”shall mean any C₁₋₄alkyl group as defined above substituted with atleast one halogen atom, preferably substituted with a least one fluoroatom. Suitable examples include but are not limited to —CH₂F, —CF₃,—CH₂Cl, —CCl₃, —CH₂—CF₃, —CH₂—CCl₃, —CF₂—CF₂—CF₂—CF₃, and the like.Similarly, the term “fluorinated C₁₋₄alkyl” shall mean any C₁₋₄alkylgroup as defined above substituted with at least one fluoro atom.Suitable examples include but are not limited to —CH₂F, —CHF₂, —CF₃,—CH₂—CF₃, —CF₂—CF₂—CF₂—CF₃, and the like.

As used herein, unless otherwise noted, “alkoxy” shall denote an oxygenether radical of the above described straight or branched chain alkylgroups. For example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy,n-hexyloxy and the like. Similarly, the term “C_(X-Y)alkoxy”, wherein Xand Y are each integers shall include oxygen ether radicals of straightor branched chain alkyl groups containing between X and Y carbon atoms.For example, “C₁₋₄alkoxy” shall mean straight and branched chainsbetween 1 and 4 carbon atoms and include methoxy, ethoxy, n-propoxy,isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy.

When a particular group is “substituted”, that group may have one ormore substituents, preferably from one to five substituents, morepreferably from one to three substituents, most preferably from one totwo substituents, independently selected from the list of substituents.With reference to substituents, the term “independently” means that whenmore than one of such substituents is possible, such substituents may bethe same or different from each other.

As used herein, the notation “*” shall denote the presence of astereogenic center.

Where the compounds according to this invention have at least one chiralcenter, they may accordingly exist as enantiomers. Where the compoundspossess two or more chiral centers, they may additionally exist asdiastereomers. It is to be understood that all such isomers and mixturesthereof are encompassed within the scope of the present invention.Preferably, wherein the compound is present as an enantiomer, theenantiomer is present at an enantiomeric excess of greater than or equalto about 80%, more preferably, at an enantiomeric excess of greater thanor equal to about 90%, more preferably still, at an enantiomeric excessof greater than or equal to about 95%, more preferably still, at anenantiomeric excess of greater than or equal to about 98%, mostpreferably, at an enantiomeric excess of greater than or equal to about99%. Similarly, wherein the compound is present as a diastereomer, thediastereomer is present at an diastereomeric excess of greater than orequal to about 80%, more preferably, at an diastereomeric excess ofgreater than or equal to about 90%, more preferably still, at andiastereomeric excess of greater than or equal to about 95%, morepreferably still, at an diastereomeric excess of greater than or equalto about 98%, most preferably, at an diastereomeric excess of greaterthan or equal to about 99%.

Furthermore, some of the crystalline forms for the compounds of thepresent invention may exist as polymorphs and as such are intended to beincluded in the present invention. In addition, some of the compounds ofthe present invention may form solvates with water (i.e., hydrates) orcommon organic solvents, and such solvates are also intended to beencompassed within the scope of this invention.

Under standard nomenclature used throughout this disclosure, theterminal portion of the designated side chain is described first,followed by the adjacent functionality toward the point of attachment.Thus, for example, a “phenylC₁-C₆alkylaminocarbonylC₁-C₆alkyl”substituent refers to a group of the formula

Abbreviations used in the specification, particularly the Schemes andExamples, are as follows:

aq. = Aqueous ATP = Adenosine Triphosphate Boc or tert-Boc =Tert-Butoxycarbonyl BSA = Bovine Serum Albumin CBz = Carboxybenzyl (i.e.—C(O)—CH₂-phenyl) CoA = Coenzyme-A DCE = Dichloroethane DCM =Dichloromethane DDQ = 2,3-dichloro-5,6-dicyanobenzoquinone DIPEA or DIEA= Diisopropylethylamine or (i-Pr)₂Net DMEM = Dulbecco's Modified EagleMedium DMF = N,N-Dimethylformamide DMSO = Dimethylsulfoxide EDTA =Ethylene Diamine Tetraacetic Acid Et₃N = Triethylamine Et₂O = Diethylether EtOAc = Ethyl acetate EtOH = Ethanol FBS = Fetal Bovine Serum HBSS= Hanks' Buffered Salt Solution HPLC = High Pressure LiquidChromatography HPMC = Hydroxypropyl Methylcellulose LiHMDS = Lithiumbis(trimethylsilyl)amide MeOH = Methanol Mesyl = MethylsulfonylNaBH(OAc)₃ = Sodium triacetoxyborohydride β-NADH =beta-Nicotinamide-Adenine Dinucleotide (reduced) NaHMDS = Sodiumbis(trimethylsilyl)amide NASH = Non-Alcoholic Steatohepatitis PBS =Phosphate Buffered Saline Pd₂(dppf)Cl₂ =1,1′-Bis(diphenylphosphino)ferrocene- palladium(II)dichloride Pd(PPh₃)₄= Tetrakistriphenylphosphine palladium (0) Pd(PPh₃)₂Cl₂ =Bis(triphenylphosphine)palladium (II) chloride RLM = Rat LiverMicrosomes SCD1 = Stearoyl-CoA Desaturase 1 Sn(n-butyl)₃ = Tri(n-butyl)Tin TEA = Triethylamine TFA = Trifluoroacetic Acid THF = TetrahydrofuranTLC = Thin Layer Chromatography TMSI = Iodotrimethylsilane Tosyl =p-Toluenesulfonyl Tris HCl or Tris-Cl = Tris[hydroxymethyl]aminomethylhydrochloride p-TSA = para-Toluene Sulfonic Acid

As used herein, unless otherwise noted, the term “isolated form” shallmean that the compound is present in a form which is separate from anysolid mixture with another compound(s), solvent system or biologicalenvironment. In an embodiment of the present invention, the compound offormula (I) is present in an isolated form.

As used herein, unless otherwise noted, the term “substantially pureform” shall mean that the mole percent of impurities in the isolatedcompound is less than about 5 mole percent, preferably less than about 2mole percent, more preferably, less than about 0.5 mole percent, mostpreferably, less than about 0.1 mole percent. In an embodiment of thepresent invention, the compound of formula (I) is present as asubstantially pure form.

As used herein, unless otherwise noted, the term “substantially free ofa corresponding salt form(s)” when used to described the compound offormula (I) shall mean that mole percent of the corresponding saltform(s) in the isolated base of formula (I) is less than about 5 molepercent, preferably less than about 2 mole percent, more preferably,less than about 0.5 mole percent, most preferably less than about 0.1mole percent. In an embodiment of the present invention, the compound offormula (I) is present in a form which is substantially free ofcorresponding salt form(s).

As used herein, unless otherwise noted, the term “SCD1 disorder” shallinclude obesity, type-II diabetes, Syndrome X (also known as metabolicsyndrome), hypertriglyceridemia, dyslipidemia, NASH (Non-AlcoholicSteatohepatitis), hypercholesterolemia, hyperlipidemia, mixeddyslipidemia, fatty liver, nonalcoholic fatty liver disease and liverfibrosis. Preferably, the SCD1 disorders is obesity or type-II diabetes,more preferably type-II diabetes.

As used herein, unless otherwise noted, the terms “treating”,“treatment” and the like, shall include the management and care of asubject or patient (preferably mammal, more preferably human) for thepurpose of combating a disease, condition, or disorder and includes theadministration of a compound of the present invention to prevent theonset of the symptoms or complications, alleviate the symptoms orcomplications, or eliminate the disease, condition, or disorder.

As used herein, unless otherwise noted, the term “prevention” shallinclude (a) reduction in the frequency of one or more symptoms; (b)reduction in the severity of one or more symptoms; (c) the delay oravoidance of the development of additional symptoms; and/or (d) delay oravoidance of the development of the disorder or condition.

One skilled in the art will recognize that wherein the present inventionis directed to methods of prevention, a subject in need of thereof (i.e.a subject in need of prevention) shall include any subject or patient(preferably a mammal, more preferably a human) who has experienced orexhibited at least one symptom of the disorder, disease or condition tobe prevented. Further, a subject in need thereof may additionally be asubject (preferably a mammal, more preferably a human) who has notexhibited any symptoms of the disorder, disease or condition to beprevented, but who has been deemed by a physician, clinician or othermedical profession to be at risk of developing said disorder, disease orcondition. For example, the subject may be deemed at risk of developinga disorder, disease or condition (and therefore in need of prevention orpreventive treatment) as a consequence of the subject's medical history,including, but not limited to, family history, pre-disposition,co-existing (comorbid) disorders or conditions, genetic testing, and thelike.

The term “subject” as used herein, refers to an animal, preferably amammal, most preferably a human, who has been the object of treatment,observation or experiment. Preferably, the subject has experiencedand/or exhibited at least one symptom of the disease or disorder to betreated and/or prevented.

The term “therapeutically effective amount” as used herein, means thatamount of active compound or pharmaceutical agent that elicits thebiological or medicinal response in a tissue system, animal or humanthat is being sought by a researcher, veterinarian, medical doctor orother clinician, which includes alleviation of the symptoms of thedisease or disorder being treated.

As used herein, the term “composition” is intended to encompass aproduct comprising the specified ingredients in the specified amounts,as well as any product which results, directly or indirectly, fromcombinations of the specified ingredients in the specified amounts.

As more extensively provided in this written description, terms such as“reacting” and “reacted” are used herein in reference to a chemicalentity that is any one of: (a) the actually recited form of suchchemical entity, and (b) any of the forms of such chemical entity in themedium in which the compound is being considered when named.

One skilled in the art will recognize that, where not otherwisespecified, the reaction step(s) is performed under suitable conditions,according to known methods, to provide the desired product. One skilledin the art will further recognize that, in the specification and claimsas presented herein, wherein a reagent or reagent class/type (e.g. base,solvent, etc.) is recited in more than one step of a process, theindividual reagents are independently selected for each reaction stepand may be the same of different from each other. For example whereintwo steps of a process recite an organic or inorganic base as a reagent,the organic or inorganic base selected for the first step may be thesame or different than the organic or inorganic base of the second step.Further, one skilled in the art will recognize that wherein a reactionstep of the present invention may be carried out in a variety ofsolvents or solvent systems, said reaction step may also be carried outin a mixture of the suitable solvents or solvent systems. One skilled inthe art will further recognize that wherein two consecutive reaction orprocess steps are run without isolation of the intermediate product(i.e. the product of the first of the two consecutive reaction orprocess steps), then the first and second reaction or process steps maybe run in the same solvent or solvent system; or alternatively may berun in different solvents or solvent systems following solvent exchange,which may be completed according to known methods.

To provide a more concise description, some of the quantitativeexpressions given herein are not qualified with the term “about”. It isunderstood that whether the term “about” is used explicitly or not,every quantity given herein is meant to refer to the actual given value,and it is also meant to refer to the approximation to such given valuethat would reasonably be inferred based on the ordinary skill in theart, including approximations due to the experimental and/or measurementconditions for such given value.

To provide a more concise description, some of the quantitativeexpressions herein are recited as a range from about amount X to aboutamount Y. It is understood that wherein a range is recited, the range isnot limited to the recited upper and lower bounds, but rather includesthe full range from about amount X through about amount Y, or any amountor range therein.

Examples of suitable solvents, bases, reaction temperatures, and otherreaction parameters and components are provided in the detaileddescriptions which follows herein. One skilled in the art will recognizethat the listing of said examples is not intended, and should not beconstrued, as limiting in any way the invention set forth in the claimswhich follow thereafter. One skilled in the art will further recognizethat wherein a reaction step of the present invention may be carried outin a variety of solvents or solvent systems, said reaction step may alsobe carried out in a mixture of the suitable solvents or solvent systems.

As used herein, unless otherwise noted, the term “leaving group” shallmean a charged or uncharged atom or group which departs during asubstitution or displacement reaction. Suitable examples include, butare not limited to, Br, Cl, I, mesylate, tosylate, and the like.

During any of the processes for preparation of the compounds of thepresent invention, it may be necessary and/or desirable to protectsensitive or reactive groups on any of the molecules concerned. This maybe achieved by means of conventional protecting groups, such as thosedescribed in Protective Groups in Organic Chemistry, ed. J. F. W.McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, ProtectiveGroups in Organic Synthesis, John Wiley & Sons, 1991. The protectinggroups may be removed at a convenient subsequent stage using methodsknown from the art.

As used herein, unless otherwise noted, the term “nitrogen protectinggroup” shall mean a group which may be attached to a nitrogen atom toprotect said nitrogen atom from participating in a reaction and whichmay be readily removed following the reaction. Suitable nitrogenprotecting groups include, but are not limited to carbamates—groups ofthe formula —C(O)O—R wherein R is for example methyl, ethyl, t-butyl,benzyl, phenylethyl, CH₂═CH—CH₂—, and the like; amides—groups of theformula —C(O)—R′ wherein R′ is for example methyl, phenyl,trifluoromethyl, and the like; N-sulfonyl derivatives—groups of theformula —SO₂—R″ wherein R″ is for example tolyl, phenyl,trifluoromethyl, 2,2,5,7,8-pentamethylchroman-6-yl-,2,3,6-trimethyl-4-methoxybenzene, and the like. Other suitable nitrogenprotecting groups may be found in texts such as T.W. Greene & P.G.M.Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.

Where the processes for the preparation of the compounds according tothe invention give rise to mixture of stereoisomers, these isomers maybe separated by conventional techniques such as preparativechromatography. The compounds may be prepared in racemic form, orindividual enantiomers may be prepared either by enantiospecificsynthesis or by resolution. The compounds may, for example, be resolvedinto their component enantiomers by standard techniques, such as theformation of diastereomeric pairs by salt formation with an opticallyactive acid, such as (−)-di-p-toluoyl-D-tartaric acid and/or(+)-di-p-toluoyl-L-tartaric acid followed by fractional crystallizationand regeneration of the free base. The compounds may also be resolved byformation of diastereomeric esters or amides, followed bychromatographic separation and removal of the chiral auxiliary.Alternatively, the compounds may be resolved using a chiral HPLC column.

Additionally, chiral HPLC against a standard may be used to determinepercent enantiomeric excess (% ee). The enantiomeric excess may becalculated as follows[(Rmoles−Smoles)/(Rmoles+Smoles)]×100%

where Rmoles and Smoles are the R and S mole fractions in The resultingmixture such that Rmoles+Smoles=1. The enantiomeric excess mayalternatively be calculated from the specific rotations of the desiredenantiomer and the prepared mixture as follows:ee=([α−obs]/[α−max])×100.

The present invention includes within its scope prodrugs of thecompounds of this invention. In general, such prodrugs will befunctional derivatives of the compounds which are readily convertible invivo into the required compound. Thus, in the methods of treatment ofthe present invention, the term “administering” shall encompass thetreatment of the various disorders described with the compoundspecifically disclosed or with a compound which may not be specificallydisclosed, but which converts to the specified compound in vivo afteradministration to the patient. Conventional procedures for the selectionand preparation of suitable prodrug derivatives are described, forexample, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.

For use in medicine, the salts of the compounds of this invention referto non-toxic “pharmaceutically acceptable salts.” Other salts may,however, be useful in the preparation of compounds according to thisinvention or of their pharmaceutically acceptable salts. Suitablepharmaceutically acceptable salts of the compounds include acid additionsalts which may, for example, be formed by mixing a solution of thecompound with a solution of a pharmaceutically acceptable acid such ashydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinicacid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonicacid or phosphoric acid. Furthermore, where the compounds of theinvention carry an acidic moiety, suitable pharmaceutically acceptablesalts thereof may include alkali metal salts, e.g., sodium or potassiumsalts; alkaline earth metal salts, e.g., calcium or magnesium salts; andsalts formed with suitable organic ligands, e.g., quaternary ammoniumsalts. Thus, representative pharmaceutically acceptable salts include,but are not limited to, the following: acetate, benzenesulfonate,benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calciumedetate, camsylate, carbonate, chloride, clavulanate, citrate,dihydrochloride, edetate, edisylate, estolate, esylate, fumarate,gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate,hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide,isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate,mesylate, methylbromide, methylnitrate, methylsulfate, mucate,napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate(embonate), palmitate, pantothenate, phosphate/diphosphate,polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate,tannate, tartrate, teoclate, tosylate, triethiodide and valerate.

Representative acids which may be used in the preparation ofpharmaceutically acceptable salts include, but are not limited to, thefollowing: acids including acetic acid, 2,2-dichloroacetic acid,acylated amino acids, adipic acid, alginic acid, ascorbic acid,L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoicacid, (+)-camphoric acid, camphorsulfonic acid,(+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylicacid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid,ethane-1,2-disulfonic acid, ethanesulfonic acid,2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaricacid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronicacid, L-glutamic acid, α-oxo-glutaric acid, glycolic acid, hipuric acid,hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, (±)-DL-lacticacid, lactobionic acid, maleic acid, (−)-L-malic acid, malonic acid,(±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid,naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotincacid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid,pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid,4-amino-salicylic acid, sebaic acid, stearic acid, succinic acid,sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid,p-toluenesulfonic acid and undecylenic acid.

Representative bases which may be used in the preparation ofpharmaceutically acceptable salts include, but are not limited to, thefollowing: bases including ammonia, L-arginine, benethamine, benzathine,calcium hydroxide, choline, deanol, diethanolamine, diethylamine,2-(diethylamino)-ethanol, ethanolamine, ethylenediamine,N-methyl-glucamine, hydrabamine, 1H-imidazole, L-lysine, magnesiumhydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassiumhydroxide, 1-(2-hydroxyethyl)-pyrrolidine, secondary amine, sodiumhydroxide, triethanolamine, tromethamine and zinc hydroxide.

General Synthetic Methods

Compounds of formula (I) may be prepared according to the processoutlined in Scheme 1, below.

Accordingly, a suitably substituted compound of formula (V), a knowncompound or compound prepared by known methods, is reacted with asuitably substituted compound of formula (VI), wherein LG¹ and LG² aresuitably selected leaving groups, such as chloro, bromo, iodo, and thelike, preferably chloro, preferably LG¹ and LG² are the same, and areeach chloro (i.e. 3,6-dichloropyradizine, a known compound); in thepresence of a suitably selected organic base such as TEA, DIPEA,pyridine, and the like; in a suitably selected organic solvent such asDMSO, DMF, acetonitrile, and the like; under microwave heating or underthermal heating to about 200° C.; to yield the corresponding compound offormula (VII).

The compound of formula (VII) is reacted with a suitably selectedcompound of formula (VIII), wherein Q is

—B(OH₂), or —Sn(n-butyl)₃, a known compound or compound prepared byknown methods; to yield the corresponding compound of formula (I).

Wherein the compound of formula (VIII), Q is

or —B(OH₂), the compound of formula (VII) is reacted with the compoundof formula (VIII) under Suzuki coupling conditions, more particularly inthe presence of a suitably selected palladium catalyst such asPd(PPh₃)₄, Pd(PPh₃)₂Cl₂, Pd(dppf)Cl₂, and the like; in the presence of asuitably selected base such as K₂CO₃, Cs₂CO₃, Na₂CO₃, NaOH_((aq)), andthe like; in a suitably selected solvent such as aqueous 1,4-dioxane,ethanol, toluene, and the like.

Similarly, wherein the compound of formula (VIII), Q is —Sn(n-butyl)₃,the compound of formula (VII) is reacted with the compound of formula(VIII) under Stille coupling conditions, more particularly in thepresence of a suitably selected palladium catalyst such as Pd(PPh₃)₄,Pd(PPh₃)₂Cl₂, Pd(dppf)Cl₂, and the like; in a suitably selected solventsuch as aqueous 1,4-dioxane, ethanol, DMF, toluene, and the like; undermicrowave heating.

Compounds of formula (I) wherein R¹ is selected from the groupconsisting of

may alternatively be prepared according to the process outlined inScheme 2, below.

Accordingly, 1,4-dioxa-8-azaspiro[4.5]decane, a known compound orcompound prepared by known methods, is reacted with a suitablysubstituted compound of formula (VI), wherein LG¹ and LG² are suitablyselected leaving groups, such as chloro, bromo, iodo, and the like,preferably chloro, preferably LG¹ and LG² are the same, and are eachchloro (i.e. 3,6-dichloropyradizine, a known compound); in the presenceof a suitably selected organic base such as DIPEA, TEA, pyridine, andthe like; in a suitably selected organic solvent such as DMSO, DMF, andthe like; to yield the corresponding compound of formula (IX).

The compound of formula (IX) is reacted with a suitably substitutedcompound of formula (VIII), wherein Q is

or —B(OH₂), a known compound or compound prepared by known methods;under Suzuki coupling conditions, more particularly in the presence of asuitably selected palladium catalyst such as Pd(PPh₃)₄, Pd(PPh₃)₂Cl₂,Pd(dppf)Cl₂, and the like; in the presence of a suitably selected basesuch as K₂CO₃, Cs₂CO₃, Na₂CO₃, NaOH_((aq)), and the like; in a suitablyselected solvent such as aqueous 1,4-dioxane, ethanol, toluene, and thelike; to yield the corresponding compound of formula (X).

The compound of formula (X) is reacted with a suitably selected acidsuch as p-TSA, HCl, and the like; in a suitably selected solvent such asaqueous acetone, 2-butanone, and the like; to yield the correspondingcompound of formula (XI).

The compound of formula (XI) is reacted with a suitably selectedcompound of formula (XIIa) (a compound of formula (XII)R¹—H  (XII)

wherein the R¹ group contains a terminal nucleophillic nitrogen—i.e. R¹is other than

a known compound or compound prepared by known methods; in the presenceof a suitably selected reducing agent such as NaBH(OAc)₃, NaBH₃CN, andthe like; in a suitably selected organic solvent such as DCM, DCE, THF,and the like; to yield the corresponding compound of formula (Ia).

Compounds of formula (I) may alternatively be prepared according to theprocess outlined in Scheme 3, below.

Accordingly, a suitably substituted compound of formula (V), a knowncompound or compound prepared by known methods, is reacted with asuitably substituted compound of formula (XIII), wherein LG1 is asuitably selected leaving group, such as chloro, bromo, iodo, and thelike, preferably chloro, a known compound or compound prepared by knownmethods; in the presence of a suitably selected organic base such asTEA, DIPEA, pyridine, and the like; in a suitably selected organicsolvent such as DMSO, DMF, acetonitrile, and the like; under microwaveheating or under thermal heating to about 200° C.; to yield thecorresponding compound of formula (I).

Compounds of formula (I) wherein R³ is selected from the groupconsisting of

may alternatively be prepared according to the process outlined inScheme 4, below.

Accordingly, a suitably substituted compound of formula (VI), whereinLG¹ and LG² are suitably selected leaving groups, such as chloro, bromo,iodo, and the like, preferably chloro, preferably LG¹ and LG² are thesame, and are each chloro (i.e. 3,6-dichloropyradizine, a knowncompound) is reacted with a compound of formula (XIV), wherein X is Nand Y is C or X is C and Y is N, a known compound or compound preparedby known methods; in the presence of a suitably selected inorganic basesuch as Cs₂CO₃, K₂CO₃, Na₂CO₃, and the like; in a suitably selectedorganic solvent such as acetonitrile, DMSO, DMF, and the like; to yieldthe corresponding compound of formula (XIIIa) (a compound of formula(XIII) wherein R³ is selected from the group consisting of

The compound of formula (XIIa) is reacted with a suitably substitutedcompound of formula (V), a known compound or compound prepared by knownmethods, in the presence of a suitably selected organic base such asTEA, DIPEA, pyridine, and the like; in a suitably selected organicsolvent such as DMSO, DMF, and the like; to yield the correspondingcompound of formula (Ib).

Compounds of formula (V) wherein R¹ is selected from the groupconsisting of

are known compounds or compounds which may be prepared according toknown methods, for example, as outlined in Scheme 5, below.

Accordingly, a suitably substituted compound of formula (XIIa) (acompound of formula (XII) wherein the R¹ group contains a terminalnucleophillic nitrogen—i.e. R¹ is other than

a known compound or compound prepared by known methods, is reacted witha suitably substituted compound of formula (XV), wherein PG¹ is asuitably selected nitrogen protecting group such as Boc, CBz, and thelike, preferably Boc, a known compound or compound prepared by knownmethods; in the presence of a suitably selected hydride source such asNaBH(OAc)₃, NaBH₃CN, and the like, preferably NaBH(OAc)₃; in a suitablyselected organic solvent such as DCM, DCE, THF, and the like; to yieldthe corresponding compound of formula (XVII).

Alternatively, a suitably substituted compound of formula (XIIa) (acompound of formula (XII) wherein the R¹ group contains a terminalnucleophillic nitrogen—i.e. R¹ is other than

a known compound or compound prepared by known methods, is reacted witha suitably substituted compound of formula (XVI), wherein PG¹ is asuitably selected nitrogen protecting group such as Boc, CBz, and thelike, preferably Boc, and wherein LG³ is a suitably selected leavingsuch as —O—SO₂-(p-tolyl), —O—SO₂—CH₃, Br, Cl, I, and the like, a knowncompound or compound prepared by known methods; in the presence of asuitably selected base such as NaH, LiHMDS, NaHDMS, and the like,preferably NaH; in a suitably selected organic solvent such as THF, DMF,and the like; to yield the corresponding compound of formula (XVII).

The compound of formula (XVII) is de-protected according to knownmethods; to yield the corresponding compound of formula (Va). Forexample, wherein PG¹ is Boc, the compound of formula (XVII) may bede-protected by reacting with a suitably selected acid such as HCl, TFA,and the like, in a suitably solvent such as methylene chloride,1,4-dioxane, and the like. For example, wherein PG¹ is CBz, the compoundof formula (XVII) may b de-protected by hydrogenation or by reactingwith TMSI, according to known methods.

Compounds of formula (I) wherein R¹ is

may alternatively be prepared from the corresponding compound of formula(I)wherein R¹ is

as outlined in Scheme 6, below.

Accordingly, a suitably substituted compound of formula (Ic) is reactedwith for example, DDQ, and the like; in a suitably selected organicsolvent such as THF, and the like; according to known methods, to yieldthe corresponding compound of formula (Id) (see for example, Example 12which follows herein).

Compounds of formula (I) wherein R³ is

may alternatively be prepared for example, as described in BONGARTZ,J-P., et al., “Synthesis and Anti-Angiogenic Activity of6-(1,2,4-Thiadiazol-5-yl)-3-amino-pyridazine Derivatives, Bioorg. Med.Chem. Lett., 2002, pp 589-591, Vol. 12(4); PCT Publication WO 98/58929;and/or U.S. Pat. No. 5,985,878.

Compounds of formula (I) wherein R³ is

may alternatively be prepared as described in Scheme 7, below.

Accordingly, a suitably substituted compound of formula (XVIII), whereinLG⁴ is a suitably selected leaving group such as Cl, Br, I, and thelike, preferably chloro, a known compound or compound prepared by knownmethods, is reacted with a suitably selected source of sulfur such asSOCl₂, and the like;

and then reacted with a suitably substituted compound of formula (XIX)(wherein the compound of formula (XIX) is present as its correspondingHCl salt as noted in the scheme above), a known compound or compoundprepared by known methods; in the presence of a suitably selectedaqueous base such as NaOH, KOH, and the like; in a suitably selectedorganic solvent such as DCM, DCE, and the like; to yield thecorresponding compound of formula (XX).

The compound of formula (XX) is reacted with a suitably substitutedcompound of formula (V), a known compound or compound prepared by knownmethods, in the presence of a suitably selected organic base such asTEA, DIPEA, pyridine, and the like; in a suitably selected organicsolvent such as DMSO, DMF, acetonitrile, and the like; under microwaveheating or under thermal heating to about 200° C.; to yield thecorresponding compound of formula (Ie).

Compounds of formula (V) wherein R¹ is

may be prepared as described in Scheme 8, below.

Accordingly, a suitably substituted compound of formula (XIIb), (acompound of formula (XII) wherein the R¹ is

a known compound or compound prepared by known methods, is reacted witha suitably substituted compound of formula (XV), wherein PG¹ is asuitably selected nitrogen protecting group such as Boc, CBz, benzyl,and the like, preferably Boc, a known compound or compound prepared byknown methods; in the presence of a suitably selected organic base suchas KOH, NaOH, and the like; in a suitably selected organic solvent suchas methanol, ethanol, isopropanol, and the like; to yield thecorresponding compound of formula (XXI).

The compound of formula (XXI) is hydrogenated, according to knownmethods, for example in the presence of hydrogen source, such as H₂,ammonium formate, and the like; in the presence of suitably selectedcatalyst, such as Pd/C, Pt/C and the like, preferably Pd/C; in thepresence of suitably selected solvent, such as MeOH, EtOH, and the like;to yield the corresponding compound of formula (XXII).

The compound of formula (XXII) is de-protected according to knownmethods; to yield the corresponding compound of formula (Vb). Forexample, wherein PG¹ is Boc, the compound of formula (XXII) may bede-protected by reacting with a suitably selected acid such as HCl, TFA,and the like, in a suitable solvent such as dichloromethane, and thelike. Alternatively, wherein PG¹ is Cbz or benzyl, the protecting groupmay be de-protected simultaneously during the formation of formula(XXII), under the hydrogenated conditions, as described above.

Compounds of formula (V) wherein R¹ is

may be prepared as described Scheme 9, below.

Accordingly, a suitably substituted compound of formula (XXIII), a knowncompound or compound prepared by known methods, is reacted with asuitably substituted compound of formula (XXIV), wherein LG⁵ is asuitably selected leaving group such as fluoro, bromo, chloro, and thelike and wherein PG^(Z) is a suitably selected nitrogen protecting groupsuch as acetyl, Cbz, benzyl, and the like, preferably acetyl, a knowncompound or compound prepared by known methods; in the presence asuitably selected Lewis acid, such as AlCl₃, and the like; to yield thecorresponding compound of formula (XXV).

The compound of formula (XXV) is reacted with hydroxylamine HCl salt inthe presence of a suitably selected base, such as KOH, NaOH, ammoniumacetate, and the like; in a suitable selected solvent, such as ethanol,methanol, isopropanol, and the like; at a temperature in the range offrom about room temperature to about reflux temperature, preferably atabout 85° C., to yield the corresponding compound of formula (XXVI),which compound is preferably not isolated.

The compound of formula (XXVI) is reacted in the presence of a suitablyselected base, such as KOH, sodium ethoxide, and the like, at atemperature in the range of from about room temperature to about refluxtemperature, to yield the corresponding compound of formula (XXVII).

The compound of formula (XXVII) is de-protected according to knownmethods, to yield the corresponding compound of formula (Vc). Forexample, wherein PG² is Cbz or benzyl, the compound of formula (XXVII)may be de-protected under hydrogenation conditions, according to knownmethods.

Alternatively, wherein PG² is acetyl, the compound of formula (XXVI) maybe reacted to cyclize and remove the protecting group in step, byreacting with a suitably selected base such as KOH, NaOH, and the like,wherein the base is present in an excess amount, at about refluxtemperature, to yield the corresponding compound of formula (Vc).

One skilled in the art will recognize that wherein the R³ group on thecompound of formula (I) is substituted (as defined herein), saidsubstituent group(s) may be present in the reactant compound(s) used inthe synthesis of the compound of formula (I), as described herein (e.g.in the compound of formula (VIII), in the compound of formula (XI),etc.). Alternatively, said substituent group(s) may be incorporated intothe compound of formula (I) by reacting a compound of formula (I)substituted with a precursor group, according to known methods/chemicaltransformation, to convert said precursor group to the desiredsubstituent group. Representative examples of such transformation are asdescribed below.

Compounds of formula (I) wherein the R³ group is substituted with—C₁₋₂alkyl-O—C₁₋₂alkyl may be prepared from the corresponding compoundof formula (I) wherein the R³ group is substituted with —C₁₋₂alkyl-OH byreacting with a suitably selected alkylating agent, according to knownmethods. (See for example, Example 18 which follows herein.)

Compounds of formula (I) wherein the R³ group is substituted with—C₂alkyl-OH may be prepared from the corresponding compound of formula(I) wherein the R³ group is substituted with —C₂alkyl-C(O)O—C₁₋₂alkyl byreacting with a suitably selected reducing agent, such as NaBH₄, and thelike; in a suitably selected organic solvent such as EtOH, and the like,according to known methods. (See for example, Example 21 which followsherein.)

Compounds of formula (I) wherein the R³ group is substituted with—C₁₋₂alkyl-C(O)—NR^(A)R^(B) may be prepared from the correspondingcompound of formula (I) wherein the R³ group is substituted with—C₁₋₂alkyl-C(O)OCH₃ or —C₁₋₂alkyl-C(O)O—CH₂CH₃ by reacting with asuitably substituted amine of formula (NHR^(A)R^(B)), in a suitablyselected organic solvent such as EtOH, and the like, according to knownmethods. (See for example, Example 22 which follows herein.)

Compounds of formula (I) wherein R³

and wherein R⁵ is (C₂₋₃alkyl)-O—(C₁₋₂ alkyl) may be prepared by reactingthe corresponding compound of formula (I) wherein R⁵ is hydrogen with asuitably substituted compound of the formulaLG⁵-(C₂₋₃alkyl)-O—(C₁₋₂alkyl), wherein LG⁵ is a suitably selectedleaving group such as Br, according to known methods. (See for example,Example 23, which follows herein.)

The present invention further comprises pharmaceutical compositionscontaining one or more compounds of formula (I) with a pharmaceuticallyacceptable carrier. Pharmaceutical compositions containing one or moreof the compounds of the invention described herein as the activeingredient can be prepared by intimately mixing the compound orcompounds with a pharmaceutical carrier according to conventionalpharmaceutical compounding techniques. The carrier may take a widevariety of forms depending upon the desired route of administration(e.g., oral, parenteral). Thus for liquid oral preparations such assuspensions, elixirs and solutions, suitable carriers and additivesinclude water, glycols, oils, alcohols, flavoring agents, preservatives,stabilizers, coloring agents and the like; for solid oral preparations,such as powders, capsules and tablets, suitable carriers and additivesinclude starches, sugars, diluents, granulating agents, lubricants,binders, disintegrating agents and the like. Solid oral preparations mayalso be coated with substances such as sugars or be enteric-coated so asto modulate major site of absorption. For parenteral administration, thecarrier will usually consist of sterile water and other ingredients maybe added to increase solubility or preservation. Injectable suspensionsor solutions may also be prepared utilizing aqueous carriers along withappropriate additives.

To prepare the pharmaceutical compositions of this invention, one ormore compounds of the present invention as the active ingredient isintimately admixed with a pharmaceutical carrier according toconventional pharmaceutical compounding techniques, which carrier maytake a wide variety of forms depending of the form of preparationdesired for administration, e.g., oral or parenteral such asintramuscular. In preparing the compositions in oral dosage form, any ofthe usual pharmaceutical media may be employed. Thus, for liquid oralpreparations, such as for example, suspensions, elixirs and solutions,suitable carriers and additives include water, glycols, oils, alcohols,flavoring agents, preservatives, coloring agents and the like; for solidoral preparations such as, for example, powders, capsules, caplets,gelcaps and tablets, suitable carriers and additives include starches,sugars, diluents, granulating agents, lubricants, binders,disintegrating agents and the like. Because of their ease inadministration, tablets and capsules represent the most advantageousoral dosage unit form, in which case solid pharmaceutical carriers areobviously employed. If desired, tablets may be sugar coated or entericcoated by standard techniques. For parenterals, the carrier will usuallycomprise sterile water, through other ingredients, for example, forpurposes such as aiding solubility or for preservation, may be included.Injectable suspensions may also be prepared, in which case appropriateliquid carriers, suspending agents and the like may be employed. Thepharmaceutical compositions herein will contain, per dosage unit, e.g.,tablet, capsule, powder, injection, teaspoonful and the like, an amountof the active ingredient necessary to deliver an effective dose asdescribed above. The pharmaceutical compositions herein will contain,per unit dosage unit, e.g., tablet, capsule, powder, injection,suppository, teaspoonful and the like, of from about 0.01 mg to about1000 mg or any amount or range therein, and may be given at a dosage offrom about 0.01 mg/kg/day to about 300 mg/kg/day, or any amount or rangetherein, preferably from about 0.1 mg/kg/day to about 50 mg/kg/day, orany amount or range therein, preferably from about 0.05 mg/kg/day toabout 15 mg/kg/day, or any amount or range therein. The dosages,however, may be varied depending upon the requirement of the patients,the severity of the condition being treated and the compound beingemployed. The use of either daily administration or post-periodic dosingmay be employed.

Preferably these compositions are in unit dosage forms from such astablets, pills, capsules, powders, granules, sterile parenteralsolutions or suspensions, metered aerosol or liquid sprays, drops,ampoules, autoinjector devices or suppositories; for oral parenteral,intranasal, sublingual or rectal administration, or for administrationby inhalation or insufflation. Alternatively, the composition may bepresented in a form suitable for once-weekly or once-monthlyadministration; for example, an insoluble salt of the active compound,such as the decanoate salt, may be adapted to provide a depotpreparation for intramuscular injection. For preparing solidcompositions such as tablets, the principal active ingredient is mixedwith a pharmaceutical carrier, e.g. conventional tableting ingredientssuch as corn starch, lactose, sucrose, sorbitol, talc, stearic acid,magnesium stearate, dicalcium phosphate or gums, and otherpharmaceutical diluents, e.g. water, to form a solid preformulationcomposition containing a mixture of a compound of the present invention,or a pharmaceutically acceptable salt thereof. This solid preformulationcomposition is then subdivided into unit dosage forms of the typedescribed above containing from about 0.01 mg to about 1,000 mg, or anyamount or range therein, of the active ingredient of the presentinvention. The tablets or pills of the novel composition can be coatedor otherwise compounded to provide a dosage form affording the advantageof prolonged action. For example, the tablet or pill can comprise aninner dosage and an outer dosage component, the latter being in the formof an envelope over the former. The two components can be separated byan enteric layer which serves to resist disintegration in the stomachand permits the inner component to pass intact into the duodenum or tobe delayed in release. A variety of material can be used for suchenteric layers or coatings, such materials including a number ofpolymeric acids with such materials as shellac, cetyl alcohol andcellulose acetate.

The liquid forms in which the novel compositions of the presentinvention may be incorporated for administration orally or by injectioninclude, aqueous solutions, suitably flavoured syrups, aqueous or oilsuspensions, and flavoured emulsions with edible oils such as cottonseedoil, sesame oil, coconut oil or peanut oil, as well as elixirs andsimilar pharmaceutical vehicles. Suitable dispersing or suspendingagents for aqueous suspensions, include synthetic and natural gums suchas tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose,methylcellulose, polyvinyl-pyrrolidone or gelatin.

The method of treating SCD1 disorders described in the present inventionmay also be carried out using a pharmaceutical composition comprisingany of the compounds as defined herein and a pharmaceutically acceptablecarrier. The pharmaceutical composition may contain between about 0.01mg and about 1000 mg of the compound, or any amount or range therein;preferably from about 1.0 mg to about 500 mg of the compound, or anyamount or range therein, and may be constituted into any form suitablefor the mode of administration selected. Carriers include necessary andinert pharmaceutical excipients, including, but not limited to, binders,suspending agents, lubricants, flavorants, sweeteners, preservatives,dyes, and coatings. Compositions suitable for oral administrationinclude solid forms, such as pills, tablets, caplets, capsules (eachincluding immediate release, timed release and sustained releaseformulations), granules, and powders, and liquid forms, such assolutions, syrups, elixers, emulsions, and suspensions. Forms useful forparenteral administration include sterile solutions, emulsions andsuspensions.

Advantageously, compounds of the present invention may be administeredin a single daily dose, or the total daily dosage may be administered individed doses of two, three or four times daily. Furthermore, compoundsfor the present invention can be administered in intranasal form viatopical use of suitable intranasal vehicles, or via transdermal skinpatches well known to those of ordinary skill in that art. To beadministered in the form of a transdermal delivery system, the dosageadministration will, of course, be continuous rather than intermittentthroughout the dosage regimen.

For instance, for oral administration in the form of a tablet orcapsule, the active drug component can be combined with an oral,non-toxic pharmaceutically acceptable inert carrier such as ethanol,glycerol, water and the like. Moreover, when desired or necessary,suitable binders; lubricants, disintegrating agents and coloring agentscan also be incorporated into the mixture. Suitable binders include,without limitation, starch, gelatin, natural sugars such as glucose orbeta-lactose, corn sweeteners, natural and synthetic gums such asacacia, tragacanth or sodium oleate, sodium stearate, magnesiumstearate, sodium benzoate, sodium acetate, sodium chloride and the like.Disintegrators include, without limitation, starch, methyl cellulose,agar, bentonite, xanthan gum and the like.

The liquid forms in suitably flavored suspending or dispersing agentssuch as the synthetic and natural gums, for example, tragacanth, acacia,methylcellulose and the like. For parenteral administration, sterilesuspensions and solutions are desired. Isotonic preparations whichgenerally contain suitable preservatives are employed when intravenousadministration is desired.

To prepare a pharmaceutical composition of the present invention, acompound of formula (I) as the active ingredient is intimately admixedwith a pharmaceutical carrier according to conventional pharmaceuticalcompounding techniques, which carrier may take a wide variety of formsdepending of the form of preparation desired for administration (e.g.oral or parenteral). Suitable pharmaceutically acceptable carriers arewell known in the art. Descriptions of some of these pharmaceuticallyacceptable carriers may be found in The Handbook of PharmaceuticalExcipients, published by the American Pharmaceutical Association and thePharmaceutical Society of Great Britain.

Methods of formulating pharmaceutical compositions have been describedin numerous publications such as Pharmaceutical Dosage Forms: Tablets,Second Edition, Revised and Expanded, Volumes 1-3, edited by Liebermanet al; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2,edited by Avis et al; and Pharmaceutical Dosage Forms: Disperse Systems,Volumes 1-2, edited by Lieberman et al; published by Marcel Dekker, Inc.

Compounds of this invention may be administered in any of the foregoingcompositions and according to dosage regimens established in the artwhenever treatment of SCD1 disorders is required.

The daily dosage of the products may be varied over a wide range fromabout 0.01 mg to about 1,000 mg per adult human per day, or any amountor range therein. For oral administration, the compositions arepreferably provided in the form of tablets containing, 0.01, 0.05, 0.1,0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500milligrams of the active ingredient for the symptomatic adjustment ofthe dosage to the patient to be treated. An effective amount of the drugis ordinarily supplied at a dosage level of from about 0.01 mg/kg toabout 500 mg/kg of body weight per day, or any amount or range therein.Preferably, the range is from about 0.1 to about 50.0 mg/kg of bodyweight per day, or any amount or range therein. More preferably, fromabout 0.5 to about 15.0 mg/kg of body weight per day, or any amount orrange therein. More preferably, from about 1.0 to about 7.5 mg/kg ofbody weight per day, or any amount or range therein. The compounds maybe administered on a regimen of 1 to 4 times per day.

Optimal dosages to be administered may be readily determined by thoseskilled in the art, and will vary with the particular compound used, themode of administration, the strength of the preparation, the mode ofadministration, and the advancement of the disease condition. Inaddition, factors associated with the particular patient being treated,including patient age, weight, diet and time of administration, willresult in the need to adjust dosages.

One skilled in the art will recognize that, both in vivo and in vitrotrials using suitable, known and generally accepted cell and/or animalmodels are predictive of the ability of a test compound to treat orprevent a given disorder.

One skilled in the art will further recognize that human clinical trailsincluding first-in-human, dose ranging and efficacy trials, in healthypatients and/or those suffering from a given disorder, may be completedaccording to methods well known in the clinical and medical arts.

The following Examples are set forth to aid in the understanding of theinvention, and are not intended and should not be construed to limit inany way the invention set forth in the claims which follow thereafter.

In the Examples which follow, some synthesis products are listed ashaving been isolated as a residue. It will be understood by one ofordinary skill in the art that the term “residue” does not limit thephysical state in which the product was isolated and may include, forexample, a solid, an oil, a foam, a gum, a syrup, and the like.

EXAMPLE 16-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #11)

The title compound was prepared according to two different syntheticmethods, as described in more detail below.

Method A

Step 1: tert-butyl 4-(6-fluoroindolin-1-yl)piperidine-1-carboxylate

To a solution of 6-fluoroindoline (9.36 g, 68 mmol) in CH₂Cl₂ (100 mL)was added 1-Boc-4-piperidone (13.6 g, 68 mmol). The resulting mixturewas stirred at room temperature for 1 h and NaBH(OAc)₃ (18 g, 85 mmol,1.25 equiv) was added. The resulting mixture was stirred at roomtemperature for 24 h and was then poured slowly to a vigorously stirredNa₂CO_(3(aq)). After 30 min stirring, the layers were separated. Theaqueous layer was extracted with CH₂Cl₂ (100 mL). The combined organiclayer was washed with brine (100 mL), dried (Na₂SO₄), and filtered.

The solvent was removed by roto-evaporator and then, Et₂O (10 mL) andthen hexane (150 mL) were added to the resulting residue. The resultingmixture was allowed to stand, resulting in the formation of a whitesolid, which was collected and washed with 5% Et₂O/hexane and thendried. This procedure was repeated to yield tert-butyl4-(6-fluoroindolin-1-yl)piperidine-1-carboxylate as a white solid.

Step 2: 6-fluoro-1-(piperidin-4-yl)indoline

To a solution of tert-butyl4-(6-fluoroindolin-1-yl)piperidine-1-carboxylate prepared as in STEP 1above (16.64 g, 52 mmol) in CH₂Cl₂ (45 mL) was added TFA (30 mL) slowlyat room temperature. The resulting mixture was stirred at roomtemperature for 3 h (monitor by HPLC). The resulting mixture was thenconcentrated to remove most of the solvent and TFA. The resultingresidue was partitioned in CH₂Cl₂/H₂O (100 mL/50 mL) and stirred. 3NNaOH(aq) was then added slowly until the pH value of aqueous layerwas >11. The aqueous layer was then extracted with CH₂Cl₂ (100 mL×10).The combined CH₂Cl₂ layer was dried (Na₂SO₄) and filtered. The solventwas removed and the resulting residue was dissolved in Et₂O (100 mL) andthen 1N HCl (1M in Et₂O, 60 mL, 60 mmol) was added slowly at 0° C. Theresulting mixture was allowed to warm to room temperature for another 30min. Hexane (100 mL) was added and the resulting mixture was stirred for15 min. The resulting white solid was filtered and washed with 50%Et₂O/hexane (30 mL×3), then dried to yield6-fluoro-1-(piperidin-4-yl)indoline as a white HCl salt.

Step 3: 1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline

In a 100 mL flask was placed 6-fluoro-1-(piperidin-4-yl)indoline as itscorresponding HCl salt, prepared as in STEP 2 above (7.7 g, 30 mmol, 1equiv) and 3,6-dichloropyridazine (4.69 g, 31.5 mmol, 1.05 equiv). DMSO(40 mL) and Et₃N (12.54 mL, 90 mmol, 3 equiv) were added sequentially.The resulting mixture was heated at 80° C. for 7 h. The resultingmixture was then poured into vigorously stirred H₂O (800 mL) and stirredfor 1 h. The resulting solid was filtered and washed with H₂O (30 mL×2),50% Et₂O/hexane (30 mL×2), and the dried to yield1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline as asolid.

Step 4:6-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline

In a two-neck flask was placed1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline, preparedas in STEP 3 above (2.33 g, 7 mmol, 1 equiv), 1-methylpyrazole-4-boronicacid pinacol ester (1.75 g, 8.4 mmol, 1.2 equiv), K₂CO₃ (3.86 g, 28mmol, 4.0 equiv), and Pd(PPh₃)₄ (809 mg, 0.7 mmol, 0.1 equiv). Theresulting mixture was degassed and refilled with N₂ (3 times).1,4-Dioxane/H₂O (30 mL/6 mL) was added and the resulting mixture washeated at 100° C. for 3 h. The resulting mixture was poured intoEtOAc/H₂O (100 mL/100 mL). The organic layer was washed with brine (100mL), dried (Na₂SO₄), and filtered. The solvent was removed byroto-evaporator, and the resulting residue was purified by column usingEtOAc as the eluent to yield the title compound as a solid.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.96 (s, 1 H), 7.91 (s, 1 H), 7.39 (d,J=9.6 Hz, 1 H), 6.98 (d, J=9.6 Hz, 1 H), 6.88-6.96 (m, 1 H), 6.27 (ddd,J=2.3, 7.8, 9.7 Hz, 1 H), 6.15 (dd, J=2.3, 10.6 Hz, 1 H), 4.50-4.61 (m,2 H), 3.93-4.00 (m, 3 H), 3.52-3.67 (m, 1 H), 3.40 (t, J=8.5 Hz, 2 H),2.97-3.11 (m, 2 H), 2.90 (t, J=8.3 Hz, 2 H), 1.93 (d, J=13.6 Hz, 2 H),1.74 (qd, J=3.9, 12.4 Hz, 2 H); MS: 379 (M⁺+1).

Method B

Step 1: 3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine

In a two-neck flask was placed 3,6-dichloropyridazine (1.49 g, 10 mmol),1-methylpyrazole-4-boronic acid pinacol ester (1.04 g, 5 mmol), K₂CO₃(1.38 g, 10 mmol), and Pd(PPh₃)₄ (289 mg, 0.25 mmol). The resultingmixture was degassed and refilled with N₂ (3 times). 1,4-Dioxane/H₂O (9mL/2 mL) was added and the resulting mixture was heated at 100° C. for 5h. The resulting mixture was poured into EtOAc/H₂O (30 mL/30 mL). Theorganic layer was washed with brine (30 mL), dried (Na₂SO₄), andfiltered. The solvent was removed and the resulting residue was purifiedby column using 90-100% EtOAc/hexane as the eluent to yield3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine.

Step 2:6-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline

To a mixture of 6-fluoro-1-(piperidin-4-yl)indoline (256 mg, 1 mmol),3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine prepared as in STEP 1above (194 mg, 1.0 mmol) in DMSO (3 mL) was added DIPEA (0.52 mL, 3mmol). The resulting mixture was sealed and heated at 180° C. for 1.5 hunder microwave irradiation. The resulting mixture was poured into H₂O(30 mL) and the aqueous layer was extracted with 30% CH₂Cl₂/Et₂O (30mL×5). The combined organic layer was dried (Na₂SO₄) and filtered. Thesolvent was removed and the resulting residue was purified by columnusing 90-100% EtOAc/hexane as the eluent to yield the title compound,6-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline.

EXAMPLE 21-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #10)

The title compound was prepared according to the procedure as describedin Example 1, Method B, reacting 1-(piperidin-4-yl)indoline HCl salt and3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.96 (s, 1 H), 7.91 (s, 1 H), 7.39 (d,J=9.6 Hz, 1 H), 7.02-7.11 (m, 2 H), 6.98 (d, J=9.6 Hz, 1 H), 6.63 (t,J=7.3 Hz, 1 H), 6.48 (d, J=7.8 Hz, 1 H), 4.44-4.62 (m, 2 H), 3.91-4.01(m, 3 H), 3.62-3.75 (m, 1 H), 3.35 (t, J=8.3 Hz, 2 H), 3.04 (td, J=2.4,12.9 Hz, 2 H), 2.95 (t, J=8.3 Hz, 2 H), 1.94 (d, J=10.6 Hz, 2 H), 1.75(qd, J=4.2, 12.3 Hz, 2H); MS: 361 (M⁺+1).

EXAMPLE 31-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indole(Compound #9)

The title compound was prepared according to the procedure as describedin Example 1, Method B, reacting 1-(piperidin-4-yl)indole HCl salt and3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.98 (s, 1 H), 7.93 (s, 1 H), 7.65 (d,J=7.8 Hz, 1 H), 7.43 (dd, J=3.5, 8.8 Hz, 2 H), 7.20-7.25 (m, 1 H), 7.19(d, J=3.3 Hz, 1 H), 7.09-7.15 (m, 1 H), 7.04 (d, J=9.6 Hz, 1 H), 6.53(d, J=2.8 Hz, 1 H), 4.58-4.69 (m, 2 H), 4.46-4.58 (m, 1 H), 3.98 (s, 3H), 3.11-3.27 (m, 2 H), 2.18-2.31 (m, 2 H), 2.04-2.18 (m, 2 H); MS: 359(M⁺+1).

EXAMPLE 4 5-fluoro-3-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole (Compound#3)

The title compound was prepared following the procedure as described inExample 1, Method B, reacting 5-fluoro-3-(piperidin-4-yl)benzisoxazoleHCl salt and 3-chloro-6-(1-methyl-1 H-pyrazol-4-yl)pyridazine.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.97 (s, 1 H), 7.92 (s, 1 H), 7.53 (dd,J=3.7, 9.0 Hz, 1 H), 7.42 (d, J=9.6 Hz, 1 H), 7.27-7.38 (m, 2 H), 7.02(d, J=9.3 Hz, 1 H), 4.52 (d, J=13.4 Hz, 2 H), 3.98 (s, 3 H), 3.31-3.45(m, 1 H), 3.11-3.31 (m, 2 H), 2.03-2.31 (m, 4 H); MS: 379 (M⁺+1).

EXAMPLE 54-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #66)

Step 1: 8-(6-chloropyridazin-3-yl)-1,4-dioxa-8-azaspiro[4.5]decane

To a mixture of 3,6-dichloropyridazine (2.98 g, 20 mmol) in DMSO (10 mL)was added 1,4-dioxa-8-azaspiro[4.5]decane (3 g, 21 mmol) and DIPEA (4.18mL, 24 mmol). The resulting mixture was heated at 80° C. for 4 h and wasthen poured into H₂O (300 mL). The resulting solid was washed with H₂O(10 mL×3) and hexane (10 mL×3) and then dried to yield8-(6-chloropyridazin-3-yl)-1,4-dioxa-8-azaspiro[4.5]decane.

Step 2:8-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl-1,4-dioxa-8-azaspiro[4.5]decane

In a two-neck flask was placed8-(6-chloropyridazin-3-yl)-1,4-dioxa-8-azaspiro[4.5]decane, prepared asin STEP 1 above (3.07 g, 12 mmol), 1-methylpyrazole-4-boronic acidpinacol ester (3.24 g, 15.6 mmol), K₂CO₃ (6.62 g, 48 mmol), andPd(PPh₃)₄ (693 mg, 0.6 mmol). The resulting mixture was degassed andrefilled with N₂ (3 times). 1,4-Dioxane/H₂O (15 mL/5 mL) was added andthe resulting mixture was heated at 100° C. for 4 h. The resultingmixture was then poured into EtOAc/H₂O (100 mL/100 mL). The organiclayer was washed with brine (100 mL), dried (Na₂SO₄), and filtered. Thesolvent was removed by roto-evaporator and the resulting residuepurified by column using EtOAc as the eluent to yield8-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)-1,4-dioxa-8-azaspiro[4.5]decane.

Step 3: 1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one

To a solution of8-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)-1,4-dioxa-8-azaspiro[4.5]decane,prepared as in STEP 2 above (1.8 g, 6 mmol) in acetone/H₂O (30 mL/30 mL)was added p-TSA.H₂O (1.37 g, 7.2 mmol). The resulting mixture wasstirred at 65° C. for 6 h and then concentrated to remove most oforganic solvent. The residue was poured into CH₂Cl₂/H₂O/Na₂CO₃(aq) (50mL/25 mL/25 mL). The aqueous layer was extracted with CH₂Cl₂ (50 mL).The combined organic layer was dried (Na₂SO₄), and filtered. The solventwas removed by roto-evaporator to yield1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one as asolid.

Step 4:4-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline

To a mixture of 4-fluoroindoline (62 mg, 0.45 mmol) and1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one, preparedas in STEP 3 above (77 mg, 0.3 mmol) in CH₂Cl₂ (3 mL) was addedNaBH(OAc)₃ (126 mg, 0.6 mmol). The resulting mixture was stirred at roomtemperature for 24 h and then concentrated. The resulting mixture waspurified by column using 90-100% EtOAc/(CH₂Cl₂/hexane=1/1) as the eluentto yield the4-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indolineas a residue. The title compound was then converted to its correspondingHCl salt.

¹H NMR (400 MHz, DMSO-d₆) δ=8.54 (s, 1 H), 8.26 (d, J=10.2 Hz, 1 H),8.11-8.22 (m, 2 H), 6.96-7.07 (m, 1 H), 6.41 (d, J=7.8 Hz, 1 H), 6.33(t, J=8.6 Hz, 1 H), 4.45 (d, J=14.1 Hz, 2 H), 3.92 (s, 3 H), 3.79-3.90(m, 1 H), 3.36 (t, J=10 Hz, 2 H), 3.26 (t, J=12.1 Hz, 2 H), 2.89 (t,J=8.6 Hz, 2 H), 1.76-1.88 (m, 2 H), 1.60-1.76 (m, 2 H); MS: 379 (M⁺+1).

EXAMPLE 65-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #46)

The title compound was prepared following the procedure as described inExample 5, STEP 4, reacting 5-fluoroindoline and1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.96 (s, 1 H), 7.90 (s, 1 H), 7.39 (d,J=9.3 Hz, 1 H), 6.98 (d, J=9.3 Hz, 1 H), 6.69-6.85 (m, 2 H), 6.35 (dd,J=4.2, 8.5 Hz, 1 H), 4.48-4.61 (m, 2 H), 3.93-4.01 (m, 3 H), 3.61 (tt,J=3.7, 11.7 Hz, 1 H), 3.33 (t, J=8.3 Hz, 2 H), 3.03 (td, J=2.3, 12.9 Hz,2 H), 2.92 (t, J=8.3 Hz, 2 H), 1.92 (d, J=13.6 Hz, 2 H), 1.72 (qd,J=4.0, 12.4 Hz, 2 H); MS: 379 (M⁺+1).

EXAMPLE 75-chloro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #65)

The title compound was prepared following the procedure as described inExample 5, STEP 4, reacting 5-chloroindoline and1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one.

¹H NMR (400 MHz, DMSO-d₆) δ=8.56 (s, 1 H), 8.28 (d, J=9.8 Hz, 1 H), 8.21(s, 1 H), 8.16 (d, J=10.2 Hz, 1 H), 6.98-7.07 (m, 2 H), 6.58 (d, J=8.2Hz, 1 H), 4.47 (d, J=12.9 Hz, 2 H), 3.94 (s, 3 H), 3.74-3.91 (m, 1 H),3.17-3.34 (m, 4 H), 2.88 (t, J=8.6 Hz, 2 H), 1.76-1.90 (m, 2 H),1.60-1.76 (m, 2 H); MS: 395 (M⁺+1).

EXAMPLE 86-chloro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #59)

The title compound was prepared following the procedure as described inExample 5, STEP 4, reacting 6-chloroindoline and1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one.

¹H NMR (400 MHz, DMSO-d₆) δ=8.55 (s, 1 H), 8.22-8.30 (m, 1 H), 8.20 (s,1 H), 8.15 (d, J=9.9 Hz, 1 H), 6.98 (d, J=7.8 Hz, 1 H), 6.57-6.65 (m, 1H), 6.52 (dd, J=1.6, 7.7 Hz, 1 H), 4.46 (d, J=12.4 Hz, 2 H), 3.94 (s, 3H), 3.82-3.93 (m, 1 H), 3.20-3.42 (m, 4 H), 2.85 (t, J=8.2 Hz, 2 H),1.82 (d, J=11.6 Hz, 2 H), 1.59-1.77 (m, 2 H); MS: 395 (M⁺+1).

EXAMPLE 96-methyl-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #57)

The title compound was prepared following the procedure as described inExample 5, STEP 4, reacting 6-methylindoline and1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one.

¹H NMR (400 MHz, DMSO-d₆) δ=8.55 (s, 1 H), 8.23-8.31 (m, 1 H), 8.20 (s,1 H), 8.16 (d, J=9.9 Hz, 1 H), 6.91 (d, J=6.6 Hz, 1 H), 6.36-6.55 (m, 2H), 4.47 (d, J=13.4 Hz, 2 H), 3.94 (s, 3 H), 3.79-3.91 (m, 1 H),3.21-3.35 (m, 4 H), 2.82 (t, J=8.0 Hz, 2 H), 2.23 (s, 3 H), 1.78-1.89(m, 2 H), 1.61-1.78 (m, 2H); MS: 375 (M⁺+1).

EXAMPLE 106-methoxy-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #62)

The title compound was prepared following the procedure as described inExample 5, STEP 4, reacting 6-methoxyinoline and1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one.

¹H NMR (400 MHz, DMSO-d₆) δ=8.56 (s, 1 H), 8.28 (d, J=9.9 Hz, 1 H),8.09-8.23 (m, 2 H), 6.90 (d, J=7.8 Hz, 1 H), 6.22 (s, 1 H), 6.08-6.17(m, 1 H), 4.46 (d, J=13.1 Hz, 2 H), 3.94 (s, 3 H), 3.78-3.91 (m, 1 H),3.69 (s, 3 H), 3.20-3.35 (m, 4 H), 2.79 (t, J=8.1 Hz, 2 H), 1.84 (d,J=12.1 Hz, 2 H), 1.61-1.78 (m, 2 H); MS: 391 (M⁺+1).

EXAMPLE 111-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-(trifluoromethyl)indoline(Compound #60)

The title compound was prepared following the procedure as described inExample 5, STEP 4, reacting 6-trifluoromethylindoline and1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-one.

¹H NMR (400 MHz, DMSO-d₆) δ=8.53 (s, 1 H), 8.21-8.30 (m, 1 H), 8.19 (s,1 H), 8.14 (d, J=10.6 Hz, 1 H), 7.17 (d, J=7.3 Hz, 1 H), 6.84 (d, J=7.1Hz, 1 H), 6.80 (s, 1 H), 4.46 (d, J=13.6 Hz, 2H), 3.96-4.05 (m, 1 H),3.94 (s, 3 H), 3.35-3.45 (m, 2 H), 3.21-3.35 (m, 2 H), 2.95 (t, J=8.0Hz, 2 H), 1.73-1.89 (m, 2 H), 1.62-1.73 (m, 2 H); MS: 429 (M⁺+1).

EXAMPLE 126-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indole(Compound #63)

To a solution of6-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(75 mg, 0.2 mmol) in THF (3 mL) was added DDQ (54 mg, 0.24 mmol). Theresulting mixture was stirred at room temperature for 30 min and waspoured into EtOAc (30 mL). The organic layer washed with Na₂CO₃(aq) (30mL), H₂O (30 mL), dried (Na₂SO₄), and filtered. The solvent was removedand the resulting residue purified by column using 80-90-100%EtOAc/(CH₂Cl₂/hexane=1/1) as the eluent to yield6-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indole,which was then converted to its corresponding HCl salt.

¹H NMR (400 MHz, DMSO-d₆) δ=8.53 (s, 1 H), 8.16-8.30 (m, 2 H), 8.11 (d,J=10.4 Hz, 1 H), 7.41-7.60 (m, 3 H), 6.8-6.96 (m, 1 H), 6.48 (d, J=3.0Hz, 1 H), 4.79 (t, J=7.8 Hz, 1 H), 4.55 (d, J=13.1 Hz, 2 H), 3.94 (s, 3H), 3.26-3.46 (m, 2 H), 1.97-2.15 (m, 4 H); MS: 377 (M⁺+1).

EXAMPLE 136-fluoro-1-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #4)

To a mixture of 6-fluoro-1-(piperidin-4-yl)indoline (128 mg, 0.5 mmol),3-chloro-6-(4-methylimidazol-1-yl)pyridazine (78 mg, 0.4 mmol) in DMSO(1.5 mL) was added DIPEA (0.25 mL, 1.5 mmol). The resulting mixture wassealed and heated at 180° C. for 1.5 h under microwave irradiation. Theresulting mixture was then poured into H₂O (30 mL) and the aqueous layerwas extracted with 10% CH₂Cl₂/Et₂O (80 mL×4). The combined organic layerwas dried (Na₂SO₄) and filtered. The solvent was removed and theresulting residue was purified by column (dry loading) using EtOAc then3% MeOH/EtOAc as the eluent to yield6-fluoro-1-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)indoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.15 (d, J=1.3 Hz, 1 H), 7.29-7.37 (m,2 H), 7.12 (d, J=9.6 Hz, 1 H), 6.89-6.97 (m, 1 H), 6.28 (ddd, J=2.3,7.9, 9.8 Hz, 1 H), 6.15 (dd, J=2.1, 10.5 Hz, 1 H), 4.47-4.60 (m, 2 H),3.53-3.69 (m, 1 H), 3.40 (t, J=8.5 Hz, 2 H), 3.01-3.15 (m, 2 H), 2.91(t, J=8.3 Hz, 2H), 2.31 (s, 3 H), 1.88-2.01 (m, 2 H), 1.67-1.84 (m, 2H); MS: 379 (M⁺+1).

EXAMPLE 141-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-imidazol-4-yl)methanol(Compound #15

Step 1: (1-(6-chloropyridazin-3-yl)-1H-imidazol-4-yl)methanol

To a mixture of 3,6-dichloropyridazine (3.73 g, 25 mmol),4(5)-hydroxymethylimidazole (1.96 g, 20 mmol), and Cs₂CO₃ (8.14 g, 25mmol) was added acetonitrile (80 mL). The resulting mixture was refluxedfor 3 h and was then poured into H₂O (200 mL). 1N HCl(aq) was addedslowly until the pH was ˜7-8. The aqueous layer was extracted with EtOAc(150 mL) and then CH₂Cl₂ (100 mL×5). The combined organic layer wasdried (Na₂SO₄) and filtered. The solvent was removed and the resultingresidue was triturated with 10% CH₂Cl₂/Et₂O (30 mL×3) to yield(1-(6-chloropyridazin-3-yl)-1H-imidazol-4-yl)methanol. The filtrate wasconcentrated and was purified by column using 60-70-80%EtOAc/(CH₂Cl₂/hexane=1/1) as the eluent to yield a second crop of(1-(6-chloropyridazin-3-yl)-1H-imidazol-4-yl)methanol.

Step 2:(1-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-imidazol-4-yl)methanol

To a mixture of 6-fluoro-1-(piperidin-4-yl)indoline (100 mg, 0.4 mmol)and (1-(6-chloropyridazin-3-yl)-1H-imidazol-4-yl)methanol, prepared asin STEP 1 above (63 mg, 0.3 mmol) in DMSO (1.5 mL) was added DIPEA (0.16mL, 0.9 mmol). The resulting mixture was sealed and heated at 180° C.for 1.5 h under microwave irradiation. The resulting mixture was thenpoured into H₂O (30 mL) and the aqueous layer was extracted with 10%CH₂Cl₂/Et₂O (80 mL×4). The combined organic layer was dried (Na₂SO₄) andfiltered. The solvent was removed and the resulting residue was purifiedby column using EtOAc then 3-5% MeOH/EtOAc as the eluent to yield(1-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-imidazol-4-yl)methanol.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.24 (s, 1 H), 7.57 (s, 1 H), 7.35 (d,J=9.9 Hz, 1 H), 7.13 (d, J=9.9 Hz, 1 H), 6.87-6.98 (m, 1 H), 6.29 (ddd,J=2.3, 7.8, 9.7 Hz, 1 H), 6.15 (dd, J=2.3, 10.6 Hz, 1 H), 4.70 (s, 2 H),4.46-4.64 (m, 2 H), 3.51-3.72 (m, 1 H), 3.41 (t, J=8.3 Hz, 2 H), 3.10(td, J=2.3, 12.9 Hz, 2 H), 2.91 (t, J=8.3 Hz, 2 H), 1.88-2.02 (m, 2 H),1.75 (qd, J=4.0, 12.5 Hz, 2 H) (OH not seen); MS: 395 (M⁺+1).

EXAMPLE 156-fluoro-1-(1-(6-(4-methyl-1H-pyrazol-1-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #16)

The title compound was prepared following the procedure as described inExample 14, reacting 4-methylpyrazole, 3,6-dichloropyridazine, and6-fluoro-1-(piperidin-4-yl)indoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.37 (s, 1 H), 7.97 (d, J=9.6 Hz, 1 H),7.51-7.58 (m, 1 H), 7.14 (d, J=9.6 Hz, 1 H), 6.87-6.98 (m, 1 H), 6.28(ddd, J=2.3, 7.8, 9.7 Hz, 1 H), 6.15 (dd, J=2.3, 10.4 Hz, 1 H), 4.52(dt, J=2.1, 13.6 Hz, 2 H), 3.50-3.68 (m, 1 H), 3.41 (t, J=8.5 Hz, 2 H),3.07 (td, J=2.5, 13.0 Hz, 2 H), 2.91 (t, J=8.3 Hz, 2 H), 2.17 (s, 3 H),1.88-1.99 (m, 2 H), 1.76 (qd, J=4.0, 12.5 Hz, 2 H); MS: 379 (M⁺+1).

EXAMPLE 161-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-4-yl)methanol(Compound #22

The title compound was prepared following the procedure as described inExample 14, reacting 4-hydroxymethylpyrazole, 3,6-dichloropyridazine,and 6-fluoro-1-(piperidin-4-yl)indoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.60 (s, 1 H), 7.98 (d. J=9.9 Hz, 1 H),7.76 (s, 1 H), 7.16 (d, J=9.9 Hz, 1 H), 6.85-6.97 (m, 1 H), 6.28 (ddd,J=2.3, 7.8, 9.7 Hz, 1 H), 6.16 (dd, J=2.3, 10.6 Hz, 1 H), 4.70 (d, J=5.8Hz, 2 H), 4.46-4.61 (m, 2 H), 3.52-3.69 (m, 1 H), 3.41 (t, J=8.3 Hz, 2H), 2.99-3.15 (m, 2 H), 2.91 (t, J=8.3 Hz, 2 H), 1.87-2.02 (m, 2 H),1.66-1.84 (m, 2 H) (OH not seen); MS: 395 (M⁺+1).

EXAMPLE 172-(1-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-4-yl)ethanol(Compound #43)

The title compound was prepared following the procedure as described inExample 14, reacting 4-(2-hydroxyethyl)pyrazole, 3,6-dichloropyridazine,and 6-fluoro-1-(piperidin-4-yl)indoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.49 (s, 1 H), 7.97 (d. J=9.6 Hz, 1 H),7.63 (s, 1 H), 7.15 (d, J=9.9 Hz, 1 H), 6.93 (dd, J=5.9, 8.0 Hz, 1 H),6.28 (ddd, J=2.3, 7.8, 9.7 Hz, 1 H), 6.15 (dd, J=2.3, 10.6 Hz, 1 H),4.53 (dd, J=2.0, 11.4 Hz, 2 H), 3.86 (q, J=6.4 Hz, 2 H), 3.51-3.68 (m, 1H), 3.32-3.47 (m, 2 H), 3.08 (td, J=2.4, 12.8 Hz, 2 H), 2.91 (t, J=8.5Hz, 2 H), 2.83 (t, J=6.4 Hz, 2 H), 1.95 (d, J=11.6 Hz, 2 H), 1.76 (qd,J=3.9, 12.4 Hz, 2 H) (OH not seen); MS: 409 (M⁺+1).

EXAMPLE 181-(1-(6-(4-(ethoxymethyl)-1H-pyrazol-1-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline(Compound #72)

To a mixture of(1-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-4-yl)methanol(59 mg, 0.15 mmol, 1 equiv) and ethyl iodide (93 mg, 0.6 mmol, 4 equiv)was added solvent THF (5 mL) and DMF (1 mL). NaH (36 mg, 60% in mineraloil, 0.9 mmol, 6 equiv) was then added. The resulting mixture wasstirred at room temperature for 1.5 h and then poured into Et₂O/H₂O (20mL/20 mL). The organic layer was washed with brine (20 mL), dried(Na₂SO₄), and filtered. The solvent was removed and the resultingresidue was purified by column using 40-60% EtOAc/hexane as the eluentto yield1-(1-(6-(4-(ethoxymethyl)-1H-pyrazol-1-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline,which was then re-crystallized from CH₂Cl₂/hexane upon slow evaporation.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.58 (s, 1 H), 7.98 (d, J=9.6 Hz, 1 H),7.73 (s, 1 H), 7.15 (d, J=9.6 Hz, 1 H), 6.93 (dd, J=5.8, 7.8 Hz, 1 H),6.28 (ddd, J=2.4, 7.8, 9.7 Hz, 1 H), 6.16 (dd, J=2.1, 10.5 Hz, 1 H),4.46-4.60 (m, 4 H), 3.50-3.68 (m, 3 H), 3.35-3.46 (m, 2 H), 3.01-3.14(m, 2 H), 2.91 (t, J=8.3 Hz, 2 H), 1.95 (d, J=12.9 Hz, 2 H), 1.76 (qd,J=3.8, 12.5 Hz, 2 H), 1.17-1.29 (m, 3 H); MS: 423 (M⁺+1).

EXAMPLE 191-(1-(6-(1-ethyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline(Compound #21)

The title compound was prepared following the procedure as described inExample 1, Method A, reacting 1-ethylpyrazole-4-boronic acid pinacolester and 1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.01 (s, 1 H), 7.92 (s, 1 H), 7.40 (d,J=9.6 Hz, 1 H), 6.99 (d, J=9.6 Hz, 1 H), 6.89-6.96 (m, 1 H), 6.27 (ddd,J=2.3, 7.8, 9.7 Hz, 1 H), 6.15 (dd, J=2.3, 10.6 Hz, 1 H), 4.49-4.61 (m,2H), 4.24 (q, J=7.3 Hz, 2 H), 3.51-3.66 (m, 1 H), 3.40 (t, J=8.5 Hz, 2H), 3.04 (td, J=2.3, 12.9 Hz, 2 H), 2.90 (t, J=8.3 Hz, 2 H), 1.86-1.98(m, 2 H), 1.75 (qd, J=3.9, 12.4 Hz, 2 H), 1.54 (d, J=7.0 Hz, 3 H); MS:393 (M⁺+1).

EXAMPLE 206-fluoro-1-(1-(6-(1-propyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #79)

The title compound was prepared following the procedure as described inExample 1, Method A, reacting 1-propylpyrazole-4-boronic acid pinacolester and 1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=8.60 (s, 1 H), 8.28 (d, J=10.1 Hz, 1H), 8.22(s, 1 H), 8.16 (d, J=9.9 Hz, 1 H), 6.96 (dd, J=6.1, 7.8 Hz, 1 H), 6.45(dd, J=2.4, 11.0 Hz, 1 H), 6.27 (ddd, J=2.5, 7.8, 9.9 Hz, 1 H), 4.47 (d,J=13.4 Hz, 2 H), 4.16 (t, J=6.9 Hz, 2 H), 3.77-3.90 (m, 1 H), 3.21-3.43(m, 4 H), 2.84 (t, J=8.5 Hz, 2 H), 1.77-1.89 (m, 4 H), 1.60-1.72 (m, 2H), 0.86 (t, J=7.3 Hz, 3 H); MS: 407 (M⁺+1).

EXAMPLE 212-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)ethanol(Compound #49)

Step 1: Ethyl2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)acetate

Ethyl2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)acetatewas prepared according to the procedure as described in Example 1,Method A, STEP 4, reacting 1-(ethoxycarbonylmethyl)pyrazole-4-boronicacid pinacol ester and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

Step 2:2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)ethanol

To a solution of ethyl2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)acetate(90 mg, 0.2 mmol) in EtOH (3 mL) was added NaBH₄ (76 mg, 2 mmol). Theresulting mixture was heated at 65° C. for 2 h and then poured intoCH₂Cl₂/H₂O (50 mL/50 mL). The aqueous layer was extracted with CH₂Cl₂(50 ml). The combined organic layer was dried (Na₂SO₄) and filtered. Thesolvent was removed and the resulting residue was purified by silica gelcolumn using EtOAc to 2% MeOH/EtOAc as the eluent to yield2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)ethanol.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.03 (s, 1 H), 7.97 (s, 1 H), 7.40 (d,J=9.6 Hz, 1 H), 6.99 (d, J=9.3 Hz, 1 H), 6.88-6.96 (m, 1 H), 6.27 (ddd,J=2.3, 7.7, 9.7 Hz, 1 H), 6.15 (dd, J=2.3, 10.4 Hz, 1 H), 4.48-4.62 (m,2 H), 4.26-4.36 (m, 2 H), 3.99-4.10 (m, 2 H), 3.53-3.67 (m, 1 H), 3.40(t, J=8.3 Hz, 2 H), 2.96-3.11 (m, 3 H), 2.90 (t, J=8.3 Hz, 2 H), 1.93(d, J=12.1 Hz, 2 H), 1.66-1.84 (m, 2 H); MS: 409 (M⁺+1).

EXAMPLE 222-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)-N-methylacetamide(Compound #64)

In a flask was placed ethyl2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)acetate(45 mg, 0.1 mmol) and MeOH (2 mL) was added. Then, 40 wt % CH₃NH_(2(aq))(8 mL) was added. The resulting mixture was stirred at room temperaturefor 30 min and H₂O (10 mL) was added. The solid was filtered and washedwith H₂O (5 mL×3), then dried to yield2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)-N-methylacetamideas a white solid.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.10 (s, 1 H), 8.00 (s, 1 H), 7.40 (d,J=9.8 Hz, 1 H), 7.00 (d, J=9.4 Hz, 1 H), 6.87-6.97 (m, 1 H), 6.20-6.34(m, 2 H), 6.15 (dd, J=2.0, 10.6 Hz, 1 H), 4.87 (s, 2 H), 4.57 (d, J=12.9Hz, 2 H), 3.61 (t, J=11.7 Hz, 1 H), 3.40 (t, J=8.4 Hz, 2 H), 3.06 (t,J=12.1 Hz, 2 H), 2.90 (t, J=8.2 Hz, 2 H), 2.81 (d, J=5.1 Hz, 3 H), 1.94(d, J=11.7 Hz, 2 H), 1.57-1.85 (m, 2 H); MS: 436 (M⁺+1).

EXAMPLE 231-(1-(6-(1-(2-ethoxyethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline(Compound #78)

Step 1:1-(1-(6-(1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline

1-(1-(6-(1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindolinewas prepared according to the procedure described in Example 1, MethodA, STEP 4, reacting pyrazole-4-boronic acid pinacol ester and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

Step 2:1-(1-(6-(1-(2-ethoxyethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline

To a mixture of1-(1-(6-(1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline(55 mg, 0.15 mmol, 1.0 equiv) and 2-ethoxyethylbromide (0.17 mL, 1.5mmol, 10 equiv) was added THF (2 mL) and DMF (0.5 mL). NaH (30 mg, 60%in mineral oil, 0.75 mmol, 5 equiv) was then added. The resultingmixture was stirred at room temperature for 1.5 h and then poured intoEt₂O/H₂O (20 mL/20 mL). The organic layer was washed with brine (20 mL),dried (Na₂SO₄), and filtered. The solvent was removed and the resultingresidue was purified by column using 90-100% EtOAc/hexane as the eluentto yield1-(1-(6-(1-(2-ethoxyethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.07 (s, 1 H), 7.96 (s, 1 H), 7.40 (d,J=9.3 Hz, 1 H), 6.98 (d, J=9.6 Hz, 1 H), 6.89-6.96 (m, 1 H), 6.27 (ddd,J=2.4, 7.8, 9.7 Hz, 1 H), 6.15 (dd, J=2.3, 10.6 Hz, 1 H), 4.55 (dd,J=2.1, 11.2 Hz, 2 H), 4.34 (t, J=5.3 Hz, 2 H), 3.77-3.88 (m, 2 H),3.53-3.66 (m, 1 H), 3.44-3.53 (m, 2 H), 3.40 (t, J=8.3 Hz, 2 H), 3.04(td, J=2.4, 12.9 Hz, 2 H), 2.90 (t, J=8.5 Hz, 2 H), 1.93 (d, J=9.9 Hz, 2H), 1.66-1.82 (m, 2 H), 1.11-1.21 (m, 3 H); MS: 437 (M⁺+1).

EXAMPLE 246-fluoro-1-(1-(6-(5-methylthiophen-2-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #52)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting 5-methylthiophene-2-boronic acidpinacol ester and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.48-7.54 (m, 1 H), 7.24 (d, J=3.5 Hz,1 H), 6.88-6.99 (m, 2 H), 6.75 (dd, J=1.0, 3.5 Hz, 1 H), 6.27 (ddd,J=2.3, 7.8, 9.6 Hz, 1 H), 6.15 (dd, J=2.3, 10.6 Hz, 1 H), 4.57 (d,J=13.4 Hz, 2 H), 3.53-3.67 (m, 1 H), 3.39 (t, J=8.5 Hz, 2 H), 3.04 (t,J=13.0 Hz, 2 H), 2.83-2.96 (m, 2 H), 2.52 (s, 3 H), 1.92 (d, J=13.4 Hz,2 H), 1.66-1.81 (m, 2 H); MS: 395 (M⁺+1).

EXAMPLE 252-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-5-methylthiazole(Compound #31)

To a mixture of1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline (100 mg,0.3 mmol) and Pd(PPh₃)₄ (35 mg, 0.03 mmol) was added 1,4-dioxane (2 mL)and then 3-methyl-2-tributylstannylthiazole (232 mg, 0.6 mmol). Theresulting mixture was sealed and heated at 140° C. for 1.5 h. Theresulting mixture was then absorbed on silica gel and purified by silicagel column using 40% EtOAc/hexane as the eluent to yield2-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-5-methylthiazole.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.01 (d, J=8.0 Hz, 1 H), 7.52 (d, J=1.3Hz, 1 H), 7.02 (d, J=9.6 Hz, 1 H), 6.90-6.96 (m, 1 H), 6.28 (ddd, J=2.3,7.7, 9.7 Hz, 1 H), 6.16 (dd, J=2.3, 10.6 Hz, 1 H), 4.60-4.72 (m, 2 H),3.55-3.71 (m, 1 H), 3.39 (t, J=8.3 Hz, 2 H), 3.09 (td, J=2.1, 12.9 Hz, 2H), 2.90 (t, J=8.5 Hz, 2 H), 2.53 (d, J=1.0 Hz, 3 H), 1.90-2.00 (m, 2H), 1.74 (qd, J=4.0, 12.5 Hz, 2 H); MS: 396 (M⁺+1).

EXAMPLE 262-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-4-methylthiazole(Compound #29)

The title compound was prepared following the procedure as described inExample 25, reacting 4-methylthiophene-2-boronic acid pinacol ester and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=7.95 (d, J=9.6 Hz, 1 H), 7.42 (d, J=9.6 Hz,1 H), 7.31 (d, J=1.0 Hz, 1 H), 6.94 (t, J=6.9 Hz, 1 H), 6.42 (dd, J=2.3,11.1 Hz, 1 H), 6.25 (ddd, J=2.5, 7.8, 9.9 Hz, 1 H), 4.62 (d, J=12.9 Hz,2 H), 3.80 (t, J=11.7 Hz, 1 H), 3.34-3.40 (m, 2 H), 3.10 (t, J=13.0 Hz,2 H), 2.82 (t, J=8.5 Hz, 2 H), 2.43 (s, 3 H), 1.80 (d, J=12.4 Hz, 2 H),1.49-1.70 (m, 2 H); MS: 396 (M⁺+1).

EXAMPLE 275-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-3-methyl-1,2,4-thiadiazole(Compound #12)

Step 1: 5-(6-chloropyridazin-3-yl)-3-methyl-1,2,4-thiadiazole

To 3-chloro-6-methylpyridazine (5 g, 39 mmol) was added SOCl₂ (29 mL)and the resulting mixture was heated at 73-75° C. for 20 h. Theresulting mixture then was concentrated and the residue was dried invacuo for 30 min. The residue was then dissolved in CH₂Cl₂ (80 mL) andethanimidamide hydrochloride (3.69 g, 39 mmol) was added. 50% NaOH(aq)(10 mL) was then added dropwise at 0° C. The resulting mixture wasallowed to warm to room temperature and stirred for another 1 h. Theresulting mixture was then poured into CH₂Cl₂/H₂O (100 mL/200 mL). Theaqueous layer was extracted with CH₂Cl₂ (200 mL). The combined organiclayer was dried (Na₂SO₄) and filtered. The solvent was removed and theresulting residue was purified by column using EtOAc/CH₂Cl₂/hexane(40/10/50) as the eluent to yield5-(6-chloropyridazin-3-yl)-3-methyl-1,2,4-thiadiazole.

Step 2:5-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-3-methyl-1,2,4-thiadiazole

5-(6-(4-(6-Fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-3-methyl-1,2,4-thiadiazolewas prepared according to the procedure as described in Example 1,Method B, STEP 2, reacting 6-fluoro-1-(piperidin-4-yl)indoline as itscorresponding HCl salt and5-(6-chloropyridazin-3-yl)-3-methyl-1,2,4-thiadiazole, prepared as inSTEP 1 above.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.98 (d, J=9.6 Hz, 1 H), 7.03 (d, J=9.9Hz, 1 H), 6.89-6.99 (m, 1 H), 6.23-6.35 (m, 1 H), 6.16 (dd, J=2.3, 10.6Hz, 1 H), 4.72 (d, J=13.9 Hz, 2 H), 3.56-3.73 (m, 1 H), 3.33-3.47 (m,2H), 3.05-3.21 (m, 2 H), 2.91 (t, J=8.3 Hz, 2 H), 2.73 (s, 3 H),1.92-2.04 (m, 2 H), 1.74 (qd, J=4.3, 12.5 Hz, 2 H); MS: 397 (M⁺+1).

EXAMPLE 286-fluoro-1-(1-(6-(p-tolyl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #36)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting 4-methylphenylboronic acid and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=7.82-7.99 (m, 3 H), 7.38 (d, J=9.9 Hz, 1 H),7.29 (d, J=7.8 Hz, 2 H), 6.87-7.00 (m, 1 H), 6.41 (dd, J=2.3, 11.1 Hz, 1H), 6.25 (ddd, J=2.5, 7.8, 9.9 Hz, 1 H), 4.56 (br. s., 2 H), 3.68-3.85(m, 1 H), 3.33-3.41 (m, 2 H), 2.95-3.12 (m, 2 H), 2.82 (t, J=8.5 Hz, 2H), 2.28-2.40 (m, 3 H), 1.77 (br. s., 2 H), 1.50-1.70 (m, 2 H); MS: 389(M⁺+1).

EXAMPLE 294-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)phenyl)methanol(Compound #51

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting 4-hydroxymethylphenylboronic acidand 1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=8.49 (d, J=9.9 Hz, 1 H), 8.20 (d, J=10.1 Hz,1 H), 7.94-8.08 (m, J=8.1 Hz, 2 H), 7.45-7.58 (m, J=8.3 Hz, 2 H),6.89-7.03 (m, 1 H), 6.47 (dd, J=2.1, 11.0 Hz, 1 H), 6.21-6.34 (m, 1 H),5.76 (s, 1 H), 4.49-4.66 (m, 4 H), 3.78-3.97 (m, 1 H), 3.29-3.45 (m, 4H), 2.84 (t, J=8.3 Hz, 2 H), 1.61-1.85 (m, 4 H); MS: 405 (M⁺+1).

EXAMPLE 306-fluoro-1-(1-(6-(4-fluorophenyl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #53)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting 4-fluorophenylboronic acid and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=8.42 (d, J=9.9 Hz, 1 H), 7.99-8.19 (m, 3 H),7.36-7.48 (m, 2 H), 6.90-7.01 (m, 1 H), 6.46 (dd, J=2.3, 11.1 Hz, 1 H),6.27 (ddd, J=2.3, 7.8, 9.9 Hz, 1 H), 4.54 (d, J=13.6 Hz, 2 H), 3.76-3.95(m, 1 H), 3.22-3.45 (m, 4 H), 2.84 (t, J=8.3 Hz, 2 H), 1.81-1.93 (m, 2H), 1.63-1.81 (m, 2 H); MS: 393 (M⁺+1).

EXAMPLE 316-fluoro-1-(1-(6-(4-(trifluoromethyl)phenyl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #54)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting 4-trifluoromethylphenylboronicacid and 1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=8.41 (d, J=9.6 Hz, 1 H), 8.19-8.33 (m, J=8.3Hz, 2 H), 8.00 (br. s., 1 H), 7.86-7.96 (m, J=8.3 Hz, 2 H), 6.96 (t, J10=6.9 Hz, 1 H), 6.46 (dd, J=2.1, 11.0 Hz, 1 H), 6.27 (ddd, J=2.3, 7.9,9.8 Hz, 1 H), 4.58 (d, J=13.1 Hz, 2 H), 3.87 (t, J=11.7 Hz, 1 H),3.20-3.43 (m, 4 H), 2.84 (t, J=8.2 Hz, 2 H), 1.80-1.93 (m, 2 H),1.63-1.80 (m, 2 H); MS: 443 (M⁺+1).

EXAMPLE 324-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)benzoic acid(Compound #58)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting 4-(t-butylcarbonyl)phenylboronicacid and 1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindolineto yield the corresponding Boc-protected title compound, which was thensubjected to TFA de-protection.

¹H NMR (400 MHz, DMSO-d₆) δ=13.01 (br. s., 1 H), 8.17 (d, J=8.6 Hz, 2H), 7.95-8.10 (m, 3 H), 7.43 (d, J=9.6 Hz, 1 H), 6.83-7.04 (m, 1 H),6.42 (dd, J=2.3, 11.1 Hz, 1 H), 6.25 (ddd, J=2.4, 7.9, 9.9 Hz, 1 H),4.55-4.72 (m, 2 H), 3.69-3.88 (m, 1 H), 3.34-3.43 (m, 2 H), 3.08 (t,J=12.8 Hz, 2 H), 2.82 (t, J=8.3 Hz, 2 H), 1.80 (d, J=10.4 Hz, 2 H),1.50-1.70 (m, 2 H); MS: 419 (M⁺+1).

EXAMPLE 336-fluoro-1-(1-(6-(6-methylpyridin-3-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #30)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP4, reacting 2-methylpyridine-5-boronic acid and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=9.04 (d, J=2.0 Hz, 1 H), 8.28 (dd,J=2.3, 8.1 Hz, 1 H), 7.66 (d, J=9.6 Hz, 1 H), 7.28 (d, J=8.0 Hz, 1 H),7.05 (d, J=9.6 Hz, 1 H), 6.89-6.97 (m, 1 H), 6.24-6.33 (m, 1 H), 6.16(dd, J=2.1, 10.5 Hz, 1 H), 4.57-4.69 (m, 2 H), 3.56-3.70 (m, 1 H), 3.40(t, J=8.3 Hz, 2 H), 3.09 (td, J=2.4, 12.9 Hz, 2 H), 2.90 (t, J=8.5 Hz, 2H), 2.62 (s, 3 H), 1.89-2.02 (m, 2 H), 1.75 (qd, J=3.7, 12.2 Hz, 2 H);MS: 390 (M⁺+1).

EXAMPLE 345-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)pyridin-2-yl)methanol(Compound #39

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting 2-hydroxymethylpyridine-5-boronicacid and 1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=9.18-9.32 (m, 1 H), 8.84 (br. s., 1 H), 8.40(d, J=9.9 Hz, 1 H), 7.93 (d, J=8.1 Hz, 2 H), 6.90-7.03 (m, 1 H), 6.46(dd, J=2.1, 11.0 Hz, 1 H), 6.19-6.34 (m, 1 H), 5.76 (s, 1 H, OH), 4.83(s, 2 H), 4.62 (d, J=13.1 Hz, 2 H), 3.74-3.94 (m, 1 H), 3.20-3.45 (m, 4H), 2.84 (t, J=8.3 Hz, 2 H), 1.85 (d, J=11.9 Hz, 2 H), 1.57-1.77 (m, 2H); MS: 406 (M⁺+1).

EXAMPLE 356-fluoro-1-(1-(6-(6-(trifluoromethyl)pyridin-3-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #76)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting2-trifluoromethylpyridine-5-boronic acid and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=9.41 (s, 1 H), 8.62-8.76 (m, 1 H), 8.33 (d,J=9.9 Hz, 1 H), 8.07 (d, J=8.3 Hz, 1 H), 7.83 (br. s., 1 H), 6.89-7.03(m, 1H), 6.45 (dd, J=2.4, 11.0 Hz, 1 H), 6.18-6.33 (m, 1 H), 4.62 (d,J=13.1 Hz, 2H), 3.85 (t, J=11.6 Hz, 1 H), 3.36 (t, J=8.3 Hz, 2 H), 3.23(t, J=12.5 Hz, 2 H), 2.83 (t, J=8.2 Hz, 2 H), 1.84 (d, J=12.1 Hz, 2 H),1.68 (q, J=12.5 Hz, 2 H); MS: 444 (M⁺+1).

EXAMPLE 366-fluoro-1-(1-(6-(6-methoxypyridin-3-yl)pyridazin-3-yl)piperidin-4-yl)indoline(Compound #37)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting 2-methoxypyridine-5-boronic acidand 1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, DMSO-d₆) δ=8.80 (d, J=2.5 Hz, 1 H), 8.35 (dd, J=2.5,8.6 Hz, 1 H), 7.94 (d, J=9.6 Hz, 1 H), 7.41 (d, J=9.6 Hz, 1 H),6.89-6.98 (m, 2 H), 6.41 (dd, J=2.3, 11.1 Hz, 1 H), 6.16-6.30 (m, 1 H),4.58 (d, J=13.1 Hz, 2 H), 3.91 (s, 3 H), 3.67-3.84 (m, 1 H), 3.34-3.42(m, 2 H), 3.05 (t, J=12.6 Hz, 2 H), 2.82 (t, J=8.5 Hz, 2 H), 1.79 (d,J=14.1 Hz, 2 H), 1.51-1.69 (m, 2H); MS: 406 (M⁺+1).

EXAMPLE 375-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-N,N-dimethylpyridin-2-amine(Compound #44)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting2-(N,N-dimethylamino)pyridine-5-boronic acid and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.67 (d, J=2.5 Hz, 1 H), 8.27 (dd,J=2.4, 9.0 Hz, 1 H), 7.58 (d, J=9.6 Hz, 1 H), 7.01 (d, J=9.6 Hz, 1 H),6.89-6.97 (m, 1 H), 6.63 (d, J=9.1 Hz, 1 H), 6.27 (ddd, J=2.3, 7.8, 9.7Hz, 1 H), 6.16 (dd, J=2.3, 10.6 Hz, 1 H), 4.58 (dd, J=2.0, 11.4 Hz, 2H), 3.60 (tt, J=3.8, 11.7 Hz, 1 H), 3.40 (t, J=8.5 Hz, 2 H), 3.16 (s, 6H), 3.05 (td, J=2.4, 12.9 Hz, 2 H), 2.90 (t, J=8.5 Hz, 2 H), 1.88-2.00(m, 2 H), 1.75 (qd, J=4.3, 12.4 Hz, 2 H); MS: 419 (M⁺+1).

EXAMPLE 385-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-N-methylpicolinamide(Compound #42)

The title compound was prepared following the procedure as described inExample 1, Method A, STEP 4, reacting2-(N-methylaminocarbonyl)pyridine-5-boronic acid and1-(1-(6-chloropyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline.

¹H NMR (400 MHz, CHLOROFORM-d) δ=9.21 (d, J=1.5 Hz, 1 H), 8.40 (dd,J=2.3, 8.3 Hz, 1 H), 8.28 (d, J=7.6 Hz, 1 H), 8.05 (q, J=5.3 Hz, 1 H),7.67-7.73 (m, 1 H), 7.07 (d, J=9.6 Hz, 1 H), 6.89-6.98 (m, 1 H), 6.29(ddd, J=2.3, 7.7, 9.7 Hz, 1 H), 6.16 (dd, J=2.3, 10.4 Hz, 1 H), 4.68 (d,J=13.6 Hz, 2 H), 3.58-3.71 (m, 1 H), 3.40 (t, J=8.5 Hz, 2 H), 3.08-3.17(m, 2 H), 3.07 (d, J=5.1 Hz, 3 H), 2.91 (t, J=8.5 Hz, 2 H), 1.98 (d,J=12.4 Hz, 2 H), 1.75 (qd, J=3.9, 12.3 Hz, 2 H); MS: 433 (M⁺+1).

EXAMPLE 396-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole(Compound #47)

Step 1: tert-butyl 4-(6-fluoro-1H-indazol-1-yl)piperidine-1-carboxylate

To 6-fluoro-1H-indazole (6.46 mmol, 880 mg) in DMF (15 mL) cooled to 0°C. under Ar was added 95% NaH (6.46 mmol, 163 mg). The resulting mixturewas stirred for 15 minutes before tert-butyl4-(tosyloxy)piperidine-1-carboxylate (7.11 mmol, 2.52 g) was added.After an additional 15 minutes at 0° C., the ice bath was removed andthe reaction vessel placed in a 110° C. bath for 2.75 hours. Aftercooling to ambient temperature, the DMF was removed in vacuo and ethylacetate (100 mL) was added. The organic layer was washed with water andbrine, dried (MgSO₄), filtered and the solvent removed in vacuo. Theresulting residue was purified by SiO₂ column chromatography (0-40%EtOAc/hexanes) to yield tert-butyl4-(6-fluoro-1H-indazol-1-yl)piperidine-1-carboxylate.

Step 2: 6-fluoro-1-(piperidin-4-yl)-1H-indazole

To tert-butyl 4-(6-fluoro-1H-indazol-1-yl)piperidine-1-carboxylateprepared as in STEP 1 above (998 mg, 3.10 mmol) in DCM (20 mL) at 0° C.was added TFA (10 mL). The resulting mixture was then stirred for 1hour. The solvent was removed in vacuo. To the resulting residue wasadded 0.5N NaOH (15 mL), followed repeated extraction with CHCl₃. Theorganic layer was dried with MgSO₄ and filtered to yield6-fluoro-1-(piperidin-4-yl)-1H-indazole.

Step 3:6-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole

6-Fluoro-1-(piperidin-4-yl)-1H-indazole (260 mg, 1.19 mmol),3-chloro-6-(1-methyl-1H-pyrazol-4-yl)pyridazine (230 mg, 1.19 mmol) andDIEA (269 uL) in DMSO (4 ml) under Ar were heated in a microwave reactorat 200° C. for 1 hour. After removal of most of the DMSO in vacuo, water(10 mL) was added and the aqueous layer extracted several times withCHCl₃ (50 mL). The organic layer was washed with brine, dried (MgSO₄),decolorized with NORITE, filtered and the solvent removed in vacuo. Theresulting residue was purified via ISCO column chromatography (Amine“Redisep” 14 gram column eluded 0-100% EtOAc/hexane over 20 columnvolumes), then re-crystallized from DCM with heptanes to yield6-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole.

¹H NMR (400 MHz) δ 2.17-2.20 (m, 2H), 2.32-2.43 (dq, 2H), 3.20-.3.25 (t,2H), 4.00 (s, 3H), 4.58-4.54 (m, 3H), 6.90-6.97 (t, 1H), 7.02-7.06 (d,1H), 7.40-7.42 (d, 1H), 7.68-7.71 (m, 1H), 7.92 (s, 1H), 7.98 (s, 2H);MS: 378.0 (M⁺+1); Elemental analysis for C₂₀H₂₀FN₇: Theory(+0.1% water)C, 63.34; H, 5.37; N, 25.85. Found C, 63.17; H, 5.27; N, 25.81

Additional representative compounds of the present invention weresimilarly prepared according to the procedures as described in thegeneral synthesis schemes and examples, above. Table 3 below, listsmeasured ¹HMR and/or MS values for the prepared compounds of formula(I).

TABLE 3 Measured Properties for Prepared Compounds of Formula (I) ID No.Compound Name, Structure and Measured ¹HNMR and/or MS 11-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)indoline  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.15 (s, 1 H), 7.28-7.37 (m, 2 H),7.04-7.14 (m, 3 H), 6.64 (t, J = 7.3 Hz, 1 H), 6.48 (d, J = 8.3 Hz, 1H), 4.54 (d, J = 13.4 Hz, 2 H), 3.64-3.76 (m, 1 H), 3.29- 3.40 (m, 2 H),3.02-3.15 (m, 2 H), 2.95 (t, J = 8.3 Hz, 2 H), 2.31 (s, 3 H), 1.97 (d, J= 11.9 Hz, 2 H), 1.75 (qd, J = 4.2, 12.4 Hz, 2 H); MS: 361 (M⁺ + 1) 55-fluoro-3-(1-(6-(3-methyl-1,2,4-thiadiazol-5-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.01 (d, J = 9.6 Hz, 1 H), 7.55(dd, J = 3.9, 9.0 Hz, 1 H), 7.28-7.37 (m, 2 H), 7.07 (d, J = 9.6 Hz, 1H), 4.66 (d, J = 13.6 Hz, 2 H), 3.33-3.49 (m, 3 H), 2.73 (s, 3 H),2.24-2.33 (m, 2 H), 2.06-2.19 (m, 2 H); MS: 397 (M⁺ + 1) 65-(6-(4-(1H-indol-1-yl)piperidin-1-yl)pyridazin-3-yl)-3-methyl-1,2,4-thiadiazole  

¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.03 (d, J = 9.6 Hz, 1 H), 7.65 (d, J= 7.8 Hz, 1 H), 7.42 (d, J = 7.8 Hz, 1 H), 7.20-7.25 (m, 1 H), 7.17 (d,J = 3.3 Hz, 1 H), 7.11-7.16 (m, 1 H), 7.09 (d, J = 9.6 Hz, 1 H), 6.54(d, J = 2.8 Hz, 1 H), 4.80 (d, J = 13.6 Hz, 2 H), 4.61 (tt, J = 3.9,11.7 Hz, 1 H), 3.22-3.36 (m, 2 H), 2.74 (s, 3 H), 2.25- 2.35 (m, 2 H),2.10 (qd, J = 4.0, 12.5 Hz, 2 H); MS: 377 (M⁺ + 1) 75-(6-(4-(indolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-3-methyl-1,2,4-thiadiazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.98 (d, J = 9.6 Hz, 1 H),7.05-7.11 (m, 2 H), 7.02 (d, J = 9.6 Hz, 1 H), 6.65 (t, J = 7.3 Hz, 1H), 6.48 (d, J = 8.1 Hz, 1 H), 4.72 (d, J = 13.6 Hz, 2 H), 3.75 (tt, J =3.8, 11.8 Hz, 1 H), 3.34 (t, J = 8.3 Hz, 2 H), 3.14 (td, J = 2.3, 13.0Hz, 2 H), 2.95 (t, J = 8.3 Hz, 2 H), 2.72 (s, 3 H), 2.00 (d, J = 10.9Hz, 2 H), 1.74 (qd, J = 4.3, 12.5 Hz, 2 H); MS: 379 (M⁺ + 1) 85-fluoro-3-(1-(6-(pyridin-3-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazote  

MS: 376 (M⁺ + 1) 133-(1-(6-(1-ethyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-5-fiuorobenzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.02 (s, 1 H), 7.93 (s, 1 H), 7.53(dd, J = 3.8, 9.1 Hz, 1 H), 7.43 (d, J = 9.6 Hz, 1 H), 7.27- 7.38 (m, 2H), 7.03 (d, J = 9.3 Hz, 1 H), 4.47-4.57 (m, 2 H), 4.24 (q, J = 7.3 Hz,2 H), 3.37 (tt, J = 3.9, 11.3 Hz, 1 H), 3.18-3.29 (m, 2 H), 2.19-2.27(m, 3 H), 2.06-2.18 (m, 2 H), 1.55 (t, J = 8 Hz, 3 H); MS: 393 (M⁺ + 1)18 5-fluoro-3-(1-(6-(5-methyl-1,3,4-oxadiazol-2-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

¹H NMR (400 MHz, DMSO-d₆) δ = 8.03 (d, J = 9.6 Hz, 1 H), 7.95 (dd, J =2.5, 8.3 Hz, 1 H), 7.79 (dd, J = 3.8, 9.1 Hz, 1 H), 7.52-7.62 (m, 2H),4.64 (d, J = 13.4 Hz, 2 H), 3.58 (tt, J = 3.3, 11.5 Hz, 1 H), 3.26-3.39(m, 2 H), 2.62 (s, 3 H), 2.22 (d, J = 10.9 Hz, 2 H), 1.81- 1.97 (m, 2H); MS: 381 (M⁺ + l) 19(5-(6-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazin-3-yl)-1,3,4-oxadiazol-2-yl)methyl acetate  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.09 (d, J = 9.6 Hz, 1 H),7.51-7.58 (m, 1 H), 7.28-7.37 (m, 2 H), 7.07 (d, J = 9.6 Hz, 1 H), 5.38(s, 2 H), 4.67 (d, J = 13.9 Hz, 2 H), 3.34-3.51 (m, 3 H), 2.23- 2.33 (m,2 H), 2.18 (s, 3 H), 2.06-2.17 (m, 2 H); MS: 439 (M⁺ + 1) 20(5-(6-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazin-3-yl)-1,3,4-oxadiazol-2-yl)methanol  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 8.01 (d, J = 9.6 Hz, 1 H), 7.95 (d, J =7.6 Hz, 1 H), 7.79 (d, J = 5.3 Hz, 1 H), 7.45-7.63 (m, 2 H), 6.01 (t, J= 5.8 Hz, 1 H), 4.75 (d, J = 6.1 Hz, 2 H), 4.66 (d, J = 12.1 Hz, 2 H),3.57 (br. s., 1 H), 3.23-3.32 (m, 2 H), 2.22 (d, J = 11.9 Hz, 2 H),1.79-1.98 (m, 2 H); MS: 397 (M⁺ + 1) 235-fluoro-3-(1-(6-(4-methylthiazol-2-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazoie  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.07 (d, J = 9.6 Hz, 1 H), 7.54(dd, J = 4.0, 9.6 Hz, 1 H), 7.28-7.38 (m, 2 H), 7.06 (d, J = 9.6 Hz, 1H), 6.93 (d, J = 1.0 Hz, 1 H), 4.62 (dt, J = 3.1, 13.5 Hz, 2 H), 3.41(tt, J = 4.0, 11.2 Hz, 1 H), 3.27-3.37 (m, 2 H), 2.51 (d, J = 1.0 Hz, 3H), 2.20-2.30 (m, 2 H), 2.05-2.19 (m, 2 H); MS: 396 (M⁺ + 1) 245-fluoro-3-(1-(6-(6-methylpyridin-3-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazote  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 9.09 (d, J = 2.3 Hz, 1 H), 8.29 (dd, J =2.3, 8.1 Hz, 1 H), 8.01 (d, J = 9.6 Hz, 1 H), 7.93 (dd, J = 2.5, 8.3 Hz,1 H), 7.79 (dd, J = 3.8, 9.1 Hz, 1 H), 7.55 (td, J = 2.8, 9.1 Hz, 1 H),7.47 (d, J = 9.6 Hz, 1 H), 7.37 (d, J = 8.1 Hz, 1 H), 4.58 (d, J = 13.6Hz, 2 H), 3.47-3.61 (m, 1 H), 3.17-3.28 (m, 2 H), 2.53 (s, 3 H), 2.19(d, J = 10.4 Hz, 2 H), 1.87 (qd, J = 3.8, 12.3 Hz, 2 H); MS: 390(M⁺ + 1) 255-fluoro-3-(1-(6-(2-methylpyridin-4-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.60 (d, J = 5.1 Hz, 1 H), 7.83 (s,1 H), 7.66-7.74 (m, 2 H), 7.51-7.58 (m, 1 H), 7.28-7.38 (m, 2 H), 7.08(d, J = 9.6 Hz, 1 H), 4.63 (d, J = 13.6 Hz, 2 H), 3.38- 3.48 (m, 1 H),3.34 (ddd, J = 2.7, 11.4, 13.8 Hz, 2 H), 2.65 (s, 3 H), 2.21-2.32 (m, 2H), 2.08-2.20 (m, 2 H); MS: 390 (M⁺ + 1) 263-(1-(6-(1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-5-fluorobenzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 10.23 (br s, 1 H), 8.14 (s, 2 H),7.53 (dd, J = 3.9, 9.0 Hz, 1 H), 7.47 (d, J = 9.3 Hz, 1 H), 7.27- 7.38(m, 2 H), 7.04 (d, J = 9.3 Hz, 1 H), 4.48-4.59 (m, 2 H), 3.38 (tt, J =4.0, 11.2 Hz, 1 H), 3.19-3.31 (m, 2 H), 2.19-2.29 (m, 2 H), 2.05-2.19(m, 2 H); MS: 365 (M⁺ + 1) 275-fluoro-3-(1-(6-(4-methylthiophen-2-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.51-7.58 (m, 2 H), 7.27- 7.37 (m,3 H), 7.01 (d, J = 9.3 Hz, 1 H), 6.94 (s, 1 H), 4.55 (dt, J = 3.1, 13.5Hz, 2 H), 3.38 (tt, J = 3.9, 11.4 Hz, 1 H), 3.20-3.31 (m, 2 H), 2.30 (s,3 H), 2.19-2.27 (m, 2 H), 2.05-2.18 (m, 2 H); MS: 395 (M⁺ + 1) 285-fluoro-3-(1-(6-(5-methylthiazol-2-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.04 (d, J = 9.6 Hz, 1 H),7.50-7.57 (m, 2 H), 7.28-7.38 (m, 2 H), 7.06 (d, J = 9.6 Hz, 1 H), 4.61(dt, J = 3.2, 13.8 Hz, 2 H), 3.41 (tt, J = 4.0, 11.3 Hz, 1 H), 3.26-3.36 (m, 2 H), 2.53 (d, J = 1.3 Hz, 3 H), 2.20-2.29 (m, 2 H), 2.05- 2.19(m, 2 H); MS: 396 (M⁺ + 1) 325-fluoro-3-(1-(6-(p-tolyl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.92 (d, J = 8.3 Hz, 2 H), 7.67 (d,J = 9.6 Hz, 1 H), 7.53 (dd, J = 3.7, 9.0 Hz, 1 H), 7.27-7.38 (m, 4 H),7.07 (d, J = 9.6 Hz, 1 H), 4.58 (d, J = 13.4 Hz, 2 H), 3.39 (tt, J =3.8, 11.4 Hz, 1 H), 3.23-3.32 (m, 2 H), 2.41 (s, 3 H), 2.20- 2.29 (m, 2H), 2.07-2.20 (m, 2 H); MS: 389 (M⁺ + 1) 335-fluoro-3-(1-(6-(6-methoxypyridin-3-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 8.89 (d, J = 2.3 Hz, 1 H), 8.51 (d, J =10.1 Hz, 1 H), 8.35 (dd, J = 2.5, 8.8 Hz, 1 H), 8.23 (d, J = 10.1 Hz, 1H), 8.01 (dd, J = 2.3, 8.3 Hz, 1 H), 7.81 (dd, J = 3.9, 9.0 Hz, 1 H),7.52-7.61 (m, 1 H), 7.05 (d, J = 8.6 Hz, 1 H), 4.55 (d, J = 13.1 Hz, 2H), 3.95 (s, 3 H), 3.65 (t, J = 11.2 Hz, 1 H), 3.52 (t, J = 12.3 Hz, 2H), 2.24 (d, J = 12.4 Hz, 2 H), 1.94-2.11 (m, 2 H); MS: 406 (M⁺ + 1) 345-fluoro-3-(1-(6-(2-methoxypyrimidin-5-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 9.24 (s, 2 H), 8.41 (d, J = 10.1 Hz, 1H), 8.09 (d, J = 9.1 Hz, 1 H), 7.99 (dd, J = 2.5, 8.3 Hz, 1 H), 7.80(dd, J = 3.8, 9.1 Hz, 1 H), 7.57 (td, J = 2.5, 9.1 Hz, 1 H), 4.55 (d, J= 13.6 Hz, 2 H), 4.02 (s, 3 H), 3.55-3.69 (m, 1 H), 3.40-3.52 (m, 2 H),2.24 (d, J = 10.9 Hz, 2 H), 1.90-2.07 (m, 2 H); MS: 407 (M⁺ + 1) 35(5-(6-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazin-3-yl)pyridin-2-yl)methanol  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 9.17-9.28 (m, 1 H), 8.77 (d, J = 6.6 Hz,1 H), 8.38 (d, J = 9.9 Hz, 1 H), 7.97 (dd, J = 2.3, 8.3 Hz, 1 H), 7.87(d, J = 8.8 Hz, 2 H), 7.80 (dd, J = 3.9, 9.2 Hz, 1 H), 7.52- 7.62 (m, 1H), 4.79 (s, 2 H), 4.59 (d, J = 13.1 Hz, 2 H), 3.51-3.68 (m, 1 H),3.33-3.48 (m, 3 H), 2.23 (d, J = 11.6 Hz, 2 H), 1.90-2.00 (m, 2 H); MS:406 (M⁺ + 1) 386-fluoro-1-(1-(6-(2-methoxypyrimidin-5-yl)pyridazin-3-yl)piperidin-4-yl)indoline  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 9.21 (s, 2 H), 8.00 (d, J = 9.6 Hz, 1H), 7.46 (d, J = 9.6 Hz, 1 H), 6.89-6.98 (m, 1 H), 6.42 (dd, J = 2.3,11.1 Hz, 1 H), 6.25 (ddd, J = 2.3, 7.8, 9.9 Hz, 1 H), 4.60 (d, J = 12.9Hz, 2 H), 3.98 (s, 3 H), 3.72-3.85 (m, 1 H), 3.33-3.39 (m, 2 H), 3.07(t, J = 11.9 Hz, 2 H), 2.82 (t, J = 8.3 Hz, 2 H), 1.79 (d, J = 12.1 Hz,2 H), 1.50-1.67 (m, 2 H); MS: 407 (M⁺ + 1) 401-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole  

  ¹H NMR(400 MHz, CHLOROFORM-d) δ 8.00 (s, 1H), 7.99 (s, 1H), 7.95 (s,1H), 7.75 (d, 1H), 7.38-7.52 (m, 3H), 7.15-7.19 (m, 1H), 7.02 (d, 1H),4.69-4.79 (m, 1H), 4.58-4.62 (m, 2H), 3.97 (s, 3H), 3.20- 3.29 (t, 2H),2.37-2.48 (dq, 2H), 2.10-2.20 (m, 2H); MS: 360.0 (M⁺ + 1) 411-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-2-(trifiuoromethyl)-1H-benzo[d]imidazole  

  ¹H NMR(400 MHz, CHLOROFORM-d) δ 8.01 (s, 1H), 7.95 (s, 1H), 7.90 (m,1H), 7.48-7.53 (m, 2H), 7.30-7.37 (m, 2H), 7.06 (d, 1H), 4.62-4.81 (m,3H), 4.00 (s, 3H), 3.11-3.21 (t, 2H), 2.60-2.76 (dq, 2H), 2.08-2.17 (m,2H),; MS: 428 (M⁺ + 1) 45N-(5-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)pyridin-2-yl)acetamide  

  ¹H NMR (400MHz, CHLOROFORM-d) δ = 8.91 (t, J = 1.5 Hz, 1 H), 8.31 (d,J = 2.3 Hz, 2 H), 8.00 (s, 1 H), 7.63 (d, J = 9.6 Hz, 1 H), 7.05 (d, J =9.6 Hz, 1 H), 6.93 (dd, J = 5.8, 7.8 Hz, 1 H), 6.28 (ddd, J = 2.3, 7.8,9.7 Hz, 1 H), 6.16 (dd, J = 2.0, 10.6 Hz, 1 H), 4.64 (d, J = 13.4 Hz, 2H), 3.63 (tt, J = 3.9, 11.8 Hz, 1 H), 3.40 (t, J = 8.3 Hz, 2 H),3.03-3.15 (m, 2 H), 2.90 (t, J = 8.3 Hz, 2 H), 2.24 (s, 3 H), 1.90- 2.01(m, 2 H), 1.75 (qd, J = 4.4, 12.3 Hz, 2 H); MS: 433 (M⁺ + 1) 481-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-benzo[d][1,2,3]triazoie  

  ¹H NMR(400 MHz, CHLOROFORM-d) δ 8.10 (d, 1H), 7.99 (s, 1H), 7.97 (s,1H), 7.59 (m, 1H), 7.48-7.52 (m, 2H), 7.38-7.41 (m, 1H), 7.08 (d, 1H),4.95-5.03 (m, 1H), 4.60-4.63 (m, 2H), 3.99 (s, 3H), 3.29- .3.38 (t, 2H),2.49-2.59 (dq, 2H), 2.25-2.28 (m, 2H); MS: 361 (M⁺ + 1) 50 ethyl2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)acetate  

  MS: 451 (M⁺ + 1) 55 tert-butyl4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3- yl)benzoate  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.07 (s, 4 H), 7.70 (d, J = 9.6 Hz,1 H), 7.04 (d, J = 9.6 Hz, 1 H), 6.88-6.97 (m, 1 H), 6.28 (ddd, J = 2.4,7.8, 9.7 Hz, 1 H), 6.16 (dd, J = 2.0, 10.4 Hz, 1 H), 4.66 (d, J = 13.9Hz, 2 H), 3.57-3.69 (m, 1 H), 3.34-3.45 (m, 2 H), 3.03-3.16 (m, 2 H),2.90 (t, J = 8.6 Hz, 2 H), 1.91-2.01 (m, 2 H), 1.69-1.84 (m, 2 H), 1.62(s, 9 H); MS: 475 (M⁺ + 1) 564-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)benzamide  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 8.42 (d, J = 9.9 Hz, 1 H), 8.13 (d, J =8.6 Hz, 2 H), 8.04 (d, J = 8.3 Hz, 2 H), 7.52 (br. s., 1 H), 6.96 (t, J= 6.9 Hz, 1 H), 6.46 (dd, J = 2.4, 11.0 Hz, 1 H), 6.21-6.31 (m, 1 H),4.56 (d, J = 13.1 Hz, 2 H), 3.78-3.93 (m, 1 H), 3.31-3.43 (m, 4 H), 2.84(t, J = 8.5 Hz, 2 H), 1.80-1.91 (m, 2 H), 1.64-1.80 (m, 2 H) (NH₂ notshown); MS: 418 (M⁺ + 1) 614-chloro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.98 (s, 1 H), 7.97 (s, 1 H), 7.65(d, 1 H), 7.42-7.45 (m, 3 H), 7.20-7.24 (m, 1 H), 7.02 (d, 1 H), 3.99(s, 3 H), 3.18-3.25 (t, 2 H), 2.36-2.43 (dq, 2 H), 2.15-2.19 (m, 2 H),4.58-4.67 (m, 2 H); MS: 394 (M⁺ + 1) 674-chloro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)indoline  

  MS: 395 (M⁺ + 1) 684,6-dichloro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3- yl)piperidin-4-yl)indoline  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 8.51 (s, 1 H), 8.20 (d, J = 9.6 Hz, 1H), 8.17 (s, 1 H), 8.07 (d, J = 10.1 Hz, 1 H), 6.57-6.64 (m, 2 H), 4.46(d, J = 13.4 Hz, 2 H), 3.93 (s, 3 H), 3.84-3.91 (m, 1 H), 3.45 (t, J =8.6 Hz, 2 H), 3.25 (t, J = 12.3 Hz, 2 H), 2.90 (t, J = 8.6 Hz, 2 H),1.76-1.86 (m, 2 H), 1.70 (qd, J = 3.3, 12.1 Hz, 2 H); MS: 430 (M⁺ + 1)69 2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)acetamide  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.10 (s, 1 H), 8.03 (s, 1 H), 7.40(d, J = 9.3 Hz, 1 H), 7.00 (d, J = 9.6 Hz, 1 H), 6.93 (d, J = 13.6 Hz, 1H), 6.20-6.35 (m, 2 H), 6.15 (d, J = 10.6 Hz, 1 H), 5.56 (br. s., 1 H),4.88 (s, 2 H), 4.57 (d, J = 13.4 Hz, 2 H), 3.53-3.68 (m, 1 H), 3.40 (t,J = 8.3 Hz, 2 H), 3.06 (t, J = 12.6 Hz, 2 H), 2.90 (t, J = 8.2 Hz, 2 H),1.94 (d, J = 11.4 Hz, 2 H), 1.68-1.83 (m, 2 H); MS: 422 (M⁺ + 1) 704-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole  

  ¹H NMR(400 MHz, CHLOROFORM-d) δ = 8.06 (s, 1H), 7.97 (s, 1 H), 7.92(s, 1 H), 7.42 (d, 1 H), 7.24-7.34 (m, 2 H), 7.04 (d, 1 H), 6.77- 6.81(m, 1 H), 4.67-4.75 (m, 1 H), 4.59-4.63 (m, 2 H), 3.99 (s, 3 H),3.21-.3.28 (t, 2 H), 2.35-2.45 (dq, 2 H), 2.16-2.19 (m, 2 H); MS: 378(M⁺ + 1) 714-(2-(4-(6-(4-(6-fluoroindolin-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)ethyl)morpholine  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.07 (s, 1 H), 7.91 (s, 1 H), 7.40(d, J = 9.6 Hz, 1 H), 6.99 (d, J = 9.6 Hz, 1 H), 6.89-6.96 (m, 1 H),6.27 (ddd, J = 2.3, 7.9, 9.8 Hz, 1 H), 6.15 (dd, J = 2.3, 10.6 Hz, 1 H),4.55 (d, J = 13.6 Hz, 2 H), 4.30 (t, J = 6.4 Hz, 2 H), 3.66- 3.74 (m, 4H), 3.60 (tt, J = 3.7, 11.7 Hz, 1 H), 3.40 (t, J = 8.5 Hz, 2 H),2.99-3.10 (m, 2 H), 2.82-2.94 (m, 4 H), 2.47-2.54 (m, 4 H), 1.93 (d, J =11.6 Hz, 2 H), 1.67-1.82 (m, 2 H); MS: 478 (M⁺ + 1) 735-fluoro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.98 (s, 2 H), 7.92 (s, 1 H),7.40-7.45 (m, 2 H), 7.34-7.38 (m, 1 H), 7.14-7.20 (t, 1 H), 7.02- 7.06(d, 1 H), 4.66-4.72 (m, 1 H), 4.58-4.62 (m, 2 H), 3.97 (s, 3 H),3.20-.3.27 (t, 2 H), 2.34-2.44 (dq, 2 H), 2.17-2.20 (m, 2 H); MS: 378(M⁺ + 1) 746-chloro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.97 (s, 2 H), 7.92 (s, 1 H), 7.65(d, 1 H), 7.50 (s, 1 H), 7.42 (d, 1 H), 7.13 (d, 1 H), 7.04 (d, 1 H),4.59-4.65 (m, 3 H), 3.98 (s, 3 H), 3.20-.3.27 (t, 2 H), 2.37-2.41 (dq, 2H), 2.15-2.18 (m, 2 H); MS: 394 (M⁺ + 1) 753-(1-(6-(1-(2-ethoxyethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-5-fluorobenzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.08 (s, 1 H), 7.97 (s, 1 H), 7.53(dd, J = 3.8, 9.1 Hz, 1 H), 7.43 (d, J = 9.6 Hz, 1 H), 7.29- 7.39 (m, 2H), 7.03 (d, J = 9.6 Hz, 1 H), 4.52 (d, J = 13.1 Hz, 2 H), 4.35 (t, J =5.3 Hz, 2 H), 3.79-3.88 (m, 2 H), 3.49 (q, J = 7.0 Hz, 2 H), 3.31-3.44(m, 1 H), 3.17-3.31 (m, 2 H), 2.19-2.29 (m, 2 H), 2.11-2.19 (m, 2 H),1.17 (t, J = 6.9 Hz, 3 H); MS: 437 (M⁺ + 1) 771-(1-(6-(1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-fluoroindoline  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.13 (s, 2 H), 7.44 (d, J = 9.3 Hz,1 H), 7.00 (d, J = 9.6 Hz, 1 H), 6.89-6.97 (m, 1 H), 6.27 (ddd, J = 2.3,7.9, 9.8 Hz, 1 H), 6.15 (dd, J = 2.3, 10.6 Hz, 1 H), 4.51-4.62 (m, 2 H),3.53-3.69 (m, 1 H), 3.40 (t, J = 8.3 Hz, 2 H), 3.05 (td, J = 2.3, 12.9Hz, 2 H), 2.90 (t, J = 8.5 Hz, 2 H), 1.88-2.00 (m, 2 H), 1.69-1.81 (m, 2H) (NH not shown); MS: 365 (M⁺ + 1) 801-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-4-(trifluoromethyl)-1H-indazole  

  MS: 428 (M⁺ + 1) 811-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-6-(trifluoromethyl)-1H-indazole  

  MS: 428 (M⁺ + 1) 822-(4-(6-(4-(6-fluoro-1H-indazo-1-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-1-yl)ethanol  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ 8.04 (s, 1H), 7.96 (s, 2H), 7.66-7.69(m, 1H), 7.41 (d, 1H), 7.12 (d, 1H), 7.03 (d, 1H), 6.92- 6.96 (m, 1H),4.59-4.62 (m, 3H), 4.31-4.33 (m, 2H), 4.05-4.07 (m, 2H), 3.21-.3.28 (t,2H), 2.37-2.40 (dq, 2H), 2.15-2.18 (m, 2H); MS: 408 (M⁺ + 1) 833-chloro-1-(1-(6-(1-methyl-1H-pyrazol-4-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.97 (s, 1 H), 7.92 (s, 1 H), 7.69(d, 1 H), 7.41-7.45 (m, 2 H), 7.19-7.26 (m, 2 H), 7.02 (d, 1 H),4.58-4.68 (m, 3 H), 3.98 (s, 3 H), 3.18-3.25 (t, 2 H), 2.36-2.41 (dq, 2H), 2.13-2.19 (m, 2H); MS: 394 (M⁺ + 1) 843-(1-(6-(1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)-5-fluorobenzo[d]isoxazole  

  ¹H NMR (400 MHz, DMSO-d₆) δ = 8.47 (br. s., 1 H), 7.94 (d, J = 9.1 Hz,3 H), 7.79 (dd, J = 3.8, 9.3 Hz, 1 H), 7.65 (d, J = 9.6 Hz, 1 H), 7.55(td, J = 2.0, 9.1 Hz, 1 H), 7.15 (br. s., 1 H), 4.52 (d, J = 12.9 Hz, 2H), 3.45-3.59 (m, 1 H), 3.21 (t, J = 11.4 Hz, 2 H), 2.19 (d, J = 12.4Hz, 2 H), 1.79-1.95 (m, 2 H); MS: 365 (M⁺ + 1) 855-fluoro-3-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.17 (br. s., 1 H), 7.54 (dd, J =3.9, 9.0 Hz, 1 H), 7.28-7.41 (m, 4 H), 7.16 (d, J = 9.9 Hz, 1 H), 4.50(d, J = 13.6 Hz, 2 H), 3.34-3.46 (m, 1 H), 3.22-3.34 (m, 2 H), 2.32 (s,3 H), 2.21-2.29 (m, 2 H), 2.05-2.19 (m, 2 H); MS: 379 (M⁺ + 1) 873-(1-(6-(1H-pyrazol-1-yl)pyridazin-3-yl)piperidin-4-yl)-5-fluorobenzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.64 (d, J = 2.5 Hz, 1 H), 8.04 (d,J = 9.6 Hz, 1 H), 7.75 (d, J = 1.5 Hz, 1 H), 7.54 (dd, J = 3.9, 9.0 Hz,1 H), 7.27-7.39 (m, 2 H), 7.21 (d, J = 9.9 Hz, 1 H), 6.43- 6.54 (m, 1H), 4.51 (d, J = 13.6 Hz, 2 H), 3.39 (tt, J = 3.9, 11.3 Hz, 1 H),3.22-3.33 (m, 2 H), 2.20-2.31 (m, 2 H), 2.06-2.20 (m, 2 H); MS: 365(M⁺ + 1) 881-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)-1H-indole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.17 (s, 1 H), 7.65 (d, J = 7.8 Hz,1 H), 7.42 (d, J = 7.8 Hz, 1 H), 7.33-7.39 (m, 2 H), 7.20- 7.25 (m, 2H), 7.08-7.20 (m, 2 H), 6.54 (d, J = 3.3 Hz, 1 H), 4.48- 4.67 (m, 3 H),3.17-3.30 (m, 2 H), 2.32 (s, 3 H), 2.18-2.31 (m, 2 H), 2.04-2.18 (m, 2H); MS: 359 (M⁺ + 1) 896-fluoro-3-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.11-8.19 (m, 1 H), 7.66 (dd, J =5.1, 8.8 Hz, 1 H), 7.31-7.39 (m, 2 H), 7.21-7.30 (m, 1 H), 7.16 (d, J =9.6 Hz, 1 H), 7.08 (td, J = 2.3, 8.8 Hz, 1 H), 4.40-4.56 (m, 2 H), 3.42(tt, J = 3.9, 11.2 Hz, 1 H), 3.21-3.35 (m, 2 H), 2.31 (s, 3 H),2.19-2.29 (m, 2 H), 2.05-2.19 (m, 2 H); MS: 379 (M⁺ + 1) 901-(1-(6-(4-methyl-1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)-1,2,3,4-tetrahydroquinoline  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.15 (d, J = 1.0 Hz, 1 H), 7.35 (s,1 H), 7.32 (d, J = 9.9 Hz, 1 H), 7.12 (d, J = 9.9 Hz, 1 H), 7.04-7.10(m, 1 H), 6.97 (s, 1 H), 6.73 (d, J = 8.3 Hz, 1 H), 6.60 (t, J = 7.1 Hz,1 H), 4.48-4.60 (m, 2 H), 3.89-4.02 (m, 1 H), 3.15- 3.21 (m, 2 H),3.04-3.15 (m, 2 H), 2.74 (t, J = 6.2 Hz, 2 H), 2.31 (s, 3 H), 1.79-1.98(m, 6 H); MS: 375 (M⁺ + 1) 91(1-(6-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazin-3-yl)-1H-imidazol-4-yl)methanol  

  MS: 395 (M⁺ + 1) 925-fluoro-3-(1-(6-(3-methyl-1H-pyrazol-1-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.52 (d, J = 2.3 Hz, 1 H), 7.99 (d,J = 9.6 Hz, 1 H), 7.54 (dd, J = 3.7, 9.2 Hz, 1 H), 7.27-7.38 (m, 2 H),7.18 (d, J = 9.9 Hz, 1 H), 6.27 (d, J = 2.5 Hz, 1 H), 4.49 (dt, J = 3.1,13.5 Hz, 2 H), 3.38 (tt, J = 4.1, 11.3 Hz, 1 H), 3.20- 3.32 (m, 2 H),2.38 (s, 3 H), 2.20-2.29 (m, 2 H), 2.07-2.20 (m, 2 H); MS: 379 (M⁺ + 1)93 5-fluoro-3-(1-(6-(2-methyl-1H-imidazol-1-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 7.55 (dd, J = 3.2, 9.0 Hz, 1 H),7.28-7.38 (m, 3 H), 7.20 (d, J = 1.3 Hz, 1 H), 7.14 (d, J = 9.6 Hz, 1H), 7.06 (d, J = 1.5 Hz, 1 H), 4.51-4.62 (m, 2 H), 3.28-3.48 (m, 3 H),2.58 (s, 3 H), 2.28 (d, J = 18.2 Hz, 2 H), 2.08-2.20 (m, 2 H); MS: 379(M⁺ + 1) 945-fluoro-3-(1-(6-(4-methyl-1H-pyrazol-1-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazote  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.39 (s, 1 H), 7.99 (d, J = 9.9 Hz,1 H), 7.55 (s, 1 H), 7.51-7.55 (m, 1 H), 7.28-7.38 (m, 2 H), 7.18 (d, J= 9.9 Hz, 1 H), 4.49 (dt, J = 3.1, 13.3 Hz, 2 H), 3.38 (tt, J = 3.9,11.3 Hz, 1 H), 3.21-3.32 (m, 2 H), 2.21-2.29 (m, 2 H), 2.18 (s, 3 H),2.07-2.17 (m, 2 H); MS: 379 (M⁺ + 1) 95(1-(6-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-4-yl)methanol  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.61 (s, 1 H), 8.01 (d, J = 9.6 Hz,1 H), 7.77 (s, 1 H), 7.54 (dd, J = 3.8, 9.1 Hz, 1 H), 7.27- 7.38 (m, 2H), 7.20 (d, J = 9.9 Hz, 1 H), 4.71 (d, J = 5.8 Hz, 2 H), 4.51 (dt, J =3.3, 13.5 Hz, 2 H), 3.39 (tt, J = 3.8, 11.3 Hz, 1 H), 3.22- 3.33 (m, 2H), 2.20-2.30 (m, 2 H), 2.07-2.20 (m, 2 H), 1.59 (t, J = 5.7 Hz, 1 H);MS: 395 (M⁺ + 1) 965-fluoro-3-(1-(6-(4-(methoxymethyl)-1H-pyrazol-1-yl)pyridazin-3-yl)piperidin-4-yl)benzo[d]isoxazole  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.59 (s, 1 H), 8.01 (d, J = 9.9 Hz,1 H), 7.74 (s, 1 H), 7.54 (dd, J = 3.4, 9.0 Hz, 1 H), 7.28- 7.38 (m, 2H), 7.19 (d, J = 9.9 Hz, 1 H), 4.50 (dt, J = 3.1, 13.5 Hz, 2 H), 4.46(s, 2 H), 3.39 (s, 3 H), 3.34-3.44 (m, 1 H), 3.23-3.33 (m, 2 H),2.21-2.30 (m, 2 H), 2.07-2.20 (m, 2 H); MS: 409 (M⁺ + 1) 971-(1-(6-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-4-yl)-N-methylmethanamine

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.55 (s, 1 H), 8.00 (d, J = 9.6 Hz,1 H), 7.72 (s, 1 H), 7.54 (dd, J = 4.0, 9.3 Hz, 1 H), 7.28- 7.38 (m, 2H), 7.19 (d, J = 9.6 Hz, 1 H), 4.50 (dt, J = 3.1, 13.7 Hz, 2 H), 3.77(s, 2 H), 3.38 (tt, J = 3.8, 11.2 Hz, 1 H), 3.21-3.33 (m, 2 H), 2.51 (s,3 H), 2.20-2.31 (m, 2 H), 2.07-2.20 (m, 2 H) (NH not shown); MS: 408(M⁺ + 1) 982-(1-(6-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazin-3-yl)-1H-pyrazol-4-yl)ethanol  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.50 (s, 1 H), 8.00 (d, J = 9.9 Hz,1 H), 7.64 (s, 1 H), 7.54 (dd, J = 3.8, 9.1 Hz, 1 H), 7.28- 7.38 (m, 2H), 7.19 (d, J = 9.9 Hz, 1 H), 4.44-4.55 (m, 2 H), 3.86 (q, J = 6.3 Hz,2 H), 3.38 (tt, J = 3.9, 11.3 Hz, 1 H), 3.21-3.33 (m, 2 H), 2.83 (t, J =6.4 Hz, 2 H), 2.21-2.30 (m, 2 H), 2.06-2.21 (m, 2 H), 1.54 (t, J = 5.8Hz, 1 H); MS: 409 (M⁺ + 1) I16-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazine-3-carbohydrazide  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 8.83 (br. s., 1 H), 7.99 (d, J =9.6 Hz, 1 H), 7.54 (dd, J = 3.0, 8.8 Hz, 1 H), 7.28-7.37 (m, 2 H), 7.05(d, J = 9.6 Hz, 1 H), 4.55-4.66 (m, 2 H), 4.08 (br. s., 2 H), 3.30-3.49(m, 3 H), 2.18-2.33 (m, 2 H), 2.04-2.18 (m, 2 H); MS: 357 (M⁺ + 1) I2N′-acetyl-6-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)pyridazine-3-carbohydrazide  

  ¹H NMR (400 MHz, CHLOROFORM-d) δ = 9.86 (d, J = 4.5 Hz, 1 H), 8.01 (d,J = 4.8 Hz, 1 H), 7.97 (d, J = 9.6 Hz, 1 H), 7.49-7.59 (m, 1 H),7.28-7.38 (m, 2 H), 7.04 (d, J = 9.6 Hz, 1 H), 4.62 (d, J = 13.4 Hz, 2H), 3.29-3.52 (m, 3 H), 2.28 (d, J = 13.6 Hz, 2 H), 2.14 (s, 3 H),2.00-2.19 (m, 2 H); MS: 399 (M⁺ + 1)

BIOLOGICAL EXAMPLE 1 SCD1 Enzymatic Assay (In Vitro Assay)

Step 1: Preparation of Rat Liver Microsome (RLM):

Sprague Dawley rats from Charles River (200-225 g) underwent 2-cycle offast-re-feeding (24-hour fast followed by 24-hour feeding with fat-freehigh carbohydrate diet, Reseach Diet, D00042802). The livers wereremoved and homogenized 1:4 (w/v) with pre-chilled, homogenizing buffer(10 mM Tris-HCl, 0.25 M sucrose, 1 mM EDTA, pH 7.4, supplemented withprotease inhibitor cocktail). The homogenate was spun at 12,000×g for 15min at 4° C. The supernatant was then re-centrifuged at 100,000×g for 60min at 4° C. The pellet was re-suspended in 2 ml pre-chilled 0.2 mMpotassium phosphate buffer, pH 7.2, 10 mM EDTA at a concentration of 20mg/ml. The resulting rat liver microsome (RLM) preparation was stored at−80° C.

Step 2: SCD1 Enzymatic Assay in RLM:

The SCD1 enzymatic assay was done in a volume of 50 μL using 10 μg ofRLM (prepared as described above) in a 96-well polypropylene plate(enzyme reaction buffer contains 0.1 M K-Phosphate Buffer, 10 mM ATP, 6mM MgCl_(2.) 1 mM CoA, 1 mM β-NADH, 1.6 mM L-glutathione, 20 μMStearoyl-CoA). Stearoyl-[9,10-³H]-CoA (ARC-0390, 1 mCi/mL, 60 Ci/mmol,)was added at a final concentration of 2 μCi/mL. Test compound was thenadded to the reaction mixture at the selected concentration. Afterincubation at room temperature for 2 hours, 5 μL 1 N HCl was added tostop the reaction, followed by addition of 25 μL of 10% charcoal. Thereaction mixture was then transferred to 96-well Multiscreen plate(Millipore, Cat#MSFCN6B50). [³H₂O] was collected into Opti-plate (PE,Cat#6005290) by centrifuge, at 1,000 rpm for 2 minutes. 150 μLMicroscint 40 (PE, cat #6013641) was then added to each well and countedon Topcount for [³H] counts per minute (cpm). The measured cpm valueswere fitted with Sigmoidal dose-response curve fit with Graphpad Prism.

BIOLOGICAL EXAMPLE 2 SCD1 ¹³C-Palmitic Acid Assay in A431 Cells (InVitro Assay)

Human epithelial carcinoma A431 cells were seeded at 100,000 cells/wellin complete growth medium (DMEM, Cellgro#10-013-CM, 4.5 g/L glucose, 10%FBS) in the presence of 0.05 mg/mL human insulin (Hannas PharmaceuticalSupply Co Inc, Humanlin 100 U/ml, 4 mg/ml) in 96-well tissue cultureplate. 24 hr later, the cells were washed extensively with Assay Buffer(DMEM, Cellgro#10-013-CM, 4.5 g/L glucose, supplemented with 0.05 mg/mLHuman Insulin and 0.1% Fatty Acid Free BSA). Assay Buffer including 20μM U-¹³C16 palmitic acid (100 μL) was then added to each well (CambridgeIsotope Laboratories, CLM-409-0.5) followed by addition of 5 μL ofvehicle or test compound. The cells were then returned to the tissueculture incubator (37° C. and 5% CO₂) for 4 hrs. At the end ofincubation, the cells were washed three times with 200 μL/well Hanksbuffer (HBSS) and then stored at −20° C. until extraction.

For fatty acid extraction, after thawing out the plates, 40 μL of 1N KOH(containing 5 μM of internal standard 7,7,8,8-D4 palmitate) was added toeach well and cell plates were incubated at 37° C. for 30 minutes.Subsequently, 30 μL of cell lysate was transferred to the 96-well plate(Axygen, PCR-96-FS-C plate, Cat#321-60-051) and the plate incubate at85° C. for 30 minutes. Heated cell lysate was quickly spun at roomtemperature and 5 μL formic acid (Sigma, Cat#251364) was added toneutralize the solution. Acetonitrile (100 μL) was then added to extractfatty acids, followed by centrifugation at 3000 rpm for 10 minutes. 75μL of extract was then transferred to a new glass vial in a 96-wellcluster plate. 5 μL was injected for LC/MS analysis for detection of¹³C-palmitic acid and ¹³C-palmitoleic acid. Formation of product¹³C-palmitoleic acid was determined as an index of SCD1 activity.

LC/MS analysis was performed as following. An Agilent 1100 LiquidChromatographic System (Palo Alto, Calif.) consisting of a binary pump,a degasser and an autosampler was used. Separation of free fatty acidswas performed on a Zorbax SB-C₈ column (2.1×50 mm, particle size=3.5μm). An isocratic elution was carried out with 10 mM triethylamineacetate in water: acetonitrile (3:7) at a flow rate of 0.3 mL/min. Thecolumn temperature was set at 30° C. and the sample injection volume was5 μL. The LC run cycle was 4 min. A Micromass triple-quadrupole QuattroMicro mass spectrophotometer (Waters, Beverly, Mass.) was interfacedwith the LC system through a Z-spray electrospray ion source and wasoperated in the negative ion mode. Nitrogen was used as nebulizing gas,desolvation gas and cone curtain gas and argon was chosen as collisiongas. The triple quadrupole MS source parameters were set as follows:capillary voltage, 3200V; cone voltage, 25V; exctractor 2V; sourcetemperature, 120° C.; desolvation temperature, 300° C.; cone gas flow,50 L/h; and desolvation gas flow, 700 L/h. Selected ion recording (SIR)was applied to detection of U-¹³C-palmitoleic acid at m/z 269.4 (M-H),U-¹³C-palmitic acid at m/z 271.4 (M-H) and 7,7,8,8-D4 palmitate(internal standard) at m/z 259.4 (M-H). MassLynx software version 4.0was used for system control and data processing. The signal ofU-¹³C-palmitoleic acid was normalized to an internal standard.

Plasma Desaturation Index Determination:

Total plasma lipid fatty acid desaturation index (C16:1/C16:0 andC18:1/C18:0) was determined after alkaline digestion. Briefly, 10 μl ofplasma was added to 50 μL of 1 M KOH in 65% ethanol containing 10 μMinternal standard (7,7,8,8-D4 palmitate) and incubated at 55° C. for 1hr. After neutralization with 10 μL formic acid, fatty acids wereextracted with acetonitrile and subjected to LC/MS measurement asdescribed above.

BIOLOGICAL EXAMPLE 3 SCD1 ¹⁴C-Palmitate Assay in A431 Cells (In VitroAssay)

Human epithelial carcinoma A431 cells were seeded at 400,000 cells perwell in 48-well tissue culture plate and treated with 2 cycles offasting in low glucose medium (DMEM, Cellgro#10-014-CV, 1 g/L glucose,2% Charcoal Filtered FBS) for 24 hours; and re-feeding with high glucosemedium for 24 hours (DMEM, Cellgro#10-013-CM, 4.5 g/L glucose, 10%Charcoal Filtered FBS and 0.05 mg/mL Lilly Humulin R, Cat.#, HI-210).Prior to running the assay, the cells were washed twice with highglucose medium (400 μL), followed by addition of 250 μL assay buffer(DMEM, 4.5 g/L glucose, 0.05 mg/mL Human Insulin, 0.1% Fatty Acid FreeBSA) to each well. Then, 100 μL of assay buffer containing 20 μMPalmitic Acid, 0.05 μCi ¹⁴C Palmitic Acid (Perkin Elmer, NEC075H) andtest compound (at selected concentration) was added to each well. Thecells were then Incubated at 37° C. and 5% CO₂ tissue culture incubatorfor 4 hours, followed by extensive washes with pre-chilled PBS. The cellplates were then frozen at −20° C. overnight. After thawing out theplates, 100 μL of 1N KOH was added to each well and the plates wereincubated at 37° C. for 30 mins. Cell lysates were transferred to 1 mLEppendorf tubes and incubated at 95° C. for 1 hour, followed by additionof 10 μL formic acid and 220 μL acetonitrile. The tubes were thencentrifuged at 12,000 rpm and the supernatant dried under N₂ for 2-3hours. Dried extract was re-suspended in 60 μL hexane and loaded ontoTLC plates (pre-coated with 10% AgNO₃ in acetonitrile). The TLC plateswere placed into glass running chamber containing 200 mL runningsolution (100 mL running solution: 92.5 mL chloroform, 6 mL methanol,750 μL acetic acid, 750 μL dH₂O). After running, the TLC plates were airdried and scanned on Bioscan AR-2000 for quantification of¹⁴C-palmitioleate and ¹⁴C-palmitate peaks. Area under the curve of thepeaks were used to calculate product/substrate ratio, an index of SCD1activity.

Representative compounds of the present invention were tested accordingto the procedures as outlined in Biological Examples 1-3 above, withresults as listed in Table 4, below. Where a particular compound wastested multiple times, multiple measured values are listed below.

TABLE 4 Biological Activity for Representative Compounds of Formula (I)A431 cells A431 cells ID % Inh.@ 1 μM IC₅₀ (μM) ¹³C-PA IC₅₀ (μM) ¹⁴C-PAIC₅₀ (μM)  1 86 0.076 0.257  3 87 0.126 0.377  4 95, 95, 93 0.020, 0.0120.009 0.068  5 89 0.068 0.139  6 79 0.034 0.062, 0.102  7 95 0.014 0.024 8 86 0.165 0.577  9 81 0.422 0.359 10 84 0.394 0.383 11 99, 100, 94,0.021, 0.019, 0.015, 0.012, 0.12  102 0.091, 0.016 0.017 12 95, 970.011, 0.011 0.362 13 98 0.070 0.985 15 101  0.011 0.003 16 100  0.0210.023 18 56, 52, 34, 27 0.315 0.248 20 96, 96 0.016, 0.014 0.011 21 940.017 0.040, 0.019 22 98, 91 0.022, 0.011 0.007, 0.005 23 100  0.0210.003 24 98, 94 0.011, 0.004 0.009, 0.006 25 62 0.171 0.017, 0.017 26 860.111 0.112 27 75, 55 0.114, 0.122 0.004, 0.003 28 94 0.009 0.009, 0.01629 97 0.007 0.002 30 95, 99 0.006, 0.019 0.002, 0.003, 0.002 31 97 0.0310.004, 0.019 32 45 >1    33 100  0.007 0.004 34 75 0.095 0.017 35 990.008 0.002, 0.002 36 92 0.079 0.003, 0.018 37 98 0.012 0.004 38 970.011 0.034 39 99 0.009  0.0005 40 92 0.092 0.045 41 38 >1    42 710.035 0.006 43 90 0.020 0.011 44 92, 97 0.020, 0.014 0.032, 0.028 45 980.015 0.006 46 85 0.165 0.099 47 100, 96  0.036, 0.039 0.069, 0.033 4860 0.939 49 95, 91 0.025, 0.019 0.021, 0.021, 0.022 50 93 0.031 0.044 5196 0.022 0.008 52 92 0.121 0.006 53 59 0.777 54 85 0.090 0.054 55 8 >1    56 28 >1    57 72 0.286 0.241 58 78 0.349 0.390 59 99 0.0350.028 60 81 0.173 0.042 61 101  0.015 0.017 62 79 0.317 0.407 63 990.023 0.025 64 102  0.015 0.012 65 83 0.181 0.218 66 57 0.678 6732 >1    68 34 >1    69 68 0.387 0.559 70 94 0.068 0.082 71 71 0.275  >1, 0.160 72 99 0.008 0.009 73 86 0.145 0.262 74 96 0.016 0.022 75 980.021 0.081 76 97 0.016 0.014 77 95 0.021 0.020 78 99 0.012 0.041 79 970.022 0.072 80 74 0.052 0.731 81 96 0.008 0.015 82 99 0.053 0.096 83102  0.006 0.011 84 85 0.156 0.157 85 97 0.065 0.148 87 45 88 84 0.0860.116 89 88 0.257 0.691 90 29 91 96 0.052 0.040 92 79 0.126 0.063 93 4194 96 0.012 0.040 95 88 0.096 0.062 96 98 0.008 0.022, 0.022 9711 >1, >1 98 88 0.060 0.012 I1 100  0.059 >3.00  3.065 I2 27

BIOLOGICAL EXAMPLE 4 4 Week Zucker fa/fa Rat Study (In Vivo Assay)

Male Zucker fa/fa rats were housed one rat per cage in atemperature-controlled room with 12-hour light/dark cycle. The rats werefed on regular rodent diet (Purina 5008) and allowed ad libitum accessto water. The experiment was initiated at an age of 8-9 week, and atbody weight of about 350 g.

Test compound was prepared in 0.5% HPMC for dosing q.d at 1 mg/kg, 3mg/kg and 10 mg/kg, as noted in the table of results below. Body weight,food intake and fed blood glucose were monitored weekly. On day 26, allrats were given with the last dose 1 hr prior to the necropsy. Orbitalbleeding was performed under 70%/30% CO₂/O₂ anesthesia to collectplasma.

Compound #11 of the present invention was tested according to theprocedure as described above, with results as listed in Table 5 and 6,below. In the results presented below, * indicates a calculated p value<0.05 vs. vehicle-treated group.

TABLE 5 4-Week Body Weight (in grams) Treatment Day 1 Day 8 Day 15 Day22 Day 26 Vehicle 373 ± 7 434 ± 9 476 ± 8 515 ± 7 534 ± 11 Compound 373± 7 404 ± 13 442 ± 12 * 482 ± 10 496 ± 10 #11 @ 1 mg/kg Compound 372 ± 6417 ± 7 452 ± 6 * 484 ± 6 * 498 ± 6 * #11 @ 3 mg/kg Compound 373 ± 5 402± 6 * 430 ± 7 * 445 ± 9 * 451 ± 9 * #11 @ 10 mg/kg

TABLE 6 Plasma Desaturation Index at Day 26 Treatment C16:1/C16:0C18:1/C18:0 Vehicle 0.183 ± 0.012 2.16 ± 0.07 Compound #11 @ 1 mg/kg0.122 ± 0.005 * 1.59 ± 0.08 * Compound #11 @ 3 mg/kg 0.088 ± 0.002 *1.14 ± 0.07 * Compound #11 @ 10 mg/kg 0.078 ± 0.002 * 0.92 ± 0.04 *

BIOLOGICAL EXAMPLE 5 10-Day Diet-Induced Obese C57bl/6 Mice Study (InVivo Assay)

Male DIO C57BL/6J mice from Taconic were maintained on high fat dietD12492 containing 60% kCal of mostly saturated fats (Research DietsInc.) for 4 week from 6-week old. Test compounds were prepared in 0.5%hydroxypropyl methyl cellulose for oral dosing at 30 mg/kg once a day.After 10-days of treatment, body weight change was recorded.

Representative compounds of the present invention were tested accordingto the procedure as described above, with results as listed in Table 7,below. In the results presented below, * indicates a calculated p value<0.05 vs. vehicle-treated group.

TABLE 7 10-day dosing study, 30 mg/kg dosing Vehicle   2.8 ± 0.3Compound #22   1.2 ± 0.3 * Compound #11 −2.1 ± 0.3 * Compound #39 −2.2 ±0.5 * Compound #47 −3.3 ± 0.5 * Compound #49   0.5 ± 0.1 *

FORMULATION EXAMPLE 1 Solid, Oral Dosage Form—Prophetic Example

As a specific embodiment of an oral composition, 100 mg of the Compound#11, prepared as in Example 1 is formulated with sufficient finelydivided lactose to provide a total amount of 580 to 590 mg to fill asize O hard gel capsule.

While the foregoing specification teaches the principles of the presentinvention, with examples provided for the purpose of illustration, itwill be understood that the practice of the invention encompasses all ofthe usual variations, adaptations and/or modifications as come withinthe scope of the following claims and their equivalents.

We claim:
 1. A compound of formula (I)

wherein R¹ is selected from the group consisting of

a is an integer from 0 to 3; each R² is independently selected from thegroup consisting of halogen, C₁₋₄alkyl, C₁₋₄alkoxy, halogenatedC₁₋₂alkyl, and halogenated C₁₋₂alkoxy; R³ is selected from the groupconsisting of

wherein R⁴ is selected from the group consisting of hydrogen, halogen,C₁₋₄alkyl, halogenated C₁₋₂alkyl, —C₁₋₂alkyl-OH, C₁₋₄alkoxy, halogenatedC₁₋₂alkoxy, —C₁₋₂alkyl-O—C₁₋₂alkyl, —CO₂H, —C(O)O—C₁₋₄alkyl,—C₁₋₂alkyl-C(O)O—C₁₋₂alkyl, —C₁₋₂alkyl-OC(O)—C₁₋₂alkyl, —NR^(A)R^(B),—C₁₋₂alkyl-NR^(A)R^(B), —C(O)—NR^(A)R^(B), —C₁₋₂alkyl-C(O)—NR^(A)R^(B)and —NR^(A)—C(O)—(C₁₋₂alkyl);

wherein R⁵ is selected from the group consisting of hydrogen, C₁₋₄alkyl,—C₂₋₄alkyl-OH, —C₂₋₃alkyl-O—C₁₋₂alkyl, —C₁₋₂alkyl-C(O)O—C₁₋₂alkyl,—C₂₋₃alkyl-OC(O)—C₁₋₂alkyl, —C₂₋₄alkyl-NR^(A)R^(B) and—C₁₋₂alkyl-C(O)NR^(A)R^(B); and

wherein b is an integer from 0 to 2; wherein each R⁶ is independentlyselected from the group consisting of halogen, C₁₋₄alkyl, halogenatedC₁₋₄alkyl, —C₁₋₂alkyl-OH, C₁₋₄alkoxy, halogenated C₁₋₄alkoxy,—C₁₋₂alkyl-O—C₁₋₂alkyl, —CO₂H, —C(O)O—C₁₋₄alkyl,—C₁₋₂alkyl-C(O)O—C₁₋₂alkyl,—C₁₋₂alkyl-OC(O)—C₁₋₂alkyl,—C(O)—NR^(A)R^(B),—C₁₋₂alkyl-C(O)—NR^(A)R^(B), —NR^(A)R^(B), —C₁₋₂alkyl-NR^(A)R^(B) and—NR^(A)—C(O)—C₁₋₂alkyl; and wherein R^(A) and R^(B) are eachindependently selected from the group consisting of hydrogen andC₁₋₂alkyl; alternatively R^(A) and R^(B) are taken together with thenitrogen atom to which they are bound to form piperidin-1-yl,piperazin-1-yl, morpholin-4-yl and pyrrolidin-1-yl; provided that whenR³ is 3-methyl-1,2,4-thiadiazol-5-yl, then R¹ is other thanunsubstituted indoly-3-yl; or a pharmaceutically acceptable saltthereof.
 2. A compound as in claim 1, wherein R¹ is selected from thegroup consisting of

a is an integer from 0 to 2; each R² is independently selected from thegroup consisting of halogen, C₁₋₂alkyl, C₁₋₂alkoxy, fluorinatedC₁₋₂alkyl, and fluorinated C₁₋₂alkoxy; R³ is selected from the groupconsisting of

wherein R⁴ is selected from the group consisting of hydrogen, halogen,C₁₋₄alkyl, fluorinated C₁₋₂alkyl, —C₁₋₂alkyl-OH, C₁₋₂alkoxy, fluorinatedC₁₋₂alkoxy, —C₁₋₂alkyl-O—C₁₋₂alkyl, —CO₂H, —C(O)O—C₁₋₂alkyl,—C₁₋₂alkyl-OC(O)—C₁₋₂alkyl, —NR^(A)R^(B), —C₁₋₂alkyl-NR^(A)R^(B),—C(O)—NR^(A)R^(B), —C₁₋₂alkyl-C(O)—NR^(A)R^(B) and—NR^(A)—C(O)—(C₁₋₂alkyl);

wherein R⁵ is selected from the group consisting of hydrogen, C₁₋₄alkyl,—C₂₋₄alkyl-OH, —C₂₋₃alkyl-O—C₁₋₂alkyl, —C₁₋₂alkyl-C(O)O—C₁₋₂alkyl,—C₂₋₄alkyl-NR^(A)R^(B) and —C₁₋₂alkyl-C(O)NR^(A)R^(B); and

wherein b is an integer from 0 to 1; wherein each R⁶ is independentlyselected from the group consisting of halogen, C₁₋₄alkyl, fluorinatedC₁₋₂alkyl, —C₁₋₂alkyl-OH, C₁₋₂alkoxy, fluorinated C₁₋₂alkoxy, —C(O)₂H,—C(O)O—C₁₋₄alkyl, —C₁₋₂alkyl-C(O)O—C₁₋₂alkyl, —C(O)—NR^(A)R^(B), —C₁₋₂₂alkyl-C(O)—NR^(A)R^(B), —NR^(A)R^(B) and —C₁₋₂alkyl-NR^(A)R^(B); andwherein R^(A) and R^(B) are each independently selected from the groupconsisting of hydrogen and C₁₋₂alkyl; alternatively R^(A) and R^(B) aretaken together with the nitrogen atom to which they are bound to formpiperidin-1-yl, piperazin-1-yl and morpholin-4-yl; or a pharmaceuticallyacceptable salt thereof.
 3. A compound as in claim 2, wherein R¹ isselected from the group consisting of

a is an integer from 0 to 2; each R² is independently selected from thegroup consisting of halogen, C₁₋₂alkyl, C₁₋₂alkoxy and trifluoromethyl;R³ is selected from the group consisting of

wherein R⁴ is selected from the group consisting of hydrogen, halogen,C₁₋₂alkyl, trifluoromethyl, —C₁₋₂alkyl-OH, C₁₋₂alkoxy,—C₁₋₂alkyl-O—C₁₋₂alkyl, —C₁₋₂alkyl-OC(O)—C₁₋₂alkyl, —NR^(A)R^(B),—C₁₋₂alkyl-NR^(A)R^(B), —C(O)—NR^(A)R^(B), and —NR^(A)—C(O)—(C₁₋₂alkyl);

wherein R⁵ is selected from the group consisting of hydrogen, C₁₋₃alkyl,—C₂alkyl-OH, —C₂₋₃alkyl-O—C₁₋₂alkyl, —C₁₋₂alkyl-C(O)O—C₁₋₂alkyl,—C₂₋₄alkyl-NR^(A)R^(B) and —C₁₋₂alkyl-C(O)NR^(A)R^(B); and

wherein b is 1; and wherein R⁶ is selected from the group consisting of,halogen, C₁₋₂alkyl, trifluoromethyl, —C₁₋₂alkyl-OH, —CO₂H,—C(O)O—C₁₋₄alkyl and —C(O)—NR^(A)R^(B); and wherein R^(A) and R^(B) areeach independently selected from the group consisting of hydrogen andC₁₋₂alkyl; alternatively R^(A) and R^(B) are taken together with thenitrogen atom to which they are bound to form morpholin-4-yl; or apharmaceutically acceptable salt thereof.
 4. A compound as in claim 3,wherein R¹ is selected from the group consisting of indol-1-yl,6-fluoro-indol-1-yl, indolin-1-yl, 4-fluoro-indolin-1-yl,5-fluoro-indolin-1-yl, 6-fluoro-indolin-1-yl, 4-chloro-indolin-1-yl,5-chloro-indolin-1-yl, 6-chloro-indolin-1-yl, 4,6-dichloro-indolin-1-yl,6-methyl-indolin-1-yl, 6-methoxy-indolin-1-yl,6-trifluoromethyl-indolin-1-yl, 1H-indazol-1-yl,4-fluoro-1H-indazol-1-yl, 5-fluoro-1H-indazol-1-yl,6-fluoro-1H-indazol-1-yl, 3-chloro-1H-indazol-1-yl,4-chloro-1H-indazol-1-yl, 6-chloro-1H-indazol-1-yl,4-trifluoromethyl-1H-indazol-1-yl, 6-trifluoromethyl-1H-indazol-1-yl,2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl,1H-benzo[d][1,2,3]triazol-1-yl, 5-fluoro-benzo[d]isoxazol-3-yl,6-fluoro-benzo[d]isoxazol-1-yl, and 1,2,3,4-tetrahydroquinolin-1-yl; R³is selected from the group consisting of (a) pyrazol-1-yl,3-methyl-pyrazol-1-yl, 4-methyl-pyrazol-1-yl,4-(hydroxymethyl)-pyrazol-1-yl, 4-(hydroxyethyl)-pyrazol-1-yl,4-(methoxy-methyl)-pyrazol-1-yl, 4-(ethoxy-methyl)-pyrazol-1-yl,4-(methylamino-methyl)-pyrazol-1-yl; (b) imidazol-1-yl,2-methyl-imidazol-1-yl, 4-methyl-imidazol-1-yl,4-(hydroxymethyl)-imidazol-1-yl; (c) 5-methyl-1,3,4-oxadiazol-2-yl,5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl,5-(methylcarbonyl-oxy-methyl)-1,3,4-oxadiazol-2-yl; (d)4-methyl-thien-2-yl, 5-methyl-thien-2-yl; (e) 4-methyl-thiazol-2-yl,5-methyl-thiazol-2yl; (f) 3-methyl-1,2,4-thiadiazol-5-yl; (g)pyrid-3-yl, 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,6-(methylamino-carbonyl)-pyrid-3-yl, 6-(dimethylamino)-pyrid-3-yl,6-(methylcarbonyl-amino)-pyrid-3-yl; (h) 2-methyl-pyrid-4-yl; (i)2-methyl-pyrimidin-5-yl, 2-methoxy-pyrimidin-5-yl; (j) 1H-pyrazol-4-yl,1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl, 1-(n-propyl)-pyrazol-4-yl,1-(hydroxyethyl)-pyrazol-4-yl, 1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,1-(aminocarbonyl-methyl)-pyrazol-4-yl,1-(methylamino-carbonyl-methyl)-pyrazol-4-yl,1-(morpholin-4-yl-ethyl)-pyrazol-4-yl, 1-(ethoxy-ethyl)-pyrazol-4-yl;and (k) 4-fluoro-phenyl, 4-methyl-phenyl, 4-(hydroxymethyl)-phenyl,4-(trifluoromethyl)-phenyl, 4-(tert-butoxycarbonyl)-phenyl,4-(carboxy)-phenyl, 4-(aminocarbonyl)-phenyl; or a pharmaceuticallyacceptable salt thereof.
 5. A compound as in claim 4, wherein R¹ isselected from the group consisting of indol-1-yl, 6-fluoro-indolyl,indolin-1-yl, 6-fluoro-indolin-1-yl, 1H-indazol-1-yl,4-fluoro-1H-indazol-1-yl, 6-fluoro-1H-indazol-1-yl,3-chloro-1H-indazol-1-yl, 4-chloro-1H-indazol-1-yl,6-chloro-1H-indazol-1-yl, 4-trifluoromethyl-1H-indazol-1-yl,6-trifluoromethyl-1H-indazol-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl; R³is selected from the group consisting of (a) 4-methyl-pyrazol-1-yl,4-(hydroxymethyl)-pyrazol-1-yl, 4-(hydroxyethyl)-pyrazol-1-yl,4-(methoxy-methyl)-pyrazol-1-yl, 4-(ethoxy-methyl)-pyrazol-1-yl; (b)4-methyl-imidazol-1-yl, 4-(hydroxymethyl)-imidazol-1-yl; (c)5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl; (e) 4-methyl-thiazol-2-yl,5-methyl-thiazol-2yl; (f) 3-methyl-1,2,4-thiadiazol-5-yl; (g)6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-(hydroxymethyl)-pyrid-3-yl,6-(trifluoromethyl)-pyrid-3-yl, 6-(methylamino-carbonyl)-pyrid-3-yl,6-(dimethylamino)-pyrid-3-yl, 6-(methylcarbonyl-amino)-pyrid-3-yl; (i)2-methoxy-pyrimidin-5-yl; (j) 1H-pyrazol-4-yl, 1-methyl-pyrazol-4-yl,1-ethyl-pyrazol-4-yl, 1-(n-propyl)-pyrazol-4-yl,1-(hydroxyethyl)-pyrazol-4-yl, 1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,1-(methylamino-carbonyl-methyl)-pyrazol-4-yl,1-(ethoxy-ethyl)-pyrazol-4-yl; and (k) 4-methyl-phenyl,4-(hydroxymethyl)-phenyl; or a pharmaceutically acceptable salt thereof.6. A compound as in claim 5, wherein R¹ is selected from the groupconsisting of indol-1-yl, 6-fluoro-indolyl, indolin-1-yl,6-fluoro-indolin-1-yl, 6-fluoro-1H-indazol-1-yl,3-chloro-1H-indazol-1-yl, 4-chloro-1H-indazol-1-yl,6-chloro-1H-indazol-1-yl, 6-trifluoromethyl-1H-indazol-1-yl and5-fluoro-benzo[d]isoxazol-3-yl; R³ is selected from the group consistingof (a) 4-methyl-pyrazol-1-yl, 4-(hydroxymethyl)-pyrazol-1-yl,4-(hydroxyethyl)-pyrazol-1-yl, 4-(methoxy-methyl)-pyrazol-1-yl,4-(ethoxy-methyl)-pyrazol-1-yl; (b) 4-methyl-imidazol-1-yl,4-(hydroxymethyl)-imidazol-1-yl; (c)5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl; (e) 4-methyl-thiazol-2-yl,5-methyl-thiazol-2yl; (f) 3-methyl-1,2,4-thiadiazol-5-yl; (g)6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-(hydroxymethyl)-pyrid-3-yl,6-(trifluoromethyl)-pyrid-3-yl, 6-(methylamino-carbonyl)-pyrid-3-yl,6-(dimethylamino)-pyrid-3-yl, 6-(methylcarbonyl-amino)-pyrid-3-yl; (i)2-methoxy-pyrimidin-5-yl; (j) 1H-pyrazol-4-yl, 1-methyl-pyrazol-4-yl,1-ethyl-pyrazol-4-yl, 1-(n-propyl)-pyrazol-4-yl,1-(hydroxyethyl)-pyrazol-4-yl, 1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,1-(methylamino-carbonyl-methyl)-pyrazol-4-yl,1-(ethoxy-ethyl)-pyrazol-4-yl; and (k) 4-(hydroxymethyl)-phenyl; or apharmaceutically acceptable salt thereof.
 7. A compound as in claim 4,wherein R¹ is selected from the group consisting of indol-1-yl,indolin-1-yl, 6-fluoro-indolin-1-yl, 3-chloro-1H-indazol-1-yl,4-chloro-1H-indazol-1-yl, 6-chloro-1H-indazol-1-yl,6-trifluoromethyl-1H-indazol-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl; R³is selected from the group consisting of (a) 4-methyl-pyrazol-1-yl,4-(hydroxymethyl)-pyrazol-1-yl, 4-(methoxy-methyl)-pyrazol-1-yl,4-(ethoxy-methyl)-pyrazol-1-yl; (b) 4-methyl-imidazol-1-yl,4-(hydroxymethyl)-imidazol-1-yl; (c)5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl; (e) 4-methyl-thiazol-2-yl,5-methyl-thiazol-2yl; (f) 3-methyl-1,2,4-thiadiazol-5-yl; (g)6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-(hydroxymethyl)-pyrid-3-yl,6-(trifluoromethyl)-pyrid-3-yl, 6-(dimethylamino)-pyrid-3-yl,6-(methylcarbonyl-amino)-pyrid-3-yl; (i) 2-methoxy-pyrimidin-5-yl; (j)1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl, 1-(n-propyl)-pyrazol-4-yl,1-(methylamino-carbonyl-methyl)-pyrazol-4-yl and1-(ethoxy-ethyl)-pyrazol-4-yl; or a pharmaceutically acceptable saltthereof.
 8. A compound as in claim 4, wherein R¹ is selected from thegroup consisting of indol-1-yl, 6-fluoro-indol-1-yl, indolin-1-yl,5-fluoro-indolin-1-yl, 6-fluoro-indolin-1-yl, 6-chloro-indolin-1-yl,6-trifluoromethyl-indolin-1-yl, 1H-indazol-1-yl,4-fluoro-1H-indazol-1-yl, 6-fluoro-1H-indazol-1-yl,3-chloro-1H-indazol-1-yl, 4-chloro-1H-indazol-1-yl,6-chloro-1H-indazol-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl; R³ isselected from the group consisting of (a) 3-methyl-pyrazol-1-yl,4-methyl-pyrazol-1-yl, 4-(hydroxymethyl)-pyrazol-1-yl,4-(hydroxyethyl)-pyrazol-1-yl, 4-(methoxy-methyl)-pyrazol-1-yl,4-(ethoxy-methyl)-pyrazol-1-yl; (b) 4-methyl-imidazol-1-yl,4-(hydroxymethyl)-imidazol-1-yl; (c)5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl; (d) 4-methyl-thien-2-yl,5-methyl-thien-2-yl; (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2yl;(f) 3-methyl-1,2,4-thiadiazol-5-yl; (g) 6-methyl-pyrid-3-yl,6-methoxy-pyrid-3-yl, 6-(hydroxymethyl)-pyrid-3-yl,6-(trifluoromethyl)-pyrid-3-yl, 6-(methylamino-carbonyl)-pyrid-3-yl,6-(dimethylamino)-pyrid-3-yl, 6-(methylcarbonyl-amino)-pyrid-3-yl; (h)2-methyl-pyrid-4-yl; (i) 2-methoxy-pyrimidin-5-yl; (j) 1H-pyrazol-4-yl,1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl, 1-(n-propyl)-pyrazol-4-yl,1-(hydroxyethyl)-pyrazol-4-yl, 1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,1-(methylamino-carbonyl-methyl)-pyrazol-4-yl,1-(ethoxy-ethyl)-pyrazol-4-yl; and (k) 4-methyl-phenyl,4-(hydroxymethyl)-phenyl, 4-(trifluoromethyl)-phenyl; or apharmaceutically acceptable salt thereof.
 9. A compound as in claim 8,wherein R¹ is selected from the group consisting of 6-fluoro-indol-1-yl,indolin-1-yl, 6-fluoro-indolin-1-yl, 6-chloro-indolin-1-yl,6-trifluoromethyl-indolin-1-yl, 1H-indazol-1-yl,6-fluoro-1H-indazol-1-yl, 3-chloro-1H-indazol-1-yl,4-chloro-1H-indazol-1-yl, 6-chloro-1H-indazol-1-yl and5-fluoro-benzo[d]isoxazol-3-yl; R³ is selected from the group consistingof (a) 4-methyl-pyrazol-1-yl, 4-(hydroxymethyl)-pyrazol-1-yl,4-(hydroxyethyl)-pyrazol-1-yl, 4-(methoxy-methyl)-pyrazol-1-yl,4-(ethoxy-methyl)-pyrazol-1-yl; (b) 4-(hydroxymethyl)-imidazol-1-yl; (c)5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl; (d) 4-methyl-thien-2-yl,5-methyl-thien-2-yl; (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2yl;(f) 3-methyl-1,2,4-thiadiazol-5-yl; (g) 6-methyl-pyrid-3-yl,6-methoxy-pyrid-3-yl, 6-(hydroxymethyl)-pyrid-3-yl,6-(trifluoromethyl)-pyrid-3-yl, 6-(methylamino-carbonyl)-pyrid-3-yl,6-(dimethylamino)-pyrid-3-yl, 6-(methylcarbonyl-amino)-pyrid-3-yl; (h)2-methyl-pyrid-4-yl; (i) 2-methoxy-pyrimidin-5-yl; (j) 1H-pyrazol-4-yl,1-methyl-pyrazol-4-yl, 1-ethyl-pyrazol-4-yl,1-(hydroxyethyl)-pyrazol-4-yl, 1-(ethoxycarbonyl-methyl)-pyrazol-4-yl,1-(methylamino-carbonyl-methyl)-pyrazol-4-yl; and (k) 4-methyl-phenyl,4-(hydroxymethyl)-phenyl; or a pharmaceutically acceptable salt thereof.10. A compound as in claim 8, wherein R¹ is selected from the groupconsisting of 6-fluoro-indolin-1-yl, 6-fluoro-1H-indazol-1-yl,3-chloro-1H-indazol-1-yl, 4-chloro-1H-indazol-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl; R³ is selected from the group consisting of (a)4-(hydroxymethyl)-pyrazol-1-yl, 4-(hydroxyethyl)-pyrazol-1-yl,4-(ethoxy-methyl)-pyrazol-1-yl; (b) 4-(hydroxymethyl)-imidazol-1-yl; (c)5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl; (d) 4-methyl-thien-2-yl,5-methyl-thien-2-yl; (e) 4-methyl-thiazol-2-yl, 5-methyl-thiazol-2yl;(g) 6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl,6-(hydroxymethyl)-pyrid-3-yl, 6-(trifluoromethyl)-pyrid-3-yl,6-(methylamino-carbonyl)-pyrid-3-yl; (h) 2-methyl-pyrid-4-yl; (i)2-methoxy-pyrimidin-5-yl; (j) 1-methyl-pyrazol-4-yl,1-(hydroxyethyl)-pyrazol-4-yl,1-(methylamino-carbonyl-methyl)-pyrazol-4-yl; and (k) 4-methyl-phenyl,4-(hydroxymethyl)-phenyl; or a pharmaceutically acceptable salt thereof.11. A compound as in claim 4, wherein R¹ is selected from the groupconsisting of 6-fluoro-indolin-1-yl and 5-fluoro-benzo[d]isoxazol-3-yl;R³ is selected from the group consisting of (a)4-(ethoxy-methyl)-pyrazol-1-yl; (e) 4-methyl-thiazol-2-yl; (g)6-methyl-pyrid-3-yl, 6-methoxy-pyrid-3-yl, 6-(hydroxymethyl)-pyrid-3-yl;and (j) 1-methyl-pyrazol-4-yl; or a pharmaceutically acceptable saltthereof.
 12. A pharmaceutical composition comprising a pharmaceuticallyacceptable carrier and a compound of claim
 1. 13. A pharmaceuticalcomposition made by mixing a compound of claim 1 and a pharmaceuticallyacceptable carrier.